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The following is a simplified list of the most common abbreviations used
throughout this dissertation. The list is not conclusive, however all abbreviations are
described within the corresponding text.
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U2 Auxilliary Factor/6S Kda Subunit/35 Kda Subunit

UHM

U2AF Homology Motif

ULM

UHM-Ligand Motif

UV

Ultraviolet Radiation

VEGFR

Vascular Endothelial Growth Factor Receptor
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Abstact

Alternative pre~mRNA splicing increases proteome diversity and is important in
the behavior of cells in health and disease. The processes that regulate alternative premRNA splicing are diverse and include regulation of splicing factors by phosphorylation.
Here we report that the pre-mRNA alternative splicing factor SPF45 is a novel substrate
of ERK, JNK and p38 MAP kinases in ovarian cancer cells. Using mutational analysis and
phospho-specific antibodies, we demonstrate that MAP kinases phosphorylate SPF45 on
Thr71 and Ser222 and that phosphorylation in cells is induced by a number of
extracellular stimuli including PMA, EGF, serum, H2 0 2 and UV. Exon 6 of the death
receptor Fas/CD95 has been shown to undergo alternative splicing in the presence of
SPF45. Using a Fas minigene assay, we show that ERK2 and p38 inhibit SPF45 alternative
splicing activity towards Fas, dependent upon these two phosphorylation sites. Other
than Fas, no other pre-mRNA targets of SPF45 have been reported in mammalian cells.
We generated SKOV3 cells stably-overexpressing wild-type SPF45 or a phosphorylation
site mutant and performed an exon and gene array analysis to identify novel SPF45
splicing targets and genes whose expression is changed downstream of SPF45 splicing
activity, respectively. From this analysis, 139 potential splicing targets and over 150
genes with altered expression were identified. We focus on four genes for validation
with emphasis on ErbB2 and fibronectin. We show that SPF45 downregulates cellular
proliferation in SKOV3 cells in a phosphorylation-dependent manner. Furthermore, we
demonstrate that SPF45 regulates fibronectin alternative splicing, enhances inclusion of
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FN-EDIIiA region, and affects cellular adhesion to fibronectin matrix. We also assess
SPF45 binding to SFl and SF3b15S, essential components of the spliceosome, as well as
the impact of Thr71 and Ser222 mutations on this interaction. Finally, we determine the
effect of SPF45 overexpression in SKOV3 cells on their drug resistance profile. This study
provides a link between MAP kinase signaling and splicing factors and identifies the role
of this interaction in regulating molecular processes in ovarian cancer cells. Additionally,
it provides the basis to investigate the role of SPF45 in ovarian cancer and to produce
successful therapeutic interventions targeting SPF45-mediated effects.
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Chapter 1: Introduction
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Ovarian Cancer
The most recent statistics indicate that ovarian cancer is the second most
common yet deadliest gynecological malignancy and ranks as the fourth leading cause
of cancer death among women in the western world (Jemal 2009) surpassing mortality
from both endometrial and cervical cancer combined (Ozols 2004). The etiology and
pathogenesis of the disease are still poorly understood compared to other forms of
cancer, primarily due to a lack of a progression model that can accurately explain the
course of the disease (Shih Ie 2004). Ovarian cancer is usually deSignated as epithelial
ovarian ~ancer (EOC) since 90% of ovarian tumors are believed to originate from the
ovarian ~urface epithelium (OSE) (Auersperg 2001), with granulosa cells accounting for
most of the rest, and a rare contribution from stromal or germinal cells (Auersperg
2001). The 5-year survival rate for ovarian cancer patients can be extremely good if
detected early (- 90% FIGO stage lA, IB), however it declines raidly with increased stage
(32.5% FIGO IIIC, 18.6% FIGO IV) when unfortunately most patients (> 55%) are
diagnosed (Heintz 2006).
Risk factors
The risk factors for developing ovarian cancer can be divided into three main
categories: hormonal, genetic and environmental (Chen 2010).
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Hormonal factors -

such as early menarche or late menopause)' nulligravidity,

infertility, endometriosis (mainly endometrioid and clear cell ovarian cancer) and
postmenopausal estrogen therapy.
Genetic factors - such as family history of ovarian cancer, BRCA1/2 mutations and
Lynch syndrome.
Environmental factors - such as talc powder, cigarette smoking (mainly mucinous
ovarian cancer) and obesity.
In contrast to the aforementioned risk factors, multiple pregnancies, oral
contraceptives, tubal ligation), hysterectomy and oophrectomy, and breastfeeding are
considered

protective factors from

developing ovarian cancer. Based on these

observations and other indications, two theories have been proposed to explain the
pathogenesis of ovarian cancer and are discussed later in this chapter.
Clinical manifestations, physical exam and diagnostic evaluation
Epithelial ovarian cancer is primarily a disease of menopausal and postmenopausal women. It typically manifests between the ages of 40 and 65, unlike the
non-epithelial varieties which tend to be more common in younger population. One of
the main hurdles in detecting ovarian cancer is the dull and vague presentation of
symptoms that often leads to delayed discovery)' and unfortunately at an advanced
stage. The most common symptoms include: abdominal distention, nausea and
anorexia. It is suggested that a frequent and more severe presentation of these
symptoms should prompt ovarian cancer in the differential diagnosis (Chen 2010).
Equally, an adnexal mass palpated during pelvic or rectovaginal examination should also
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prompt further workup to rule out ovarian cancer (Chen 2010). Ultrasound sonography
is the tool of choice for diagnostic evaluation of malignant growth versus ovarian cysts,
the former of which requires further surgical intervention.
Etiology of epithelial ovarian cancer - Proposed hypotheses
Two main theories have been proposed and accepted to explain the origin of
EOC. The first theory, proposed by Fathalla (Fathalla 1971), also known as lithe incessant
ovulation" theory, is based on observations of development of adenocarcinoma of the
ovaries of domestic fowls that are maintained at a continual ovulation rate without
seasonal rest. Epidemiological studies point to strong relationship between the
development of ovarian cancer and nulliparity compared with a lower risk for multiple
pregnancies especially a younger age of first pregnancy; equally, there is higher
incidence of ovarian cancer associated with fertility treatment regimens that induce
hyperovulation compared to a protective effect associated with oral contraceptives
(Cramer 1983, Greene 1984). Due to an increased rate of wound healing and repair of
the surface epithelium, the hypothesis postulates that adenocarcinoma of the OSE is
induced by the formation of foci of genetic mutations known as "inclusion cysts"
providing a fertile ground for tumor initiation and growth at the sites of ovulation,
which is greatly increased by a higher rate of ovulation similar to the cases of nulliparity
and fertility treatment. The hypothesis is also supported by observations of malignant
progression of rat OSE that are extensively subcultured (Godwin 1992, Testa 1994) and
an increase in inclusion cysts and changes of ovarian surface epithelium in women with
higher risks of ovarian cancer (Feeley 2001, Schlosshauer 2003).
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The second hypothesis, developed by Cramer and Welch (Cramer 1983), is
known as "the gonadotropin theory". The process of ovulation is under strict hormonal
regulation by pituitary-secreted gonadotropins, which

by themselves have no

tumorigenic effect on ovarian epithelial cells grown in culture (Ozols 2004), although
they cause a disruption of the ovarian epithelial basement membrane altering tissue
regeneration and cellular signaling (Roland 2003). Additionally, ovulation constitutes an
inflammatory-like process that culminates in cen rupture {Espey 1994}. Based on these
observations and the fact that inflammation is one of the hallmarks of cancer (Hanahan
2000) that increase mutagenic alterations, persistent gonadotropins secretions in the
body even after menopause, along with any other potential source of inflammation are
thought to be carcinogenic and lead to the development of ovarian cancer.
Interestingly, a third hypothesis/theory has emerged in the last decade
implicating the fallopian tube as a potential source for serous ovarian adenocarcinoma.
Studies by Piek et al identified tubal intraepithelial carcinoma (TIC) in fimbriae from
patients who underwent elective bilateral salpingo-oophorectomy due to high risk of
ovarian cancer (Piek 2001). Furthermore, a study by Carcangiu et al identified
hyperplastic changes in prophylactically resected fallopian tubes of BRCA1 mutation
carriers (Carcangiu 2004). Furthermore, TICs are identified in more than 50% of cases
with ovarian cancer, beside shared mutations in TP53 of TICs and adjacent bulky ovarian
masses (Kindelberger 2007).
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Histopathology
As mentioned earlier, the majority of ovarian cancer cases are of epithelial
origins, therefore the discussion will be limited to the different histopathological types
of EOC. EOCs are divided into the following subtypes: serous, mucinous, endometrioid,
clear cell, transitional cell {Brenner typeL squamous and mixed epithelial based on their
resemblance to the epithelia neighboring the ovaries (Seidman 2002, Scully 1999) with
each of these subtypes further divided into benign, borderline and malignant. The most
important findings of the different EOC histological types are summarized in table 1.1
below.
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Histology
Serous
(benign,
malignant)

borderline

and

Endocervival. Forms largest ovarian tumors
with a median diameter of 18 to 20 cm
(Seidman 2002)

Endometrioid (benign, borderline and
malignant)

Endometrial.
Foci
of
endometriosis:
precursor lesions (Heaps 1990, McMeekin
1995). Better survival than serous (Storey
2008).

Mucinous
malignant)

(benign,

borderline

and

Characteristics
Endosalpingeal. 75% high-grade, 25% lowgrade (Ben-Baruch, 1996). Low-grade less
responsive to CRx (Schmeler 2008,
Gershenson 2009)

Epithelial-stromal and stromal
Clear cell
malignant)

(benign,

borderline

and

Transitional cell (benign, borderline and
malignant)

Mullerian. (Also called mesonephroid). May
arise from endometriosis (Scully 1998).
Lower response rate to platinum- and
taxane-based CRx (Behbakht 1998, Goff
1996)
Transitional. Benign - small solid masses
within stroma. Intermediate - multicystic,
low malignant potential. Both unilateral.
Malignant - atypical features and invasive
characteristics.

Non-Brenner transitional cell
Squamous cell tumors
Mixed epithelial (benign, borderline and
malignant)

Squamous
Mixed. Two or more distinct histologic
types. Presence of serous carcinoma or
sarcoma associated with poorer prognosis
(Brown 2004)

Undifferentiated
Unclassfied

Anaplastic
Mesothelioma, etc

Table 1.1 EOC types and significant findings
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Genetics of Ovarian Cancer/Dualistic model of ovarian carcinogenesis
According to Robert Kurman, director of the division of gynecologic pathology at
Johns Hopkins, EOC tumors are divided into types I and II based on the histological
presentation and molecular aberrations found (Shih 2004). Type I tumors tend to follow
an indolent course and develop gradually from precursor lesions, developing from
cystadenomas and adenofibromas, progressing to borderline malignancies then finally
becoming low grade tumors. They are also associated with several signaling pathways
and genetic mutations most noticeable of which are K-Ras and B-Raf mutations. In a
way, type I tumors are reminiscent of the

progression

model of colorectal

adenocarcinoma; unfortunately, they represent a minority of ovarian cancer cases (Shih
2004). Type II tumors, on the other hand, are more common and are associated with an
aggressive and fast course, which prevents the detection of precursor lesions if any. At
times, they are thought to develop de novo (Shih 2004). Unlike type I tumors, there are
no noticeable changes in signaling pathways, but TP53 mutations are observed in at
least 80% of cases and seem to present a unifying feature of type II tumors. The
following two tables (tables 1.2 and 1.3) summarize the main characteristics of these
two types.
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Type I tumors

Common
alterations

Low-grade serous carcinoma
(invasive MPSC)

BRAF or KRAS mutations

Mucinous carcinoma

KRAS mutations
8-catenin gene mutations
Microsatellite instability
lOH or mutations of PTEN
KRAS mutations
TGF-B RII mutation
KRAS mutations
Microsatellite instability

Endometrioid carcinoma

Clear cell carcinoma

molecular

genetic

Table 1.2 Type I EOCs and significant molecular changes. Adapted from Shih and
Kurman . Ovarian tumorigenesis: a proposed model ba sed on morphological and
molecular genetic analysis. Am J Pathol 2004.

Type II tumors

Common
alterations

High-grade serous carcinoma

p53 mutations
HER2/neu gene overexpression
AKT2 gene overexpression
Inactivation of p16 gene
p53 mutations

Malignant mixed mesodermal tumor
(carcinosarcomas)

molecular

Table 1.3 Type " EOCs and significant molecular changes. Adapted from Shih and
Kurman. Ovarian tumorigenesis: a proposed model based on morphological and
molecular genetic analysis. Am J Pathol 2004.

genetic
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Chemotherapy for epithelial ovarian cancer
The standard of care for patients newly diagnosed with EOC depends on the
stage of the disease upon presentation. 75% of patients are diagnosed at an advanced
stage, usually stage III (dissemination into peritoneal cavity or lymph node involvement)
or IV (disseminated to more distant tissues). For these patients, surgical debulking
followed by chemotherapy (taxanes and platinum compounds) remains the method of
choice (Young 1983). For the remaining 25% of patients (stages I and II, I being restricted
to the ovary while II is in the pelvic cavity), surgery alone is the main approach (Young
1990, Heintz 2006), with further chemotherapy indicated in high-risk stages I or II in
order to avoid relapse. Optimal debulking (residual tumors < 1cm) has been associated
with improved relapse rates (Herzog 2010) however the majority of these patients
develop recurrent refractory disease from which they ultimately die. In the following I
will discuss the two main anti-neoplastic agents employed for ovarian cancer and then
approach recurrent ovarian cancer and the different modalities used.
Platinum compounds
Before the

introduction

of platinum

compounds,

cyclophosphamide

and

doxorubicin were the drugs of choice for cancer patients. Serendipitously discovered to
have anti-growth effects (Rosenberg 1973, 1985), cisplatin represents the prototype of
platinum compounds. Cisplatin is composed of a platinum atom complexed to two
ammonia and two chloride atoms in a square planar geometry. Cisplatin inhibits tumor
cells growth and it has been postulated that the central platinum atom binds the DNA
forming diaminoplatinum adducts causing cross-links and disrupting the DNA structure
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(Huang 1994, McGuire 1998). Addition of cisplatin to the established chemo regimens
resulted in a substantial improvement in response rates (Omura 1986, Thigpen 1994).
Due to its undesirable side effects such as neurotoxicity, nephrotoxicity, ototoxicity and
gastrointestinal toxicity (Ozols 1984), chemical modifications of the cisplatin led to the
development

of several

other

platinum

compounds

including carboplatin

and

oxaliplatin. Carboplatin has equal efficacy to the parent compound (ICON2, 1998) with
lesser associated side effects, except for an increase in myelosuppression that can be
dose-limiting (Ozols 1989). Oxaliplatin is active in ovarian cancer and overcomes
cisplatin resistant tumors in vitro (Vaisman 1998). The main side effect of oxaliplatin is
the development of peripheral neuropathy that is cumulative and dose-limiting (Chollet
1996).
Taxanes
Paclitaxel represents the parent molecule in this family, and was first isolated
from the bark of the pacific yew tree Taxus bre/ivolia (Wani 1971). Paclitaxel works by
promoting microtubule formation, inhibiting the disassembly of J3-tubulin subunits,
leading to aberrant microtubules-derived structures and arrested mitosis (Rowinsky
1993). Chemically, it has a complex molecular structure and is currently obtained as a
semi-synthetic product from 10-desacetylbaccatin precursor extracted from the yew
tree leaves. Paclitaxel displays preference to malignant tumors of epithelial origin and
occupies a central role in the treatment of cisplatin-refractory ovarian cancer (Rowinsky
1995). Modification of two side chains on paclitaxel led to the development of
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docetaxel, with enhanced clinical response in the therapies of ovarian and breast
cancer.
Recurrent epithelial ovarian cancer
Currently, 70-80 % of patients with ovarian cancer are detected at an advanced
stage, usually III or IV, with a recommended management of cytoreductive surgery
followed by combination chemotherapy of platinum compounds and taxanes. Unlike
other types of cancer, where diagnosis at an advanced stage deters surgery, the
combination of surgery and chemotherapy has shown an advantage over chemotherapy
alone, leading to remission in around 80% of cases (NIH Consensus Conference 2005).
Unfortunately, relapse rates are as high as 90%, and cancer resurges with the added
disadvantage of drug resistance. The decision for managing these patients depends on
their response to the first-line treatment (Thigpen 1993), which leads to categorizing
patients into platinum-sensitive and platinum-resistant. While platinum-sensitive
patients usually have a very favorable response to platinum in their first round of
chemotherapy,

platinum-resistant patients have the following characteristics: i.

platinum-refractory phase, where patients progress while on platinum therapy ii. at best
these patients have a stable response while on their first round of chemotherapy and iii.
they tend to relapse less than six months following the completion of the first round of
therapy (Herzog 2010). Unfortunately, the response of this category to second-line
platinum therapy is dismal and these patients are usually treated with non-cross
resistant anti-neoplastic agents. Additionally, since a cure is almost unattainable, and to
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preserve a decent quality of life for these patients, palliative therapy is more common
than an aggressive regimen that has no obvious benefit.
In the platinum-sensitive category, a higher treatment-free interval is associated
with a better outcome and helps in the decision of the second-line regimen. A phase II
study showed that addition of platinum compound (cisplatin) to cyclophosphamide and
doxorubicin regimen has a better response than the single agent paclitaxel in treatment
of recurrent EOC (Cantu 2002) and a recent randomized phase III trial showed an
advantage of combination of carboplatin and Qegylated !iposomal doxorubicin (PLD) to
carboplatin alone (59 vs. 28 percent) in recurrent ovarian cancer treatment (Markman
2010). Additionally, it was found in the same study that the combination of carboplatin
with PLD is associated with lesser alopecia and chronic neurotoxicity as well as
decreased

hypersensitivity

due

to

fewer

infusion

reactions

compared

to

the

combination of paclitaxel and carboplatin. Altogether, promising outcomes are expected
in combination therapy as a second-line treatment, demonstrating the efficacy of
inclusion of platinum compounds in the regimens. In the following, a brief overview of
the chemotherapeutic agents under investigation in the second-line management of
EOC, especially non-platinum non-taxane cross-resistant, is provided.
Etoposide belongs to the family of podophyllotoxins that inhibit topoisomerase II
causing DNA strands breaks. Oral etoposide offers an advantage in regimen scheduling
compared to intravenous administration and causes a 27% response rate in platinumresistant patients (Slayton 1979). Toxicity includes myelosuppression (neutropenia) and
gastrointestinal symptoms (nausea and vomiting) (Rose 1998). Because of its highest
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response rate compared to other antineoplastics, it is currently employed as the firstline of therapy of recurrent EOC after failure of platinum and taxane therapies.
Doxorubicin is an anthracycline antibiotic obtained from Streptomyces peucetius.
The quinone and hydroquinone moieties allow for electron transfers promoting
formation of free radicals. Several mechanisms have been proposed to explain
doxorubicin actions including: DNA intercalation, topoisomerase II inhibition and
formation of free radicals, all of which lead to destruction of DNA integrity. A pegylated
liposomal formulation of doxorubicin is employed in the treatment of EOC, and a 17%
response rate is observed with PLD monotherapy in platinum- and taxane-resistant EOC
(Lorusso 2004, Thigpen 2005). Major toxicities are stomatitis and "hand-and-foot"
syndrome.
Topotecan is a camptothecin analog that acts by inhibiting topoisomerase I and
is active against both platinum-sensitive and -resistant cancer. Myelosuppression is a
dose-limiting toxicity (neutropenia). Compared to PLD, topotecan has a similar response
rate (Gordon 2001); however the myelosuppression induced by topotecan favors PLD.
Gemcitabine is a fluorinated analog of cytidine that acts an inhibitor of DNA
synthesis during the S phase. Upon conversion to di- and tri-phosphate metabolites} it
prevents the incorporation of dNTPs into the nascent DNA. The tri-phosphate
metabolite is also incorporated into the DNA causing chain termination. In treatment of
recurrent EOC} gemcitabine is active against both platinum- and taxane-resistant disease
(Markman 2003} Rose 2003). Compared to PLD} no difference in response rate is
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observed (Mutch 2007); however due to lesser cytotoxicity, it represents a tolerable
alternative to PLD in women with platinum-resistant EOC.
Vinorelbine is a semi-synthetic analog of vinblastine, a vinca alkaloid. Vinca
alkaloids are mitotic spindle inhibitors and act by binding tubulin and preventing
polymerization. Response rate to vinorelbine in EOC-patients refractory to platinums
has been variable with no obvious advantage (Bajetta 1996, Burger 1999 and
Rothenberg 2004).
Ifosfamide is a nitrogen mustard prod rug that is converted enzymatically in the
liver to its active electrophilic metabolite which attacks the N7 nitrogen of guanine,
forming covalent bonds resulting in DNA cross-linking. In treatment of recurrent
platinum-resistant EOC, ifosfamide is moderately active (Baur 2006). Toxicity includes
hematologiC, renal and central nervous system such as disorientation, hallucinations,
somnolence and agitation (Herzog 2010).
Pemetrexed is an antifolate prodrug metabolized to its active polyglutamate
forms which inhibit THF4-dependent enzymes. Pemetrexed monotherapy showed a 21%
response rate in platinum-resistant EOC despite the severe toxicity that could be
associated with its administration (Vergote 2009) and folic acid and vitamin B12 are
required supplements during treatment.
Anti-hormone therapy, similar to that used with other hormone-dependent
cancers like breast and prostate, has been tested in ovarian cancer using tamoxifen - a
selective estrogen receptor modulator - , and letrozole and anastrazole- aromatase
inhibitors. Several trials and one meta-analysis showed that the response to hormone
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therapy in ovarian cancer is, at best, modest (Williams 2001, Smyth 2007 and Argenta
2009)
Bevacizumab is a humanized vascular endothelial growth factor (VEGF) monoclonal antibody. Several phase II trials showed improved response rates in
combination with other chemotherapeutic agents (Burger 2007, Cannistra 2007, Chura
2007, Micha 2007, Spannuth 2008), however, the high potential for GI perforation keeps
it as a last-line of treatment (3 rd ,

4th

th

or even 5 -line of treatment).

Intraperitoneal chemotherapy can provide, theoretically, a several fold increase
of drug concentration at the site of a tumor with the feasibility of overriding systemic
toxicity. Its role in ovarian cancer therapy remains controversial as it hasn't produced an
advantage over intravenous therapy (Markman 1991) and has been limited to
microscopic rather than macroscopic disease (Feun 1998, Berek 1999). Further clinical
trials are needed in order to establish the true role of IP therapy.

Ovarian Cancer and Intracellular Signaling
As in many cancers, several signaling cascades are altered in ovarian cancer
leading to the different pathological phenotypes expressed by these cells. ERKjMAP
kinase and PI3KjAkt pathways have both received special attention in ovarian cancer for
their involvement in survival, development, differentiation and migration, among other
functions. In fact, Ras or B-Raf activating mutation occur in two thirds of low grade
ovarian tumors and 16% of high grade tumors (Singer 2003

alb, Ho 2003). Additionally,

activation of ERK/MAP kinase has been observed in 80% of low grade ovarian tumors

28

and 40% of high grade tumors (Hsu 2004) indicating the existence of mechanisms,
different than upstream Ras or Raf mutational activation, responsible for elevated
signaling through this pathway and pointing to its importance in ovarian tumors. In this
dissertation I will focus on the MAP kinase pathway and provide a summary of the major
components of this cascade, as well as the therapeutic strategies targeting this pathway.

MAP Kinase pathway
The discovery of the MAP kinase pathway (Fig 1.1) in the lab of Tom Sturgill
(Rossomando 1989) about 20 years ago, marked a breakthrough in the field of signal
transduction. The MAP kinase pathway was initially described as a linear cascade of
sequentially activated protein kinases with "Iittle or no cross-reactivity" and the
namesake MAP kinase as a "unifying explanation of most, if not all, nonnuclear
oncogenes" (Seger 1995). Our view of the pathway has changed and evolved over the
last twenty years with increasing complexity and cross-talk between the different
signaling cascades; however, the linear representation of the pathway remains the best
start to examine and understand its different details. In its simplest topology, the MAP
kinase pathway is a sequentially activated pathway of three conserved protein kinases
that convey an extracellular signal in the form of phosphorylation events (Tanoue 2003).
Four pathways have been well described in mammalian cells: ERK1/ERK2, p38a/~/v/{j,
JNK1/2/3 and ERK5 MAP kinase pathways. ERK pathways are preferentially activated by
growth factors, phorbol esters and adhesion, while JNK and p38 MAP kinases are
preferentially activated by cytokines and stress. In response to these extracellular cues,
receptor tyrosine kinases, G-protein coupled receptors and integrin receptors recruit a
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small GTP-binding protein to the cell membrane (Ras superfamily) that recruit a MAP3K,
the first

kinase

in

the

cascade.

Activated

MAP3K

leads

to

the

sequential

phosphorylation, and thereby activation, of MAP2K and finally the namesake MAPK that
phosphorylates a plethora of targets across the cell, from the cell membrane to the
nucleus. In the following, we will focus on the ERK1/2 MAP kinase pathway and then
briefly discuss JNK and p38 MAP kinase pathways.
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Fig 1.1 Ras-MAP kinase pathway A simplified and linear overview of the ERK/MAP
kinase pathway topology.

31

Ras belongs to a family of small G-proteins that alternate between an inactive
GDP-bound and an active GTP-bound state (Shih 1980) due to an intrinsic GTPase
activity. Transmembrame

receptor activation

by extracellular stimuli

induces

a

conformational rearrangement that recruits the molecule adapters Grb2, Shc and
guanine-nucleotide exchange factor SOS which in turn binds and recruits Ras to be
activated at the cell membrane (Olivier 1993, Rozakis-Adcock 1993, Buday 1993 and
Egan 1993). An intricate interplay between guanine-nucleotide exchange factors (GEFs),
GTPase-activating proteins (GAPs) and guanine nucleotide dissociation inhibitors (GDls)
is believed to have a major role in activating Ras (reviewed in Konstantinopoulos 2007).
Four main isoforms of Ras have been described: K-Ras4A, K-Ras4B, H-Ras and N-Ras.
Except for the C-terminal 23-24 amino acids, known as the hypervariable region (HVRt
all isoforms share a near identical homology (Dhar 1982, Tsuchida 1982, Shimizu 1983).
Ras proteins are subject to lipid modifications in their C-termini (prenylation and
palmitoyilation) that target the proteins for cell membrane anchoring and subsequent
activation (Sefton 1982, Casey 1989, Hancock 1989). It is also believed that lipid
modifications of Ras target it for microlocalization on the cell membrane (Boyartchuk
1997, Prior 2001).
Among the first evidences into the role of Ras in cancer is the finding of its ability
to mediate cellular transformation in NIH 3T3 cells (Ellis 1981). In 1982, Channing Der
showed an elevated expression levels of K-Ras and H-Ras in human bladder and lung
carcinoma cell line and identified their role in transforming cells (Der 1982) while Luis
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Parada, then in the lab of Bob Weinberg, demonstrated H-Ras as the oncogene in EJ
human bladder carcinoma (Parada 1982). Further studies demonstrated Ras to be
activated in about 30% of all human cancers, with the highest activation observed in
pancreatic cancer (90%) - arguably the worst kind of cancers -, in colon and thyroid
(SO%)} in lung cancers (30%) (Malurnbres 2003). Elevated Ras activation in cancer can be
attributed to two main processes: i. activating mutations and ii. continuous Ras
activation via upstream stimulation. Concerning the former, several Ras mutations have
been described in a variety of diseases; however mutant K-Ras genes encoding proteins
harboring the single amino acid mutation at G12 or Q61 (or their homologs on the other
Ras isoforms) are reserved for cancer cells (Taporowsky 1983, Shimizu 1983 and Fasano
1984). Ras G12/Q61 are GAP-insensitive therefore they maintain a GTP-bound state and
remain activated in a stimulus-independent manner (Adari 1988). Alternatively, Ras is
activated by aberrant upstream stimulation. For instance} several receptor tyrosine
kinases (RTKs) such as EGFR and ErbB2 are either overexpressed or mutationally
activated in several human cancers leading to subsequent Ras-Raf-MEK-ERK activation
(Lynch 2004} Stephens 2004 and Grandis 2004). Additionally, continuous Ras activation
leads to transcriptional activation of transforming growth factor a (TGF a), heparinbinding-EGF and amphiregulin (McCarthy 1995, Gangarosa 1997 and Schulze 2001)
which are natural EGFR ligands leading to a positive feedback loop activation of Ras/ERK
pathway.
While the Raf-MEK-ERK axis is the main effector target of Ras activation, other
pathways can be induced by Ras activation. In particular, PI3KjAkt, Tiam1jRac, RalGDS
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and PLCE are additional pathways activated by oncogenic Ras and have a strong impact
on tumorigenesis {reviewed in Repasky 2004, Shaw 2006}. Accordingly, targeting the
Ras/ERK pathway for inhibition might not suffice for a complete abrogation of Ras
oncogenic effects. Alternatively, developing specific inhibitors for ERK targets might
represent a more efficient strategy in inhibiting Ras/ERK-mediated effects in cancer.
Further discussion on different inhibitors of the Ras/ERK cascade is provided later in this
chapter.
Raf
The regulation of the MAP kinase pathway at the Raf level is very complex and
remains under extensive investigation. Raf is a serine/threonine (S/T) kinase that exists
under 3 main isoforms: A-Raf, B-Raf and Raf-l (or C-Raf). Activation of Ras at the cell
membrane initiates a complex series of phosphorylations and dephosphorylations of Raf
where it constitutes a relay for several pathways like PI3K/Akt, Src, PKA, PKC and PP2A
(reviewed in McCubrey 2006), self-dimerization or heterodimerization with the Raf-like
protein kinase-suppressor of Ras (KSR) (Xing 1997), and association/disassociation with
scaffolding proteins like HSP90 and RKIP (Blagosklonny 2002, Corbit 2003). Of the three
isoforms, B-Raf is mutated most in cancer cells; more than 30 mutations of B-Raf,
clustered within the kinase's activation loop and P-Ioop, have been reported (Wan
2004). Interestingly, B-Raf(V599) is the most common mutant isoform and its basal
kinase activity exceeds 400-folds that of the wild type kinase (Wan 2004) leading to a
sustained ERK/MAP kinase pathway activation independent of Ras and Src function
(Marais 1997, Brose 2002 and Davies 2002). Also, Src-dependent activating residues on
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Raf-l and A-Raf are replaced by the negatively charged aspartic acid residues, mimicking
a continuously phosphorylated enzyme and giving B-Raf a higher basal activity to
activate MEK/ERK than A-Raf or RAf-1 (Marais 1997). B-Raf mutations are reported in up
to 70% of melanomas, 50% in thyroid cancer, 22% in colon cancer and 30% in ovarian
cancer (Davies 2002, Garnett 2004 and Libra 2005). It is interesting to notice that, in
ovarian cancer, K-Ras and B-Raf mutations are mutually exclusive (Singer 2003) as either
mutation is sufficient for

Raf-MEK-ERK activation. The exact role of B-Raf in

tumorigenesis remains to be determined as introdUCing B-Raf mutants into cells does
not initiate neoplastic transformation and hence a maintenance role for B-Raf is
predicted in these cancers (Rajagopalan 2002, Vuen 2002).
MEK
MAP/ERK kinase (MEK1/2) is the direct activator of ERK/MAP kinase. It is a dual
specificity tyrosine and serine/threonine (V/5/T) kinase (Alessi 1994) that is activated by
Raf upon phosphorylation on S218 and S222 (or 5er217 and Ser221) (Alessi 1994). MEK
is also phosphorylated on 5298 by PAKl in order for Raf to phosphorylate MEK in
response to integrin adhesion (Coles 2002, Slack-Davis 2003). MEK is inhibited by a
negative feedback phosphorylation on T292 by ERK (Brunet 1994b, Eblen 2004). In the
ERK/MAP kinase pathway, MEK targets a unique substrate, namely ERK1/2 (Crews
1992). This feature in the ERK pathway allows for specific inhibition of ERK by
pharmacologically targeting its upstream activating kinase MEK1/2. Interestingly, unlike
Ras and Raf, there are no known activating mutations of MEK in cancer. However,
mutation of Ser218/222 in MEK1 to Asp or Glu generates a constitutively active MEK1
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that is oncogenic in fibroblasts (Brunet 1994a). Recently, mutations on F35S and Y130 in
MEK1 and F57C in MEK2 have been identified as part of the cardio-facio-cutaneous
syndrome (Rodriguez-Viciana 2006), but have no implications on cancer. Also, a recent
activating mutation of MEKl (F129L) has been identified and is proposed to impart an
acquired resistance to MEK inhibitors (Wang 2011).
In resting cells, MEKs are known to localize to the cytoplasm due to a nuclear
export signal (NES) on their N-termini (Fukuda 1996, Jaaro 1997). Additionally,
interactions with scaffolding proteins and cytoplasmic anchors such as MP1, KSR1, Sefl
and paxillin confine MEKs to endosomes, the plasma membrane, outer Golgi membrane
and cytoskeleton, respectively (Shaeffer 1998, Kornfeld 1995, Therrien 1995, Torii 2004
and Ishibe 2003). More recently, MEKs were shown to localize to the mitochondrial
membranes and lumen (Poderoso 2008), however the significance of this localization
remains poorly understood. Although mainly localized to the cytoplasm, MEKs are
subject to continuous and rapid shuttling in and out of the nucleus in response to
stimulation (Jaaro 1997, Tolwinski 1999 and Yao 2001). In the nucleus, MEKs interact
with inactivated ERKs through their 0 and CD domains (described below) and are
subsequently exported via the NES/exportin system into the cytoplasm (Adachi 2000). In
that regard, MEKs explain the transport process for ERK out of the nucleus and provide a
cytoplasmic anchor for inactive ERKs.

ERK represents the last tier in the core MAP kinase pathway. Two isoforms of
ERK exist, ERKl (p44 MAPK; 44 KDa) and ERK2 (p42 MAPK; 42 KDa) with 83% amino acid
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homology (Owaki 1992). Additionally, two additional splice variants of ERK1 have been
described. The first, ERKlb, is a 46 KDa protein with a 26 amino acid insertion between
residues 340 and 341 of ERK1 and expresses similar kinetics of activation to the main
ERK isoforms, however with a tissue specific distribution and higher response to osmotic
stress

(Boulton 1991, Yung 2001). The second splice variant is ERK1c, a 42 KDa protein

with slower kinetics than ERK1/2, and displays high density in the Golgi apparatus where
it is implicated in Goigi fragmentation (Aebersold 2004, Jesch 2001).
ERK1/2 are activated by phosphorylation of the TEY motif (202/204 or 185/187)
by the dual specificity kinase MEK (Boulton

1991). As an enzyme,

ERK is a

serine/threonine kinase and phosphorylates a plethora of substrates distributed around
the cell, from the cell membrane (CD120a, calnexin), to cytoskeletal proteins and
kinases (neurofilaments, paxillin, RSK, MSK), all the way to transcription factors in the
nucleus (SRC-1, Elk1, MEF2, c-Fos, c-Myc, STAT) (reviewed in Yoon 2006). To date, more
than 160 substrates of ERK have been reported, mediating its diverse functions in
cellular proliferation, development and migration. Obviously, such a diverse response
from ERK activation requires a tight control of substrate phosphorylation in order to
maintain

a

high

fidelity

signal.

Regulation

through

kinases

scaffolds,

protein

phosphatases and localization represent the major routes to reach this end.
ERK1/2 are predominantly located in the cytoplasm of quiescent cells and
translocate to the nucleus upon activation. In the cytoplasm of resting cells, around 50%
of ERKs are bound to microtubules (Reska 1995). ERK1/2 also localize to focal adhesions
and adherens junctions where they are necessary for paxillin phosphorylation during cell
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migration (Ishibe 2003). Three mechanisms have been elucidated describing ERK1/2
nuclear translocation through the nuclear pores: i. passive diffusion of a monomer, ii.
active transport of an ERK1/2 dimer (both phosphorylated and unphosphorylated) and
iii. nuclear pore complex (NPC)-mediated translocation via active, cytosol- and ATPindependent mechanisms (Khokhlachev 1998, Adachi 2000, Matsubyashi 2001 and
Whitehurst 2002). As it doesn't have either a nuclear localization (NLS) or export signals
(NES) of its own .. ERK is anchored in the cytoplasm by binding the N-terminus of MEK1/2
(Fukuda 1996) which is disrupted upon ERK1/2 phosphorylation, inducing ERK1/2
translocation to the nucleus {Fukuda 1997}. ERK1/2 is dephosphorylated in the nucleus
by MAP kinase phosphatases (MKPs), which causes its association with MEK1/2 for
shuttling back to the cytosol (Tanoue 2000).
When localized to the nucleus, ERKs are kept under tight spatiotemporal control

by several molecules that act as scaffolds, which act to anchor kinases within close
proximity in certain areas of the cell in a way to achieve localized response in a stimulusspecific manner and integrating different signals within controlled microdomains (Elion
2001, Kolch 2005). Several cytoplasmic scaffolds have been identified, including KSR,
MP1, ~-arrestins and Sef. KSR interacts with Raf-1, MEK1/2 and ERK1/2 and is
translocated with MEK1/2 to the plasma membrane, bringing the Raf-MEK-ERK in close
proximity for increased signaling efficiency (Sundaram 1996, Therrien 1996). MPl binds
to MEK1/2 and ERK1/2 in endosomes, enhancing their interaction and ERK1/2 signaling
in response to EGF (Schaeffer 1998, Teis 2002). B-arrestins improve Raf-MEK-ERK
signaling in endosomes downstream of G protein coupled receptors (Luttrell 2001) and
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Sef colocalizes with active ERK1/2 and MEK1/2 on Golgi membranes, preventing
signaling to the nucleus (Torii 2004). Altogether, these molecules provide examples of
regulation and control of ERK signaling through ERK localization.
Phosphatases also control ERK signaling and play an essential role in positive and
negative regulation of ERK signal propagation. Similar to MAP kinases, phosphatases are
also governed by localization-mechanisms within the cell, hence they convey their
effects in a stimulus- and spatial distribution-dependent manner. Protein phosphatase
2A PP2A binds KSR and dephosphorylates it along with Raf-l, removing an inhibitory
phosphorylation on the latter and allowing Ras-Raf activation in response to growth
factor stimulation (Dougherty 2005). The nuclear phosphatase DUSPs is a specific ERKphosphatase and behaves as an inhibitor of the kinase but also as a nuclear anchor
{Mandl 2005}. Phosphatases are also regulated by phosphorylations in the vicinity of the
ERK

interaction

region.

Hematopoietic

protein

tyrosine

phosphatase

{He-PTP}

dephosphorylates ERK1/2 only when an inhibitory phosphorylation on Ser23 in the 0domain

is

removed

(Gjorloff-Wingren

2000).

STEP,

a striatal

neuron

specific

phosphatase, dephosphorylates ERK1/2 in response to NMDA receptor activation, which
activates calcineurin to dephosphorylate and subsequently activate STEP (Paul 2003).
Phosphatases are diverse and represent a crucial level of regulation and maintenance of
a high fidelity signal transducing extracellular cues, their discussion is however beyond
the scope of this work.
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Docking interactions: D~ DfF and CD motifs

Since all MAP kinases share a common substrate consensus sequence, separate
motifs within the different proteins, both enzymes and substrates, are necessary to
achieve a higher fidelity of binding and phosphorylation. Four motifs have been
described: 0, DEF, CD and ED motifs. The D-domain consists ot a cluster of basic
(positively charged) residues in the vicinity of an lXL motif, either upstream or
downstream of the phosphorylation site (Yang 1998). D-domains are thought to
enhance substrates recognition and to improve signaling specificity. They have been
described in MAP kinase regulatory proteins, such as MAPKKs (MEK1/2), phosphatases
(STEP, MKPs) and scaffolding proteins (KSR) and are believed to enhance the
propagation and regulation of the signal specificity and fidelity similar to MAP kinase
substrates (reviewed in Enslen 2001). The DEF motif (Docking site for ERK and £XFP)
forms another class of interacting domains: the (F/Y)X(F/Y)P sequence is found in
several transcription factor substrates of ERK1/2 across different species and is believed
to be an ERK specific sequence (Jacobs 1999). The FXFP motif tends to be C-terminal to
the phosphoacceptor site, and it is not mutually exclusive from the D-domain; in fact,
together (such as in Elkl and KSR) they strengthen substrate recognition and binding
(Jacobs 1999, Fantz 2001, Murphy 2002). While the DEF interacting module on ERK has
not been identified yet, hydrophobic sequence in and downstream of the common
docking {CD} motif has been shown to mediate ERK, p38 and JNK interactions with the
D-domains (Rubinfeld 1999, Tanoue 2000). It is separate from the kinase active site but
lies in its vicinity, and consists of a cluster of acidic residues (negatively charged)
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surrounded by hydrophobic residues (Rubinfeld 1999 and Tanoue 2000) mediating
electrostatic and hydrophobic interactions with the D-domain residues, respectively. Fig
1.2 below depicts ERK domains discussed above.
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Fig 1.2 Crystal structure of inactive ERK2 bound to ATP, above, was resolved in the lab

of Elizabeth Goldsmith {Zhang 1994}.
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P38 MAP kinase module
Similar to the ERK/MAP kinase pathway, the p38 pathway is a three-tiered
cascade (Han 1994, Lee 1994) consisting of several MAP3Ks including MEKK1/2/3/4,
MLK2/3, ASK1 and TAK1 that are activated in response to environmental stresses such
as UV irradiation, osmotic pressure, oxidative stress, ischemia and inflammation along
with its cytokines such as Il-1 and TNFa (reviewed in Roux 2004). Consequently,
MAP3Ks phosphorylate the dual specificity kinases MAP2Ks, MKK3 and MKK6, to finally
activate the four isoforms of p38a/~/v/o MAP kinase (Han 1993, 1994, Freshney 1994,
Rouse 1994, Lechner 1996). P38 is a serine/threonine kinase and is activated by
phosphorylation on the TGY motif in its activation loop (Han 1995, Wang 1997).
Structurally, p38 shares around 50% homology with ERK, however, it differs in the
length of its activation loop suggesting a potential explanation for the discrepancy of
substrate specificity (Wilson 1996). Similar to ERK, p38 substrates are found around the
cell (Raingeaud 1995, Ben-Levy 1998). P38 is strongly involved in immune and
inflammatory processes and is activated in macrophages and neutrophils (Dna 2000).
Accordingly, it is not surprising that several p38 inhibitors in development are being
targeted towards autoimmune and inflammatory diseases. P38 inhibitors are discussed
later in this chapter.
JNK module
In the same pattern as ERK and p38, the JNK subfamily is a three-tiered cascade
that shares similar activating stimuli with p38 MAP kinases. Environmental stresses and
inflammation are the main activators of the pathway which is commonly turned on with
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p38 by phosphorylating MEKK1/2/3/4, MLK2/3, ASKl and TAKl but also separately by
activating TAO-l/2 and ASK2 (reviewed in Bogoyevitch 2010). At the MAP2K levet MKK4
and MKK7 mediate the upstream signal to phosphorylate JNK1/2/3 on the TXY motif
where X is a proline. MKK4 also phosphorylates p38 in some cell types, suggesting a role
for MKK4 in integrating signals from two pathways activated by similar cues (Derijard
1995). Although it is localized throughout the cell, JNK is involved in the phosphorylation
and activation of transcription factors such c-jun, ATF-3, STAT-3 and HSF-l. Despite the
fact that JNK shares a similar implication in inflammation as p38, more inhibitors of the
latter managed to reach clinical trials (Roberts 2007).
Pharmacological inhibition of MAP kinases
Due to their centrality to oncogenic and mitogenic extracellular signals, the MAP
kinase pathways have been

under extensive investigation for pharmacological

inhibition, with Ras/Raf/MEK/ERK and p38 MAP kinase cascade being the most alluring
targets for intervention. The majority of inhibitors are discovered by in vitro screens of
protein kinases or in cells assays, and have focused on exploiting the ATP-binding
domain of protein kinases, to generate ATP-mimetic molecules that work by competitive
ATP inhibition. A major drawback of this approach is the non-specific inhibition of other
kinases since most of these proteins share a similar topology like the one described
above for ERK. Pharmacological inhibitors have been synthesized to inhibit the pathway
at each tier of the canonical sequence Ras~MAP3K~MAP2K~MAPK.
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Inhibitors oj Ras
Ras mutations are common in several cancers, including pancreatic, colon, lung,
gall bladder and thyroid cancer (Rowinsky 1999) and altogether account for 30%
mutations in human cancer (Bos 1989). Ras inhibitors have focused on a common
property to all Ras isoforms - the CAAX box (Giehl 2005, Roberts 2007). The CAAX box is
a common motif in the hypervariable region of Ras proteins that is subject to lipid
modification responsible for anchoring the proteins to the cell membrane. Prenylation
(addition of farnesyl group) is the most common modification to the (-terminus of Ras.
Targeting farnesyltransferase for inhibition, the enzyme that catalyzes this modification,
is the main approach followed to inhibit Ras anchoring to the cell membrane; however,
the discovery that K-Ras is the most commonly mutated isoform in cancer decreased the
interest in FTls because K-Ras undergo geranyl geranylation, another lipid modification
that compensates for the loss of farnesylation (Adjei 2001, Rajagopalan 2002).

Inhibitors oj Raj
Raf, a serine/threonine kinase that occupies the middle tier of the canonical
ERK/MAPK pathway, is under extensive regulation by no less than 13 regulatory
phosphorylations (Steelman 2004), which makes it an important crossroad for several
signaling pathways. Raf is heavily involved in cancer, and is reported to be mutated
(mainly B-Raf) in approximately 30% of solid cancers (Bos 1989) making it a valid to
target Raf for inhibition. The first successful inhibitor of Raf to reach clinical trials is
BAY439006, also known as Sorafenib, a small molecular weight inhibitor shown by
crystallographic data to bind an overlapping region of the ATP-binding domain on Raf
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and interestingly, the mechanism of inhibition is non-ATP competition (Wan 2004).
However, like most kinase inhibitors targeting the ATP-binding domain, Sorafenib shows
a promiscuous behavior towards other kinases, mainly receptor tyrosine kinases like
VEGFR-2/3, PDGFR-~, c-KIT and FGFR-1 (Wilhelm 2004). Sorafenib is currently exploited
in several clinical trials for its RTK inhibitory effects, however, the crystallographic
resolution of B-Raf led to the development of more specific inhibitors, such as PLX4032,
which is currently showing promising Raf inhibition in Phase I melanoma clinical trials
(Wellbrock 2010).
Inhibitors of MEK
Other than an enhanced activity in several types of cancer, MEK has not been
shown to be overexpressed or mutated in cancer (Hoshino 1999). Arguably, targeting
the ERK/MAP kinase pathway at the MEK level is perhaps the most effective route to
achieve strong ERK inhibition as MEK and ERK represent a unique feature among protein
kinases: one enzyme-one substrate duo (Seger 1992). PD98059 and U0126 are two small
molecule inhibitors of MEK1/2 identified by in vitro and cell-based screen for inhibitors
of ERK activation, respectively (Dudley 1995, Favata 1998). Both inactivate MEK by
allosteric interactions, non-competitive with ATP-binding (Davies 2000). Another family
of MEK inhibitors is identified from microbial extracts. This discovery led to the
development of two small molecules, Ro092210 (Williams 1997) and L783277 (Zhao
1999) that contain an active ketone moiety shown to inhibit MEK1/2 competitively with
ATP. Currently, several MEK inhibitors are in clinical development including AZD8330,
GSKl120212, and R05126766. Recently, AZD6244 (Selumetinib), a non-ATP competitive
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MEK inhibitor has shown promising results in phase II clinical trials of colorectal,
hepatocellular, non-small-cell lung, and melanoma tumors (Davies 2007, Hersey 2009,
Hainseworth 2010 and Bennouna 2010).

Inhibitors of JNK and p38 MAP kinase
P38 has received the most extensive attention among the MAP kinases from the
pharmaceutical industry due to its involvement in inflammatory diseases and several
inhibitors have entered clinical trials for rheumatoid arthritis and psoriasis (Lee 2000). In
fact, p38 inhibitors have shown promising efficacy in animal models as well as clinical
trials of arthritis and inflammatory lung disease such as: rheumatoid arthritis (e.g.

vx-

745, Scio-469, Ro-320-1195), psoriasis (e.g. HEP 689), COPD (e.g. GSK-681323) and
Crohn's disease (e.g. GSK-681323, RWJ-67657). Equally, several JNK inhibitors are also
developed and their involvement in the therapy of inflammatory diseases exceeds their
use in cancer. Examples of JNK inhibitors currently in clinical trials include CC-401, CNI1493 and CEP-1347. The list of kinase inhibitors is extensive and is beyond the topic of
this dissertation; the reader is directed to the following reviews for further information
concerning these pharmacological agents (Adcock 2006, English 2002).

Pre-mRNA Splicing and Alternative Splicing
Eukaryotic genes almost entirely consist of interrupted coding nucleotide
sequences called "exons" and non-coding sequences called "introns".

Pre-mRNA

splicing is the molecular process that leads to intron removal and subsequently, ligation
of exons to form the mature messenger RNA (mRNA) which is transported to the
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cytoplasm for translation and protein synthesis. The general mechanism of intron
removal and exon ligation has been well characterized in its broadest terms. It consists
of a sequential formation of a multiprotein-nucleic acid complex known as the
spliceosome followed by a stepwise removal of the two intronic borders. Nearly all
introns are flanked by a GU dinulceotide at the 5' splice site (ss) and an AG dinucleotide
at the 3' splice site (Grabowski 1984, Krainer 1984, Ruskin 1984). The 3' ss is preceded
by a polypyrimidine tract that separates it from an important adenine known as the
branching point in the branching point sequence (BPS) essential for the first catalytic
step (Padgett 1984).
An efficient and precise splicing reaction requires the exact recognition of the
borders of each intron/exon, a process accomplished by the spliceosome. The latter is a
large complex, consisting of 5 small nuclear ribonucleoproteins (snRNPS, U1, U2, U4/U6
and US) and more than 150 associated auxiliary proteins that coordinate the efficient
binding and recognition of the splice sites, as well as catalyzing the trans-esterification
reactions. As the spliceosome assembles, U1 binds to the 5' splice site while splicing
factor 1, SF1 (also known as mammalian branch point binding protein mBBP) binds the
adenine in the branch-point sequence (BPS), forming the E' complex (Michaud 1991). E'
complex is converted to the E complex by binding of the U2snRNP auxiliary factor
(U2AF) to the polypyrimidine tract and the 3' splice site via the 65KDa and 35KDa
subunits, respectively (Seraphin 1989, Michaud 1993). U2AF facilitates U2snRNP
recruitment to the adenine in the BPS replacing SF1 in the first ATP-dependent step of
the spliceosome formation (Frendewey 1987, Konarska 1987, Jamison 1992) forming
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complex A and inducing a conformational rearrangement facilitating the recruitment of
the tri-snRNP US/U4/U6 (Konarska 1987, Cheng 1987). US binds the upstream exon at
the 5' splice site while U6/U4 binds U2 forming complex B1, which is rapidly replaced by
complex B2 upon U1 release and U5 and U6 binding the 5' intronic splice site (Cheng
1987, Lamond 1988). Extensive remodeling and rearrangements lead to the formation
of the catalytic C complex. At this point, U4 is released, the spliceosome is fully mature
and intron splicing occurs via a stepwise two trans-esterification reactions. The
phosphodiester bond at the 5' splice site is cleaved by a nucleophilic attack of the 2'-OH
of the adenine (A) at the BPS resulting in two intermediates, the upstream exon with a
free 3'-OH on a guanosine and a lariat structure consisting of the downstream exon and
the intron coiled on itself by 2', S'-phosphodiester bond. The free 3'-OH on the
upstream exon subsequently liberates the lariat intron by another nucleophilic attack in
a 3' ,5'-phosphodiester bond on the 3' splice site leading to the release of the lariat
intron and ligation of the upstream and downstream exons. This process continues on
all intronic sequences until the mature mRNA is formed and ready for translation. The
different steps in spliceosome assembly are depicted in Fig 1.3 and the two nucleophilic
transeterification reactions are depicted in Fig 1.4.
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Fig 1.4 Double transeterification reactions and intron excision In the 1 reaction, the
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2' -OH group of the BPS Adenine cleaves the phosphodiester bond at the 5' ss. In the 2
reaction, the 3' -OH on the free upstream exon cleaves the lariat intron and joins the
nd
downstream exons at the 3'ss by a 2 nucleophilic attack.
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Alternative splicing
Alternative splicing is the process of generating two or more transcripts of the
same gene from a common pre-mRNA sequence. In eukaryotes, alternative splicing is a
common mechanism for generating a wide array of protein products involved in diverse
cellular functions that range from sex determination to growth, differentiation and even
apoptosis. It has been estimated in the recent literature, based on bioinformatics
analysis of expressed sequence tags (ESTs) and cDNA datasets, that 95-100% of premRNAs undergo alternative splicing yielding multiple mRNAs (Wang 2008, Pan 2008).
Alternative splicing gained substantial interest after the discovery that mutations in no
less than 15%, and up to 50% of human genetic diseases involve changes in alternative
splicing, either in the consensus sequence or in weak regulatory regions within the
introns and/or exons, and dictate the fate of the final isoform produced (Matlin 2005).
Similar to constitutive splicing, the process is carried out by the spliceosome; however,
differences between weak and strong sequences on the pre-mRNA, called cis-factors,
and the relative concentrations of several spliceosome associated proteins (SAPs),
known as trans-factors, playa crucial role in determining the outcome of splicing.
Additionally, the interplay between the cis and trans factors is subject to posttranslational modifications, which increases the complexity of the system. Ultimately,
introns and exons forming the nascent pre-mRNA are cut and ligated in a multitude of
combinations generating several transcripts that are translated by increased proteomic
diversity. Several patterns of alternative splicing exist, with the most common modules
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being alternative 5' or 3' splice-site selection, mutually exclusive exons, cassette-exon
inclusion or skipping, and intron retention (Nilsen 2010) and are depicted in Fig 1.5.

53

Cassette exons

Alternative 3' splice sites

Mutuallay exclusive exons

Retained intron
;

.....

Alternative 5' splice sites

Fig 1.5 Splicing patterns in mammalian cells Different combinations of splicing and
ligation can potentially generate a countless amount of transcripts. Of the multiple
patterns of alternative splicing, cassette exons splicing pattern is the most identified and
most studied form of alternative splicing.
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Regulation of pre-mRNA splicing
A major requirement for an efficient splicing reaction is the ability of the
spliceosome to differentiate exons from introns, a process known as exon definition,
which is mainly dictated by the presence of three short sequence cis elements: the 5'
splice site, the 3' splice site and the branch point. Although intronic sequences are
spliced-out and removed from the pre-mRNA, their relative length compared to average
exons (50-250 nt) supports the hypothesis that splicing occurs by exon definition first,
subsequently converted to intron definition with cross-bridging between Ul and U2
snRNPs on opposite sides of an exon. As such, controlling splice sites selection, either by
facilitating or inhibiting their recognition, is an important step in the regulation of
splicing. In yeast, the consensus of splice sites selection is strictly followed while higher
eukaryotes represent a more challenging case and divergence from the consensus is
observed (Burset 2000, 2001). To improve exon control and recognition, additional
elements known as exonic or intronic enhancers (ESE or ISE) and exonic or intronic
silencers (ESS or ISS), depending on their location and impact on splicing, are present in
the pre-mRNA. Two major classes of splicing factors, arginine-serine rich (SR) proteins
and heterogeneous nuclear ribonucleoproteins (hnRNPs), bind the regulatory elements
mentioned above to modulate splicing.

SR proteins
The serine and arginine rich proteins (SR proteins) are an essential family of
constitutive splicing factors with abilities to bind RNA specific sequences and to
modulate protein-protein interactions. SR proteins are recognized for their role as

55

molecular adapters between the pre-mRNA and the spliceosome. SR proteins are highly
conserved and consist of one or two N-terminal RNA recognition motifs (RRMs) and a Cterminal domain rich in repeating sequences of arginine and serine residues (RS
domain). RRM domains are approximately 80 amino acid in length (Nagai 1990), and
function in RNA binding (Nagai 1995). SELEX protocols (systematic evolution of ligands
through exponential enrichment; Tuerk 1990) identified purine-rich exonic enhancer
elements as preferred binding sites for individual SR proteins (Tacke 1999). The Cterminal RS domains are highly conserved among the SR proteins (Zahler 1992, Birney
1993) and function in cellular localization through protein-protein interactions with
other RS-containing proteins (Caceres 1997, Kataoka 1999, Lai 2000, 2001). Additionally,
RS domains are

necessary for mediating protein-protein

interactions with the

spliceosomal machinery (Wu 1993, Kohtz 1994, Graveley 1998). As mentioned above,
higher eukaryotes tend to diverge from the consensus exon definition, and SR proteins
have been determined as crucial factors in identification of enhancer sequences within
the exons or introns and facilitation of the interactions between the upstream 3' and
the downstream 5' splice sites surrounding an exon (Berget 1995). SR proteins are also
involved in intron bridging, the process of converting the exon definition into intron
definition, which leads ultimately to intron removal and ligation of exons (Wu 1993,
Abovich 1994, 1997 and Berglund 1997). It is noteworthy to mention that most SR
proteins were discovered by their accidental reactivity to a monoclonal antibody,
mAb104, mounted against active sites of RNA pol II on loops of the lampbrush
chromosomes and germinal vesicles (Roth 1990). Altogether, the combination of the
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RRM and RS domains functions support the role of SR proteins as facilitators of splicing:
through binding E5Es and mediating critical protein-protein interactions, SR proteins
strengthen weak splice sites, dictating the outcome of pre-mRNA splicing.
HnRNPs
Another group of essential modulators of the splicing process are the
heterogeneous nuclear ribonucleo,Qroteins (hnRNPs). HnRNPs contain one or two RNA
recognition motifs (RRMs) that mediate their binding to the pre-mRNA. The process of
specific hnRNPs binding to pre-mRNA is not fully understood and still under debate;
whereas some hnRNPs bind in a sequence-specific fashion, many others bind randomly_
HnRNPs are involved in several layers of gene expression and RNA processing including
transcription, polyadenylation, stabilizing mRNA structure, shuttling of mRNA to the
cytoplasm as well as pre-mRNA splicing. A (-terminal glycine G-rich motif" involved in
protein-protein interactions within the spliceosome, is commonly found in several
hnRNPS, although not universally. In contrast to SR proteins which function in enhancing
splicing, hnRNPs act as splicing repressors by binding to silencing sequences within the
introns and exons (ISS and ESS). More than 25 hnRNPs have been identified to date
(Dreyfuss 1993), of which SXL, PTB (also known as hnRNP I) and hnRNP A/B family have
shown to have the strongest involvement in modulating splicing. Two hypotheses are
advanced to explain the inhibitory effect of hnRNPs in both of which they sterically
encumber the interaction between positive enhancers or splicing factors to the premRNA.

In the simplest form, repressor proteins directly antagonize enhancers by

binding either close to a splice site or to ESE/ISE. PTB for instance, competitively binds
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the polypyrimidine tract blocking U2AF (Singh 1995, Spellman 2006). Similarly, SXL binds
the polypyrimidine tract of an upstream cryptic 3' splice site preventing U2AF binding,
thereby activating a downstream 3' splice site (Lin 1995, Lallena 2002). Another example
of direct steric hindrance comes from FOXl and FOX2, splicing factors expressed
specifically in the heart, brain and skeletal muscles, which bind an ISS preventing SFl
binding to the branch point of the calcitonin-related polypeptide-a, CALCA, hence
inhibiting E' complex formation (Zhou 2008). On the other hand, simple steric hindrance
fails to explain the inhibitory effect of hnRNP Al on its own exon 7B inclusion. The
exonic sequence suppressor (ESS) is > 100 nt far from the enhancers. Oligomerization of
Al through the C-terminal G-rich domain extends the inhibitory effect of Al towards the
enhancer sequence and probably mediates a conformational rearrangement leading to
the A1 observed effect (Del Gatto-Konczak 1999); a similar hnRNP Al effect has been
shown for exon 7 exclusion of SMN2 (Kashima 2007).
Combinatorial control

SR proteins and hnRNPs interactions with the pre-mRNA and the spliceosome
provide an attractive and somewhat simplistic view of the process of splicing regulation;
however, a combinatorial effect of these RNA-associated proteins is more likely to
represent a closer look into the real mechanisms of regulation. Several ways help
accomplish that combination. The simplest and most studied form is the effect of
relative abundance of enhancers and inhibitors. HIVl tat exon 3 inclusion is influenced
by the amount of the inhibitor hnRNP A1 and enhancer SF2/ASF - an SR protein through interplay of their binding to their respective sequences (Zhu 2001). SF2/ ASF and
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hnRNP Al provide similar opposing effects on (3-tropomyosin exon 6B inclusion (ExpertBezancon 2004). The picture becomes more complicated when proteins within the same
family display antagonistic influences. There are many examples of functional
antagonism within SR proteins, as well as hnRNPs. For instance, SRp20 self-regulated
splicing is antagonized by SF2/ASF (Jumaa 1997), SRrp86 is antagonized by SRp9G8 (Li
2003) and SRrp86 itself has antagonistic effects: it enhances SRp20 while repressing
5C35, SF2/ASF and SRp55 (Barnard 2000). Functional antagonism is also observed
among hnRNPs: PTB and CELF (CUG-BP and ETR3-like factors) have opposite effects on
Q-actinin (Suzuki 2002, Gromak 2003) and cardiac troponin-T (Charlet-B 2002).

Regulation of splicing factors activities by phosphorylation/signaling
Adding an extra layer of complexity, post-translational modifications of splicing
factors are also complicit in modulating their activities and hence affecting both
constitutive and alternative splicing. Phosphorylation, glycosylation and methylation are
documented post-translational modifications (PTMs) on splicing factors (Soulard 1993,
Rho 2007, Stamm 2008, Sinha 2010) and are implicated in regulating their functions. In
this subsection, I will focus on the phosphorylation PTMs as they are most pertaining to
this dissertation and the reader is directed to the references above for more
information regarding the other forms of PTMs. As discussed earlier under this section,
proteins and nucleic acids within and around the spliceosome are governed by weak
hydrophobic and electrostatic protein-protein, protein-RNA and RNA-RNA interactions,
which lead in a sort of "organized chaos" to a highly specific pattern of splicing. It is
believed that this type of weak interactions is necessary to allow smooth and efficient
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transitions in a highly complex and dynamic system. In that context, phosphorylation of
splicing factors plays an important role in "bending and twistingll these interactions to
modify the splicing outcome. Traditionally, phosphorylation modifications are studied
on the two major classes of splicing protein regulators, namely the SR proteins and
hnRNPs. In what follows, I will address the roles that phosphorylation is identified to
. play in splicing, giving examples in each case. With respect to the role of the MAP kinase
pathway in signaling to splicing factors, Sam68, remains the sole ERK/MAP kinase direct
substrate implicated in splicing so far (Matter 2002). One of the earliest evidences of the
involvement of protein phosphorylation in splicing is the fortuitous identification of SR
proteins. Indeed, SR proteins were identified based on their reactivity to the monoclonal
antibody mAB104 which reacts with a phosphate-containing peptide sequence (Roth
1990, 1991; Zahler 1992). Emerging evidence of involvement of protein kinases and
phosphatases in splicing was accumulating (Mermoud 1992, 1994; Tazi 1992, 1993;
Woppmann 1993; Gui 1994; Colwill 1996a/b; Rossi 1996). Interestingly, replacement of
ATP with ATP(yS) stalls the catalytic step of the spliceosome, but not its assembly
(Mermoud

1992, 1994; Tazi

1992) and

a continuous and

dynamic cycle of

phosphorylation/dephosphorylation is proposed to explain these observations (Tazi
1993). The main impact of phosphorylation on splicing factors is its ability to alter their
interactions within the spliceosomal complex, leading to changes in the mRNP
formation, localization, or both; examples are provided below.
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Changes in pre-mRNA/protein complex formation
Protein splicing factors interactions with the RNA are dominated by weak
hydrophobic and electrostatic interactions. Studies of the SR proteins RS domain
interactions are among the best characterized; they are responsible for determining
homophylic

and

heterophylic

SR

proteins

binding.

For

instance,

SF2/ASF

phosphorylation enhances its binding to U1-70K (U1 snRNP 70K subunit) but has no
effect on its binding U2AF
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(Xiao 1997) while it has a negative effect on its binding the

RNA export factor TAP/NXF1 (Huang 2004), SRp40, hTra2 and itself (Xiao 1997, 1998).
Not limited to protein-protein interactions, phosphorylation alters SR proteins-RNA
interactions as well, where phosphorylated RS domains prevent the non-specific RNA
binding observed under unphosphorylated forms (Xiao 1998) showing that it increases
specificity of splicing. Phosphorylation events in the process of splicing seem to playa
regulatory switch, decreasing random interactions and improving specificity.
HnRNP proteins are also subject to post-translational phosphorylation. SF1 is a
member of the hnRNP K family and is phosphorylated by cGMP-dependent protein
kinase-I (PGK-I) at Ser20 blocking its interaction with U2AF
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,

thereby pre-spliceosome

assembly (Wang 1999). HnRNP C is phosphorylated by casein kinase II-type activity
(Fung 1997), which decreases its RNA-binding capacity; however, it increases its targetspecific binding. TIA-1, an apoptosis-activated splicing factor, is also phosphorylated in

vivo by FAST (Fas-Activated Ser/Thr kinase) in response to Fas ligand binding (Tian
1995). It is interesting to note that in

most cases, an adequate amount of

phosphorylation is necessary and sufficient for optimal functioning of these splicing

61

factors, as hypo-phosphorylated and hyper-phosphorylated states tend to inhibit
splicing (Prasad 1999).

Changes in cellular localization
An efficient and precise splicing requires specific contribution from each member
of the spliceosome, therefore spatial distribution of splicing factors is a major
determinant of the reaction's outcome. Phosphorylation of SR proteins and hnRNPs
modulates their spatial distribution both between the nucleus and cytoplasm and within
the nucleus itself, rendering them more or less available to the splicing machinery.
Members of the importin ~ (imp ~) and transportin (TRN) family, TRN-SR1 and TRN-SR2
have been shown to .interact with SR proteins for nuclear import both in humans and

Drosophila (Kataoka 1999, Lai 2000, 2001) and this interaction is dependent on
phosphorylated RS domains (Lai 2000, 2001). Dephosphorylation of SRp9G8 and
SF2/ASF decreases their binding to the nuclear export factor TAP/NFX-1 leading to
cytosolic accumulation (Huang 2004), while phosphorylation of hnRNP A1 by Mnk1/2
(Guil 2006) in a MKK3/ 6/p38-dependent fashion reduces hnRNP A1 binding to
transportin-1 under osmotic stress (Allemand 2005) and confines it to the cytosol (van
der Houven van Oordt 2000). Spatial rearrangement is also observed in the nucleus
where splicing factors (SR proteins, VB-1), in response to CLK1/2/3/4 and phosphatases
activities, leave their stronghold Ifnuclear speckles" following phosphorylation, causing
their nuclear redistribution and change in splice site selection (Hartmann 2001,
Allemand 2007).
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Splicing Factor 45 KOa - SPF45
The pre-mRNA alternative splicing factor 45 KDa, SPF45, was discovered by two
groups working independently. Neubauer et al. (Neubauer 1998) used an ingenious
technique to identify components of the spliceosome multi-protein complex. Following
2D-gel separation of the components of the fully assembled spliceosome, spots were
excised, analyzed by mass spec and then coupled to EST-databases. A spot with an
apparent molecular weight of 45 KDa was named SPF45, for splicing factor 45 KDa.
SPF45 is highly homologous to the DNA damage repair protein DRT111 in A.thaliana.
Another group was working on identifying novel genes expressed in drug-resistance
cancer cells; using a suppressive-subtractive polymerase chain reaction, Sampath et al.
identified SPF45 as a gene expressed in the cyclophosphamide-resistant EMT-6 mouse
mammary cancer cells {Sampath 2003}.
SPF45 consists of 401 amino acid residues. It has an N-terminal domain that is
projected to be largely unstructured (Corsini 2007), a . . . 40-residues G-patch motif
spanning between residues 235 and 281 (Aravind 1999), and a C-terminal domain
harboring the RNA Recognition Motif {RRM}. The G-patch domain has 6 highly
conserved G nucleotides and is predicted to have an unstructured secondary structure
with possibly two a helices. It also contains repetitive RS and RGG sequences making it a
candidate for non-specific protein-RNA interactions (Aravind 1999). Directly upstream to
the G-patch is a . . . 10 residue domain named SPF45-like domain (or SF motif) and is
common

to

several

proteins with

DNA repair function

in

T.gondii,

C.elegans,

D.melanogaster and A.thaliana (Frenal 2006). The SF domain assumes a helical
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conformation and is involved in protein oligomerization (Frenal 2006). It has been
shown that SPF45 interacts with SXL (sex lethal) in Drosophila through their N-termini
(Lallena 2002) while it interacts with constitutive components of the spliceosome
through the RRM domain (Corsini 2007). This latter is highly homologous to a group of
protein-binding RRM domains in nuclear proteins such as PUF60, KIS kinase, HCCl and
U2AF65 and are thus named UHM, for U2AF-homology motifs (Corsini 2007). The UHMs
of these proteins interact with tryptophan-containing linear peptide motifs (Kielkopf
2001, Selenko 2003) and are subsequently named UHM-ligand motifs ULMs. It is
through the UHM-ULM type of interactions that SPF45-UHM binds the N-terminal ULMs
of the constitutive spliceosomal proteins U2AF65, SFl and SF3b155 (Corsini 2007) and in
fact, the C-terminus of SPF45 is capable of mediating the alternative splicing of premRNA without the need of the G-patch or the N-terminus.
SPF45 is a ubiquitously expressed protein at low levels in normal tissues. Its
highest expression is seen in breast, bladder, colon, kidneys and ovaries with main
distribution to the ductal epithelia (Sampath 2003). SPF45 is a nuclear protein that
localizes to the nuclear speckles along with other proteins from the spliceosome like
UlsnRNP and SR proteins (Neubauer 1998, Sampath 2003). In cancer cells, it has the
highest expression levels in tumors of epithtelial origin such as bladder, breast, colon,
lung, ovarian, pancreatic and prostate carcinomas (Sampath 2003).
We currently have very limited understanding of the potential targets for SPF45mediated pre-mRNA alternative splicing. So far, only 3 genes are reported to be affected

by SPF45 expression. In D.melanogaster, SPF45 is responsible for the alternative splicing
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of the sx/ gene (Lallena 2002). SPF45 activates a cryptic AG dinucleotide upstream of the
normal 3' AG-dinucleotide responsible for exon 2 definition, leading to expression of
exon 2 which contains a premature early stop codon and hence preventing its
expression. However, in the presence of SXL, it binds SPF45 through their N-termini
preventing the activation of the cryptic AG and leading to exon 2 skipping. The sex-lethal
protein, SXL, is responsible for female secondary traits maturation (Skripsky 1982). SXL is
responsible for its own auto-regulation, being expressed only in female but not male
flies. Similarly to SXL, SPF45 is involved in the development of (3-thalassemia; a single
point mutation of a guanine to adenine in the first intron of the (3-globin gene generates
a cryptic AG dinucleotide recognized by SPF45 for activation, leading to expression of
the

(3110

mutation responsible for the thalassemic condition (Lallena 2002). Another

target for SPF45-mediated alternative splicing is the death receptor FAS (Corsini 2007).
SPF45 overexpression causes skipping of las exon 6 which encodes the single pass transmembrane domain that anchors the receptor to the cell membrane (Cascino 1994).
Although exon 6 skipping does not inhibit protein expression, the product fails to anchor
into the cell membrane and is released as a soluble isoform extracellularly. The soluble
FAS acts as a decoy; it binds the FAS ligand (FASL), however it fails to initiate the
apoptotic cascade {Cheng 1994}. The FASL signal is then transformed from pro-apoptotic
to anti-apoptotic by the deletion of the trans-membrane domain.
Sampath et al. showed SPF45 to be strongly over-expressed in tumors of
epithelial origins (Sampath

2003).

More importantly, when they forced SPF45

expression in HeLa cells, they induced a drug resistance phenotype, as the cells became
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resistant to doxorubicin and vincristine. A later study by Perry et al. (Perry 2005) showed
that SPF45 overexpression in the ovarian cancer cell line A2780 -traditionally used for
measuring drug sensitivities - caused a multidrug resistant phenotype. SPF45 confered
drug resistance to the following chemotherapeutic agents: cisplatin, doxorubicin,
mitoxantrone, etoposide and vincristine. The mechanism of drug resistance is not
identified, however it was speculated to involve, at least partially, interaction between
SPF45 and ER~, since co-treatment of the cells with the selective estrogen receptor
modulator, tamoxifen, partially reversed the drug resistance (Perry 2005). SPF45 has
been also implicated in the neurodegenerative disease spinocerebellar ataxia type 1
(SCA1). Polyglutamine expansion of ataxin 1 ATXNl is linked to the development of
SCAl (Banfi 1994); SPF45 directly interacts with ATXNl through their C-termini (Lim
2008) and this interaction is necessary for SCAl development.
SPF45 mechanism of action
Our understanding of how SPF45 is utilized by the cell for alternative splicing is
limited. The first target of SPF45 to be studied is the sex lethal (sxl) mRNA in Drosophila
melanogaster (Lallena 2002) in the lab of Juan Valcarcel. Sxl has a very peculiar property

that sets it aside from most canonical intron sequences in the fact that intron 2 has two
potential AG dinucleotide around the 3' splice site that are termed AG p and AG d for
proximal and distal, respectively. SPF45 is thought to bind directly to the proximal AG
dinucleotide, priming it as the 3' splice site to be utilized. Later studies from the lab of
Juan Valcarcel into the binding partners of SPF45 in the alternative splicing of Fas, show
that the C-terminus of SPF45 harbors a UHM domain that interacts with members of the
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constitutive splicing machinery, U2AF65, SFl and SF3b155. NMR experiments show
SPF45 to interact with the aforementioned splicing factors; however, no measurable

interaction is observed between SPF45 and the pre-mRNA. Whether SPF45 interacts
with the nascent pre-mRNA or is mainly influenced by interactions with neighboring
splicing factors remains an important area to unravel the true mechanism of action.
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Rationale, hypothesis and specific aims
Identifying MAP kinase(s) targets In their natural tissue specific expression
pattern is essential for determining the impact of MAP kinases on their function(s). With
emerging studies on the effects of signaling and phosphorylation, the link between MAP
kinases and splicing factors, has been at best, very limited. Previous work from our lab
showed an increase in ERK2 activity in SKOV3 cells upon detachment and growth under
anchorage-independent conditions. Using an engineered ERK2 enzyme to determine
MAP kinase-specific substrates in SKOV3 cells, we identify SPF45 as a novel substrate
under conditions of adherence and suspension. In this dissertation, I investigate SPF45
expression

in

ovarian

cancer cells,

identify the

phosphorylation

residues and

characterize this phosphorylation both in vitro and in cells by ERK, JNK and p38 MAP
kinases. I also examine the effect of the phosphorylation on SPF45 splicing activity,
determine genetic changes in response to SPF45 overexpression as well as identify novel
splicing targets and binding partners. Finally, I will address the role of SPF45 on drug
resistance in cancer. The long term objective of this study is to understand the biological
role of SPF45 in ovarian cancer and establish a strong link between the MAP kinase
pathways, pre-mRNA alternative splicing events and the regulation of aberrant genetic
changes that occur in cancer cells in the scope of designing efficient therapeutic
interventions.
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Hypothesis
MAP kinase phosphorylation of SPF45 is responsible for altering SPF45 interactions
within the spliceosome and modulates SPF45-induced genetic changes and splicing
activity.

Specific Aims

Aim1

Identify

SPF45

as

a

novel

MAP

kinase

substrate.

Characterize

the

phosphorylation of SPF45 by ERK, JNK and p38 MAP kinases in vitro and in cells.

Aim2 Determine the effect of MAP kinase phosphorylation on SPF45 splicing activity.
Identify novel genetic and splicing events controlled by SPF45 as well as SPF45
interaction with constitutive splicing factors. Assess the role of SPF45 on drug
resistance in SKOV3 cells. Determine the impact of modulation of SPF45 functions via
mutations of the MAP kinase-targeted residues.
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Chapter 2 Identification of SPF45 as a novel MAP kinase substrate
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Introduction

MAP kinases are a ubiquitous family of protein kinases with important regulatory
functions throughout the cell: they are involved in a diverse array of processes including
but not restricted to, gene expression, differentiation, proliferation, migration and
survival (reviewed in Pratilas 2010). Several MAP kinase subfamilies have been identified
in eukaryotic cells, some of which are common to all eukaryotes while others are
organism specific. All subfamilies share a common connected topology of activation:
simplistically, an extracellular stimulus on the cell membrane activates a membrane
receptor which leads to a sequential activation of a three-tiered cascade starting with
MAP3K, followed by MAP2K and then the penultimate MAPK. Due to the similarities
between the subfamilies, substrate promiscuity is not uncommon; hence identification
of MAP kinase substrates in the cellular contexts and compartments is crucial to
understand their functions (Eblen 2003). Earlier work from our lab (Eblen 2003, Kumar
2004, Zheng 2010) led to the generation of an engineered ERK2/MAP kinase capable of
efficiently identifying specific substrates of ERK2 under physiological and pathological
cell conditions.
Interests in MAP kinase pathways stem from their intricate involvements in
several pathological conditions, especially cancer (McCubrey 2006). In ovarian cancer,
ERK/MAP kinase pathway is indeed an important player (Thant 2000, Wong 2001,
Givant-Horwitz 2003 and Ventura 2010). Previous work from our lab identified a novel
form of sustained ERK activation in several ovarian cancer cell lines upon cellular
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detachment that we showed to be necessary for anchorage-independent growth (AIAyoubi 2008). Using the engineered ERK2 kinase mentioned above to generate SKOV3ERK2Q103 stable ovarian cancer cells, we identified ~Iicing f.actor 45 KD (SPF4S) as a
novel substrate of ERK2 in ovarian cancer cells under anchorage-dependendent as well
as -independent conditions.
SPF45 is an mRNA alternative splicing factor initially identified by mass spec
analysis to localize and engage with the spliceosome complex (Neubauer 1998).
Concomitantly, studies of anti-neoplastic agents' resistance identified SPF45 as a gene
overexpressed in EMT-6 mouse mammary cancer cells selected for cyclophosphamide
resistance (Perry 2005). Overexpression of SPF45 in HeLa cervical cancer cells confers
drug

resistance

against

doxorubicin

and

vincristine

(Sampath

2003),

while

overexpression in A2780 ovarian cancer cells confers a multidrug resistance phenotype
against carboplatin, vinorelbine, etoposide, mitoxantrone, doxorubicin and vincristine
(Perry 2005). In A2780-SPF45 cells, treatment with the selective estrogen receptors
modulators tamoxifen and LYll7018 partially reverses mitoxantrone resistance, while
SPF45 knock-down sensitizes the cells to etoposide (Perry 2005). Structurally, SPF45 has
a large N-terminus that is unstructured, followed by a lO-residues SF (SPF45-like) motif,
a G-patch motif of approximately 40 amino acid residues involved in protein-protein and
protein-nucleic acid interactions and finally a C-terminus containing a modified RNA
recognition motif (RRM) important for its intrinsic splicing activity (Corsini 2007).
Crystallographic and NMR studies of the Toxoplasma gondii 55KDa DNA repair protein,
TgDRE, which shares high homology to SPF45, show the capability of the G-motif to bind
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small RNA oligonucleotides (as predicted for SPF45 G-domain) and that the RRM domain
adopts a classical

(3a(3J3aJ3 topology necessary for hydrophobic protein-protein

interactions. Subsequent experiments by Corsini et al. resolved SPF45 RRM domain to
adopt the same configuration (Corsini 2007). The SF motif is also involved in protein
oligomerization (Frenal 2006). Besides its function in splicing and drug resistance, SPF45
interacts with DNA repair proteins RAD201 (Chaouki 2006) and RAD51B (Horikoshi 2009)
indicating its involvement in DNA repair pathways and specifically through SPF45 Nterminal Iysines (Horikoshi 2009). Additionally, SPF45 is implicated in the development
of spinocerebellar ataxia through a protein complex interacting with the polyglutamine
expanded protein ATXN1 (Lim 2008).
There is evidence that phosphorylation of splicing factors is implicated in the
splicing machinery, regulating assembly, splice site selection and localization (Stamm
2008). Identification of the serine-arginine rich proteins (SR) and the heterogeneous
nuclear ribonucleic proteins (hnRNPs) as regulators of splicing had a major impact on
recognizing that splicing factors undergo post-translational phosphorylation important
for regulation of splicing. SR proteins were initially identified by their immunoreactivity
to an antibody that detects a phosphorylated epitope (Roth 1991, 1992, Zahler 1992).
Characterization of SR proteins and hnRNPs regulation led to the identification of SR
protein kinases (SRPKs), cdc2-like kinases (elK/Sty) and DNA topoisomerase I as the
main kinases regulating splicing, with a very limited contribution of MAP kinases to premRNA splicing/alternative splicing. To date, Sam68, (Src-associated in mitosis, 68Kd),
remains the only pre-mRNA alternative splicing factor to be a direct substrate of

73

ERK/MAP kinase; phosphorylation of Sam68 by ERK/MAP kinase improves its binding to
an exonic enhancer region leading to increase inclusion of CD44-v5 exon (Matter 2002).

Of note, MKK3/ 6/p38 MAP kinase is also involved in the regulation of splicing factors,
through Mnkl activation (Guil 2006), via an inhibitory phosphorylation of the splicing
repressor hnRNP Ai, causing its cytoplasmic retention (van der Houven van Oordt
2000).

In this chapter we show that SPF45 is a novel ERK2/MAP kinase substrate with
overlapping substrate specificity by JNK and p38 MAP kinase; we identify the targeted
residues for phosphorylation by MAP kinases and characterize SPF45 phosphorylation
on these sites in response to oncogenic and extracellular cues.
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Materials and methods
eel/lines and cell cultures
ES-2, CaOV3, and OV2008 cells were a gift from Runzhao Li. SKOV-3 and Cos-1 cells were
I

obtained from American Type Culture Collection (ATCC Manassas, VA). OVCAR3 cells
were a gift from Kristen Atkins, OVCARS and A2780 cells were a gift from Thomas
Hamilton. lOSE cells were a gift from Nellie Auersperg and were grown in a 50:50
mixture of media 105 and 199. Cos-1 cells were grown in DMEM (Invitrogen Carlsbad,
CAl. SKOV-3, and OVCAR5 cells were grown in McCoy's 5A (Invitrogen Carlsbad, CAl.
ES2, A2780 OVCAR3 and OV2008 cells were grown in RPMI 1640 (Invitrogen Carlsbad,
CAl. All cell lines were grown in 10% fetal bovine serum (FBS) (ThermoScientific
Rockford, I L).

Plasmids and mutagenesis
SPF45 eDNA was obtained from ATCC in the pOTB7 vector, digested with EcoR1 and
Xho1 restriction enzymes (New England Bio Ipswitch, MA) and subcloned into the multicloning site of pCMV3-2C vector encoding an N-terminal triple Myc-tag epitope
downstream of the constitutive CMV promoter. PCR-based site-directed mutagenesis of
Thr 71 and/or Ser222 was carried out using the following primers:
Thr71-7 Ala71
(GACCGGCAAATIGTGGACGCTCCACCGCATGTAGCAG
CTGGCCGTTIAACACCTGCGAGGTGGCGTACATCGTC)
Ser222 -7 Ala222
(GAACAAGACAGACCGAGAGCTCCAACCGGACCTAGC
CTTGTTCTGTCTGGCTCTCGAGGTTGGCCTGGATCG)
Th r71 -7 Asp 71
(GACCGG CAAATIGTGGACGATCCACCG CATGT AGCAG C
CTGGCCGTTTAACACCTGCTAGGTGGCGTACATCGTCG)
Ser222 -7 Asp222
(GAACAAGACAGACCGAGAGATCCAACCGGACCTAGCAAC
CTTGTTCTGTCTGG CTCTCTAG GTTGGCCTGGATCG).

&

&
&
&
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Wild type or alanine-mutants SPF45 were subcloned from this vector into pET15b
encoding a 6-Histidine tag and transformed into BL21 E. coli to generate recombinant
His-SPF45 proteins that were purified with nickel agarose (Roche Indianapolis, IN).

Generation of SKOV3-QT8 cells
Retroviral plasmids (pQCXIP) encoding empty vector/Flag-ERK2/Flag-ERK2-Ql03G were
transfected into phoenix A cells along with VSV-G and Gag/Pol for virus production and
packaging. Cellular media containing the viruses were harvested at 36 and 60 hours post
transfection, filtered with 45 f.!m syringe filters (Corning Lowell, MA) and mixed with
polybrene (Sigma St Louis, MO) to a final 2Jlg/m I concentration before infecting the
SKOV3 target cells. Cells were selected with 1.5 Jlgjml puromycin and several clones
were generated. Individual clones were harvested and grown in 24 well plates, then
screened by western blot for Flag-ERK2/or Flag-ERK2-Ql03G expression.

32P-Labeling of cyclopenty/ ADP (cpADP)

Nucleoside diphosphate kinase (NDPK, 200 units, Sigma St Louis, MO) and 800 JlCi of [v32 p]ATP were added in a 100-ml reaction containing HBS (150 mm NaCI, 20 mmHEPES,
pH 7.4, and 5 mm MgCb). The reaction was allowed to equilibrate at 30°C for 5 min.32p_
Labeled NDPK was purified from free [V-32p]ATP by two successive rounds of Microspin
GSO columns (Amersham Biosciences, Piscataway, NJ). 1000 pmol of cpADP was added
to the 32P-labeled NDPK in HBS, and the reaction was carried out for 20 min at 30°C.
After the reaction, contents were transferred to a Microcon-YM30 (Millipore, Bedford,
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MA} and centrifuged at 13,000 rpm for 15 min. With this procedure we usually obtained
~ 200 IlCi of purified [y_32 p]cyclopentyl-ATP ([V_32p]cpATP).

Identification of SPF45 as a novel ERK2 substrate

6

Four 150-mm dishes of SKOV3-QT8 cells (4 x 10 cells/dish) expressing Flag-ERK2-QI03G
were used. Cells were lysed in M2 buffer (150 mM NaCl, 5 mM KCI, 1 mM CaCI 2, 1 mM
MgCb, 50 mM HEPES, pH 7.4) supplied with protease inhibitors mix (100 JlM Na-ovanadate, 50 mM NaF, 40 mM ~-glycerophosphate, 5 mM Na-pyrophosphate, Aprotinin
and 2 mM PMSF). Immunoprecipitation was performed using M2-Flag antibody (Sigma
St Louis, MO). Immunoprecipitated ERK2-QG and associated proteins were eluted from
the M2-agarose beads with FLAG peptide and separated on 8% SOS-PAGE. Labeled
proteins were excised from the gel and microsequenced using a Finnigan LCQ ion trap
mass spectrometer with a protana nanospray ion source (W. M. Keck Biomedical Mass
Spectrometry Laboratory, University of Virginia).

Generation of antibodies - a-total SPF45~ a-pThr71-SPF45 and a-pSer222-SPF45

Total SPF45 antibody and phospho-specific antibodies to pThr71-SPF45 and pSer222SPF45 were generated in New Zealand White rabbits by Pacific Immunology, who
assisted in the design and synthesis of immunogenic peptides, as well as generation and
purification of the antibodies. Peptides used were: SPF45, PYEEDSRPRSQSSKAC; pThr71SPF45, SOORQIVD-T( P0 4 )-PPHVAAGC; pSer222-SPF45, YEEQDRPR-S(P0 4 )-PTG PSNSFC.
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ERK binding assays
His-ERK2 or buffer was added to 500 Ilg of nuclear extract from HeLa cells and mixed
overnight at 4°C. His-ERK2 was isolated with nickel agarose and washed three times with
wash buffer (20 mM Hepes pH 7.4, 2 mM EDTA and 2 mM EGTA). The pull-downs were
run on a gel and immunoblotted for SPF45 and ERK2.

Transfections
1.5 million Cos-1 cells were plated the night before transfection on 10 cm cell-culture
dishes (Corning Lowell, MA) and transfected the following day with 6 Ilg total of DNA.
Briefly, 6 Ilg total DNA and 24 III of Lipofectamine 2000 were suspended in 1.5 ml of
Opti-MEM (Invitrogen Carlsbad, CA) each for 5 minutes at RT, then mixed together for a
total of 20 minutes at RT before drop wise addition onto cells. The media and
transfection mixture were recollected 5-6 hours following transfection, washed once in
1X PBS and incubated in fresh media supplied with 10% FBS. The cells were collected 24
hours post-transfection.

In vitro kinase assay and phosphoamino acid analysis
0.5 I-lg of recombinant SPF45 was incubated with the kinases of interest (His-ERK2, GSTp38a and GST-JNK1 (Invitrogen Carlsbad, CAl at an equal activity of 500 nmol/min in 30
III of kinase buffer (20 mM Hepes pH 7.4, 10 mM Mg acetate, 1 mM dithiothreitol
(DTT)), lOOIlM ATP and lOIlCi of V

32 p _ATP

(Perkin Elmer Waltham, MA) at 30°C for

10minutes. The reaction was quenched by addition of 2X Laemmli sample buffer and the
phosphorylated protein (His-SPF45) was resolved by SDS-PAGE, transferred by western
blot into PVDF (Biorad Hercules, CAl membranes and exposed on HyBlot CL films

78

(Denville Scientific South Plainfield, NJ) for autoradiography. Radioactive bands were
excised, quantified by Cerenkov count and analyzed for phosphorylated residues by
phosphoamino acid analysis (Boyle 1991). Briefly, radioactive bands were excised,
hydrolyzed using 6N Hel (Sigma St louis, MO) at 110°C for 1h, washed and lyophilized in
water than suspended in buffer 1.9 (2.5% v/v 88% Formic acid, 7.8% v/v Acetic acid,
89.7% v/v H20). 1000 cpm of the final suspension were mixed with standard threonine,
serine and tyrosine amino acids for detection before spotting and 2-D electrophoresis
on a TlC plate. The standard amino acids were stained with 0.2% ninhydrin in ethanol
(Sigma St Louis, MO) and the plate was developed on Hyblot CL films a week after
exposure.
Immunoprecipitation

Cells were lysed in M2 buffer (150 mM NaCI, 5 mM KCI, 1 mM CaCI 2 , 1 mM MgCI 2, 50
mM HEPES, pH 7.4) supplied with protease inhibitors mix (100 J..lM Na-o-vanadate, 50
mM NaF, 40 mM l3-glycerophosphate, 5 mM Na-pyrophosphate, Aprotinin and 2 mM
PMSF). 500 J,lg of lysate were incubated with 2 1-11 of Myc-antibody (Sigma St louis, MO)
conjugated to protein A agarose with constant mixing for 2 hours at 4°C. The
precipitates were then washed 3X in M2 buffer followed by suspension in 1X laemmli
Sample buffer or washed 2X in kinase buffer in preparation for in vitro kinase reaction.
In vitro kinase reaction of SPF45/alanine mutants

Empty vector/Myc-SPF45/alanine mutants were transfected into Cos-1 cells, Mycimmunoprecipitated 24 hours post-transfection then suspended in 30 1-11 of lX
phosphatase buffer (NEB buffer3: 50mM Tris-HCI, 100 mM NaCl, lOmM MgCb and 1mM
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Dn) with 2 III of calf intestinal phosphatase CIP (New England Bio) at 37°C for 1 hour
followed by 2 washes in kinase buffer prior to in vitro kinase phosphorylation as
described above.
SPF45 dephosphorylation - Phosphatase Assay
His-5PF45 (0.5 Ilg) was recollected following the kinase assay (with ERK2) by Ni++agarose binding with rocking for 2 hours at 4°C. The 5PF45-conjugated beads were
washed twice in 1X phosphatase buffer, then re-suspended in 30 III of 1X phosphatase
buffer supplied with 2 III of Calf Intestinal Phosphatase (New England BioLabs Ipswitch,
MA) and incubated at 37°C for 1 hour. The reaction was quenched by addition of 10 III
of 4X Laemmli Sample buffer. Proteins were separated by 5DS-PAGE, transferred onto
nitrocellulose membrane and visualized using pThr71-5PF45, p5er222-SPF45, total
SPF45 and ERK2 antibodies by western blotting.
Immunoblotting
Cells were lysed and sonicated in M2 buffer with 0.5% SOS and protease inhibitors mix.
Lysates were normalized using BCA protein assay kit (Pierce Rockford, IL). Each sample
(100 Ilg) was run on a 10% polyacrylamide gel (50S-PAGE) under denaturing conditions
and

transferred

to

Protran

nitrocellulose

membrane

(Whatman-GE

Healthcare

Piscataway, NJ). After blocking with 5% milk for 1 hour at room temperature, the
membranes were incubated with relevant primary antibodies (total-SPF45, pThr715PF45, pSer222-SPF45, Myc, ERK, pERK, p38 MAP kinase, p-p38 MAP kinase, JNK, p-JNK
and Actin) in 1X PBS with 5% B5A and 0.1% Tween-20, 0.1% sodium azide (Sigma 5t
Louis, MO) at 4°C overnight. The blots were washed three times in 1X PBS + 0.1%
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Tween-20 and incubated with the appropriate secondary HRP-conjugated antibody
(Mouse, Rabbit (Biorad Hercules, CA)) in PBS-O.l%T with 1% milk for 1 hour at room
temperature. The membranes were then washed 6 times with PBS-O.1%T for a total of 1
hour at room temperature. The membranes were incubated with femto-ECL (Pierce
Rockford, IL) for 2 minutes at room temperature and the bands were exposed on Hyblot
CL films (Denville Scientific South Plainfield, NJ).
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Results
Identification of SPF45 as a novel substrate of ERK2
In previous works, we reported the generation of a mutant ERK2jMAP kinase
(ERK2-Q103G) capable of identifying specific substrate of the enzyme under the desired
cellular conditions (Eblen 2003), and show activation of the ERK2jMAP kinase pathway
in several ovarian cancer cells under anchorage-independent conditions (AI-Ayoubi
2008). Using SKOV3-QT8, an ovarian cancer cell line stably expressing ERK2-Q103G (Fig

2.1 A&B), we screened for potential ERK2-associated substrates in ovarian cancer cells.
SKOV3-QT8 cells were either grown adherent or trypsinized then put in suspension for 3
hrs. Subsequently, the cells were lysed and Flag-ERK2-Q103G immunoprecipitated
under mild conditions to preserve protein-protein interactions prior to incubation for 3
min in kinase buffer containing [32P-y]-N6-cpATP. The kinase reaction was run on a gel
and we detected radiolabeled bands by autoradiography showing labeling of a 47 kDa
band under both conditions (Fig 2.1 C left). A parallel immunoprecipitation and kinase
reaction using more cell lysate from suspended cells and unlabeled cyclopentyl ATP
displayed a silver-stainable band at the same molecular weight (Fig 2.1 C right). Mass
spec analysis of the band identifies several proteins including SPF45, a pre-mRNA
alternative splicing factor.
SPF45 is phosphorylated by ERK2, JNK and p38 MAP kinases on threonine and serine
Since

MAP

kinases

are

serine/threonine

proline-directed

kinases

that

phosphorylate the canonical TjSP or PXTjSP sequences, overlapping substrate specificity
is not uncommon among the different subfamilies. In all that follows, SPF45 cDNA was
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obtained and subcloned into pCMV3-2C (adds a Myc-tag) and pET1Sb (adds a His- tag)
for mammalian and bacterial expression, respectively. Accordingly, we tested whether
phosphorylation of SPF4S by the three MAPK subfamilies occurs, and subjected HisSPF4S to an in vitro kinase reaction with active recombinant ERK2, p38a and JNK1 in the
presence of

[32 p _y ]_ATP.

Protein fractionation by SDS-PAGE showed a radiolabeled band

around 50 KDa corresponding to phosphorylated His-SPF45 (Fig 2.1 D&E). The bands
were

excised

and

processed

for

phosphoaminoacid

analysis

(PAA)

identifying

phosphorylated threonine and serine residues on all three bands (Fig 2.1 F).
Generation of SPF4S antibodies: a-total-SPF4S, a-pThr71-SPF45 and a-pSer222-SPF45
Among the 401 amino acid residues that make SPF45, only two residues conform
to the MAPK substrates criterion. Namely, they are Thr71 and Ser222, which - by
sequence analogy - appear to be highly conserved among mammalian species .
suggesting a role for their phosphorylation in regulating the function of this protein (Fig

2.2 A). As there are no commercially available total and phospho-specific antibodies to
SPF45 . we generated polyclonal antibodies in New Zealand White rabbits. To test their
ability to recognize total-SPF45 as well as pThr71-SPF45 and pSer222-SPF4S by western
blot .. we subjected SPF45 to three different treatments: no ERK2 phosphorylation, with
ERK2 phosphorylation and ERK2 followed by phosphatase treatment (Fig 2.2 8). Antitotal-SPF45 antibody was able to detect His-SPF45 both in the presence and absence of
ERK2 kinase reaction .. but not the empty SPF45 lane. On the other hand .. anti-pThr71SPF4S and anti-pSer222-SPF45 antibodies were weakly able to detect SPF45 before it
was phosphorylated and their specificity was strongly enhanced following incubation

83

with active ERK2. Phosphatase treatment of the Ni++-purified SPF45 after the kinase
reaction showed a decrease in phospho-specific antibodies detection of SPF4S but not
of the total-SPF45 antibody. Altogether, these data support our prediction that Thr71
and Ser222 are ERK2-targeted residues, at least in vitro. To validate the specificity of the
phospho-specific antibodies, we generated single and double mutants of Thr71 and
Ser222 to either alanine (Fig 2.2 C); single and double aspartate mutants were equally
generated for subsequent experiments. As anti-total-SPF45 was mounted against an
epitope that does not encompass the phosphorylation residues, it equally detected
SPF45-mutants (SPF45 T7iA, SPF4SS222A and SPF4S AA ) both before and after ERK2-induced
phosphorylation. Anti-pThr71-SPF4S failed to detect His-SPF4ST7iA and His-SPF4S AA but
not His_SPF4SS222A, while anti-pSer222-SPF4S detects His-SPF45T7iA but not HisSPF4SS222A and His-SPF4SAA following in vitro kinase reaction with ERK2, confirming their
efficacy in specifically identifying SPF45 and its phosphorylated forms (Fig 2.2 D). It is
noteworthy to mention that phosphorylation of SPF45 on Thr71 causes a mobility shift
(Fig 2.20 S222A+ERK2); in a later experiment we show a similar mobility shift for
SPF45 T71D. Finally, we examined and showed SPF45 phosphorylation on Thr71 and
Ser222 in response to JNK and p38 MAP kinases (Fig 2.2 E). Unfortunately, the ability of
these antibodies to immunoprecipitate SPF45 and immunofluorescence cytochemistry is
not successful (data not shown). ELISA and immunohistochemistry (IHC) were not
tested.
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5PF45 and ERK2 are binding partners in vitro and in cells
5PF45 was initially identified as an ERK2-associated substrate in our search for
potential ERK2 targets in 5KOV-3 ovarian cancer cells. MAP kinases are known to bind
their targets in their non-phosphorylated state prior to activation and detachment from
the protein complex, potentially through interactions with the O-domain in the target
protein (Cobb 1995). Although not tested, the amino acid sequence of 5PF45 exhibits a
151

and a potential overlap with a

nuclear localization signal (N L5) which can possibly explain the nature of interactions
between ERK2 and 5PF45. To support the hypothesis of binding between ERK2 and
5PF45, His-ERK2 was incubated overnight at 4°C with nuclear extracts from HeLa cells,
pulled-down the following day with Ni++-conjugated agarose beads solubilized in 1X
sample buffer and fractionated by 50S-PAGE. Immunoblotting with anti-total-5PF45
antibody shows 5PF45 in the ERK2-pull-down, but not with Ni++ beads alone (Fig 2.3 A),
and the amount of 5PF45 recovered from the nuclear extract was dose-dependent to
the amount of His-ERK2 in the pull-down assay (Fig 2.3 B), indicating a stoichiometric
binding of ERK2 to 5PF45. Efforts to show the reciprocal binding of recombinant HisERK2 with recombinant 5PF45 were not successful since both proteins are His-tagged
and efforts to generate GST-SPF45 were futile possibly due to solubility issues (data not
shown) . Using SKOV3-pQCXIP and SKOV3-pQCSPF45, two cell lines stably expressing
empty vector and Myc-SPF45 respectively generated in the next chapter, we showed
that ERK2 co-immunoprecipitates with SPF45 but not the empty vector (Fig 2.3 C). Taken
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together, we confirmed that ERK2 and SPF45 bind together both in vitro and in cells
supporting a genuine interaction between ERK2 and its target, SPF45.
Phosphorylation of SPF45 in Cos-1 cells in the presence of constitutive activation of the
ERK2/MAP kinase pathway
To characterize SPF45 phosphorylation in cells in response to continuous
MEK1/ERK2 activation, we transfected Myc-SPF45/mutants (to alanine and aspartate)
into Cos-1 cells along with constitutively-active MEK1-S222/2224D (CA-MEK1{DD)) and
ERK2 (Fig 2.4 A). Twenty four hours hours post-transfection, the cells were lysed and
Myc-SPF45/mutants were

Myc-immunoprecipitated.

Immunoblotting against anti-

pThr71-SPF45, anti-pSer222-SPF45 and anti-Myc antibodies showed that SPF45 is
phosphorylated on both Thr71 and Ser222 in agreement with the in vitro kinase assay.
Mutations of Thr71 to either alanine or aspartate inhibited its phosphorylation but not
Ser222. Similarly mutations of Ser222 to either alanine or aspartate prevented its
phosphorylation but not Thr71. To note, we also observed a shift in SPF45 molecular
weight with Thr71 phosphorylation that corresponds to the mobility shift displayed by
SPF45 T71D mutant. Although CA-MEK1(DD) causes a permanent ERK2 activation, no such
mutation is observed to occur naturally in cells. Hyperactivation of the MAP kinase
pathways is linked to several mechanisms, including but not limited to: overexpression
of receptor tyrosine kinases (RTKs), pathophysiological processes such as inflammation
and stress, and in cancer due to activating mutations in the upstream signaling cascade
of ERK2 such as K-Ras, H-Ras and B-Raf (see the "Introduction" chapter for more
details). We transfected Myc-SPF4S into Cos-1 cells along with K-Ras-G12V, B-Raf-V600E
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or CA-MEK1{DD) with or without ERK2 (Fig 2.4 B). Co-transfection of each member of
the pathway stimulated SPF45 phosphorylation on both Thr71 and Ser222 above basal
levels which was further enhanced on Ser222 phosphorylation and greatly induced
Thr71 phosphorylation by addition of exogenous ERK2. Using Cos-1 cells as a "neutral"
milieu for studying SPF45 phosphorylation, we showed that hyperactivation of
ERK2/MAP kinase pathway results in Thr71 and Ser222 phosphorylation indicating that
SPF45 could be phosphorylated on these two residues in cancer cells that have elevated
ERK2/MAP kinase expression and activation levels as demonstrated by the assay above.
We further examined the validity of this hypothesis below in ovarian cancer cell lines.
Phosphorylation of endogenous SPF45 in ovarian cancer cells following extracellular
stimulation of MAP kinases pathways
Phosphorylation of endogenous SPF45 has not been reported. We showed above
that Thr71 and Ser222 are MAP kinase targets for SPF45 phosphorylation in vitro and by
forced phosphorylation of exogenous SPF45 in Cos-1 cells. Previously published data
(Sampath 2003) showed SPF45 to be overexpressed in several solid cancers including
ovarian cancer. Since SPF45 is an ERK2/MAP kinase substrate in SKOV3 cells, we sought
to validate Thr71 and Ser222 as genuine MAP kinase targets on endogenous SPF45 and
to characterize the pattern of SPF45 phosphorylation in cells. Screening for SPF45
expression levels in several ovarian cancer cells and lOSE cells, a benign immortalized
ovarian cell line, revealed the following: lOSE expressed little SPF45 and would
accordingly serve as a negative control while the A2780 cancer cell line showed the
highest levels of SPF45 expression followed by ES2, OV2008, OVCAR-3 and OVCAR-5
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cells, in no specific order (Fig 2.5 A). We observed basal levels of Thr71 and Ser222
phosphorylation in all cell lines tested (Fig 2.5 A). Immunoblotting with anti-phospho
MAP kinase antibodies revealed variable expression/activation of ERK, p38 and JNK
kinases, with most exhibiting elevated ERK1/2 activation. Based on these results, we
speculate that SPF45 maintains a basal phosphorylation level required for its ubiquitous
functions depending on cellular conditions; additionally, an elevation in Thr71 and/or
Ser222 phosphorylation levels in response to MAP kinase(s) activation can potentially
reflect increased cellular requirement of SPF45 functions, which remains to be
demonstrated.
We originally identified SPF45 as an ERK2-associated substrate from anoikisresistant SKOV-3 cells grown in suspension. Therefore, it was natural to test the
phosphorylation of endogenous SPF45 in SKOV-3 cells that are either grown adherent or
detached (Fig 2.5 B). Endogenous SPF45 was phosphorylated detached but not adherent
cells, suggesting that SPF45 phosphorylation, like ERK2 activation is anchorageindependent in ovarian cancer cells (AI-Ayoubi 2008).

In what follows, we describe several experiments performed to identify
extracellular stimuli that induce SPF45 in ovarian cancer cells and to identify the MAP
kinase pathway(s) responsible for SPF45 phosphorylation. For these experiments we
used A2780 (Fig 2.5 C), ES2 (Fig 2.5 D) and SKOV3 (Fig 2.5 E) cells as they had three
different levels of SPF45 expression: high, medium and modest, respectively. After
serum starvation overnight the cells were treated with agents that stimulate the various
MAP kinase pathways, including fetal bovine serum, phorbol myristate acid (PMA),
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H2 0 2, anisomycin, EGF, HGF, sorbitol and ultraviolet (UV) light. In A2780 cells, PMA - an
activator of ERK and p38 - stimulated high Thr71 phosphorylation and moderate Ser222
phosphorylation.

Anisomycin

-

an

activator

of JNK

-

stimulated

high

Thr71

phosphorylation, with little to no increase in Ser222 phosphorylation. Similar results
were observed with UV treatment, which activated both JNK and p38. H2 0 2, an acute
stimulator of intracellular ROS and an activator of both p38 and ERK, induced
phosphorylation of both sites equally. In ES2 cells, no change in Ser222 phosphorylation
was observed with the different stimuli tested. Thr71 on the other hand exhibited
elevated phosphorylation levels that were more pronounced an hour following UV,
anisomycin, sorbitol, H2 0 2 and EGF stimulation. Finally, in SKOV3 cells, both Thr71 and
5er222 phosphorylations were observed; Thr71 phosphorylation was more pronounced
under serum starvation, H2 0 2 and UV stimulation while Ser222 phosphorylation was
highest following UV, EGF and HGF stimulation.
To determine which MAP kinase pathway(s) was responsible for endogenous
SPF45 phosphorylation in cells, A2780 cells were serum starved, pretreated for 30 min
with a specific MAP kinase pathway inhibitor and then stimulated as above in the
presence of the inhibitor (Fig 2.5 F&G). The MAP kinase pathway inhibitors used were
U0126 for the ERK pathway, 5B203580 for the p38 pathway and 5P600025 for the JNK
pathway. U0126 inhibited 5PF45 phosphorylation in response to PMA and H2 0 2; on the
other hand, SP600025 inhibited 5PF45 phosphorylation in response to UV light, while
5B203580 inhibited 5er222 only in response to UV, suggesting that ERK, JNK and p38
MAP kinase are able to phosphorylate endogenous SPF45 in response to extracellular

89

signals in a stimulus-dependent manner. Although we were unable to find a stimulus
that significantly induced SPF45 phosphorylation on both Thr71 and Ser222 in a p38dependent manner, we have observed SPF45 phosphorylation on Thr71 and Ser222
when SPF45 was co-expressed in Cos-1 cells along with MKK3 and p38 (data not shown).
Accordingly, SPF45 phosphorylation in a p38-dependent manner, if it were to happen, is
more likely to be stimulus and cell type-dependent.
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Fig 2.1 SPF45 is a novel MAP kinase substrate A. FLAG-ERK2-Ql03G or FLAG-ERK2 is stably
expressed in SKOV-3 cells via retroviral infection. Cell Iysates are used to detect exogenous
and endogenous ERK2 expression in several clones. B. Immunofluroescence using Flag
antibody and clone QT8 demonstrates efficient ERK2-Ql03G expression. C. FLAG-ERK-Ql03G
is immunoprecipitated from SKOV-3 clone QT8 either growing adherent {Adh} or anchorageindependent (Susp) for 3 hr. Co-immunoprecipitating substrates are labeled in an in vitro
kinase reaction with [32P-y]-cyclopentyl ATP {left}. A silver-stained scaled-up non-radioactive
kinase assay is performed in parallel {right} and SPF45 is identified by mass spectrometry
from this protein band among several other targets. D. In vitro MAPK kinase reaction using
active recombinant ERK2, JNKl or p38a, and [32P-y]-ATP and His-SPF45 as substrate. The
reactions are run on a gel and exposed for autoradiography. E. Histogram of counts per
minutes (cpm) obtained from the phosphorylated SPF45 bands. F. Phosphorylated His-SPF45
from the reactions in 0 are digested with HCI and processed for 2-dimensional phosphoamino
acid analysis before exposure for autoradiography. Experiments performed with Scott Eblen.
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Discussion
Identification of MAP kinase substrates in their tissue-specific expressions as well
as their spatio-temporal regulation is an important task in order to dissect the exact
roles the different MAP kinases play in controlling cellular functions. Using the approach
developed by Shokat (Shah 1997) and modified for ERK2 by our group (Eblen, 2003), we
report the detection of SPF45, a pre-mRNA alternative splicing factor, as a novel
substrate of ERK2 in SKOV3 cells, an ovarian cancer cell line that we previously showed
to strongly activate ERK2 pathway under anchorage-independent conditions (AI-Ayoubi
2008). Radio-labeling of ERK2-associated substrates with a

32 p

isotope under anchorage-

dependent and -independent conditions revealed a phosphorylated band at 47Kda
corresponding to SPF45, which was detected by mass spec analysis of a silver-stained
equivalent band. We further showed, using phospho-amino acid and mutational
analyses, that Thr71 and Ser222 are the MAP kinase-target residues. We also confirmed
that SPF45 is similarly phosphorylated by JNK and p38 MAP kinases, in vitro, on Thr71
and Ser222. We generated polyclonal and phospho-specific antibodies against the total
protein as well the phosphorylated epitopes, and used them to determine the
phosphorylation of transfected SPF45 in Cos-1 cells in response to co-expressing
activators of the ERK2/MAP kinase pathway which had the highest response upon coexpression of activated MEKl and ERK2, simulating a continuous upstream signaling to
ERK2. We also explored the phosphorylation of endogenous SPF45 in several ovarian
cancer cell lines in response to stimulation with known activators of the different MAP
kinase pathways. In A2780, ES2 and SKOV3 cells, SPF45 phosphorylation was mainly
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induced following ERK (serum, PMA, EGF and HGF) and JNK (anisomycin and UV
irradiation) activation but weakly in response to p38 (sorbitol and H2 0 2 ). While p38 MAP
kinase strongly phosphorylated SPF45 in vitro, the response is, at best, modest in these
cells in response to the stimuli tested. Additionally, using chemical inhibitors of the
different kinase pathways supported our observation that ERK and JNK were more
involved in SPF45 phosphorylation, at least in response to the stimuli we used, even
stimulation by H2 0 2

-

a strong p38 activator - was rather mediated by ERK. While it

does not rule out the possibility that p38 MAPK has the potential of regulating SPF45
phosphorylation (such as Ser222 phosphorylation in response to UV light), it clearly
indicated the specificity of the different kinases in controlling SPF45 functions. In fact,
both Thr71 and Ser222 were phosphorylated upon ERK activation while JNK had a more
pronounced effect on the phosphorylation of Thr71 compared to Ser222. Taken
together, we predict that the phosphorylation pattern of SPF45 coupled with the spatiotemporal activation of the responsible kinase to dictate the function of the protein in a
stimulus-dependent fashion.
SPF45 is a highly conserved protein among vertebrates, exceeding 80%
homology.

Interestingly, peptide

sequences surrounding Thr71

and

Ser222 are

conserved as well, suggesting an old and preserved role of the phosphorylation in
regulating the functions of SPF45. In Xenopus, the homolog of Thr71 is however
replaced by a serine followed by a proline, which actually retains the ability to be
phosphorylated by MAP kinases and therefore potentially preserves its function. As
Thr71 lies in the N-terminal domain whose structure has not been resolved yet, it is hard
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to speculate on the role that the phosphorylation may impart on the protein. Ser222 lies
in the SPF45-like (SF) motif, in the vicinity of the G-patch domain. It is unclear what a
phosphorylation in the vicinity of a G-patch motif or within the SF-domain will do to the
protein's functions as there are no accounts linking these domains and phosphorylation.
The SF motif is involved in protein oligomerization (although no oligomerization of
SPF45 has been described yet) and the G-patch is linked to protein and ribonucleic acid
interactions. Accordingly, we suspect that the phosphorylation on Ser222 to play an
important role, possibly more so than Thr71, in modulating SPF45's interactions within
the spliceosome, as well as any other protein complex it can be involved with. Previous
studies

linked

SPF45 to

DNA repair pathways,

multidrug resistance,

apoptosis

regulation, spinocerebellar ataxia as well as ~-thalassemia. As diverse as these functions
may be, determining SPF45 targets and the effect that the phosphorylation plays is
needed to better understand how it can be mediating some or all of these effects.
Similar to the MAP kinase-targeted splicing factor Sam68, these functions can be
mediated by the impact of more than one kinase, while the same phosphorylation may
have different outcomes based on several factors - including but not limited to - the
cellular distribution of SPF45 and its interaction with spliceosomal protein complexes. In
fact, regulation of splicing factors by MAP kinase pathways is a rare event. Evidence of
involvement of signaling pathways in regulating splicing factors are accruing; however,
Sam68 remains the only splicing factor which is known to be under direct regulation of
ERK/MAP kinase pathway to date (Matter 2002). Forced expression of Sam68 leads to
an increase in inclusion of C044 variable exon vS in an ERK-dependent fashion. Fyn, a
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src-tyrosine kinase, also phosphorylates Sam68, causing an increase in the pro-apoptotic
Bcl-x(s) isoform (Paronetto 2007), but it does not have any effect on CD44 v5 inclusion,
indicating the specificity of the different phosphorylations in modulating the splicing
activity. HnRNP Al, a general repressor of splicing, is phosphorylated by Mnkl in
response to MKK3/6/p38 activation following osmotic response, inducing its detainment
in the cytosol

lifting the

ban

on

splicing (Guil

2006).

Although

not directly

phosphorylated by p38, this is another example of the implication of MAP kinases in
splicing, a function that is mainly performed by splicing factors specific kinases, such as
SRPKs, ClKs/STY and Topol. In a similar analogy, SPF45 phosphorylation in a MAP
kinase-dependent manner is expected to be involved in the regulation of many
downstream targets, the identification of which and determining the role of the splicing
in modulating their expression patterns are crucial to understand the effect that SPF45
induces in the biology of the cells in general and cancer cells more specifically.
Incessant and aberrant proliferations as well as altered genomic profiles are
among the hallmarks of cancer cells (Hanahan 2000). An interesting question that arises
in this context is the meaning of increase in splicing factors levels and activities. For
example, is SPF45 over-expression in ovarian cancer cells a cellular necessity imposed by
the new status of the cells or is it a mere bystander that evolved in the middle of the
genomic chaos of cancer? The fact that the levels of SPF45 are increased in many types
of cancer compared to their normal counterparts (Sampath 2003), as well as our
observation that - although not consistent in all tested cell lines -, there is an obvious
increase in SPF45 expression in ovarian cancer cells compared to the benign
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immortalized lOSE, suggests that SPF45 is a necessary component of what one might call

IIcancerome". Additionally, the different potential combinations of splicing factors which
in part depend on the balance of their expression levels can possibly outweigh the
number of transcription factors; as such, an increase in a specific splicing factor such as
SPF45 must have its tremendous effects on the cellular biology. Hence, identifying the
downstream targets of SPF45, as well as SPF45 interacting partners and their posttranslational modifications, becomes necessary to determine its role and to develop
successful chemotherapeutic strategies. In the next chapter, we discuss the effect of
SPF45 phosphorylation on its splicing activity, identify genetic changes induced by SPF45
overexpression, novel SPF45-splicing targets and address their impact on ovarian cancer
biology.
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Chapter 3: Regulation of SPF45 splicing activity by MAP kinase phosphorylation. Role
of Thr71 and Ser222 in modulating SPF45 functions.
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Introduction

In analogy with electronic circuits, post-translational modifications serve as
molecular switches that regulate proteins' functions, turning them "on/off" or even
changing their function radically. In that sense, protein phosphorylation is regarded as
one of the main regulatory molecular switches, and splicing factors are no exception.
Phosphorylation of SR proteins and hnRNPs has been extensively studied and shown to
regulate the formation of the mRNP-spliceosome complex -the major structure that
determines the outcome of the splicing reaction. It also controls the spatial localization
of the splicing factors in the nucleus and the cytosol (Stamm 2008). Phosphorylation of
SR proteins is central for homophilic and heterophilic interactions; for example,
phosphorylation of SR proteins is important in determining the outcome of alternative
splicing. Tripathi et al. show that a long nuclear noncoding RNA, MAlAT-l, regulates
alternative splicing through modulating the phosphorylation of SR proteins, influencing
their subnuclear localization (Tripathi 2010). Phosphorylation of SF2/ASF splicing factor
3s

has a wide array of effects on its interactions: no effect is seen on binding to U2AF , but
it positively reinforces the interactions with Ul-70K (Xiao 1997) while it negatively
affects its interactions with TAP/NXF1, SRp40, hTra2 and itself (Xiao 1997, 1998).
PI3K/Akt, elKs and Topo I phosphorylation of SRp75, SRp55 and SF2/ASF enhance
human tissue factor (HTF) mRNA splicing {Eisen reich 2009 alb}. Phosphorylation of
SRp38 on the other hand, changes its function from a repressor to activator of splicing
(Feng 2008).
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Another class of alternative splicing factors, hnRNPs, commonly identified as
repressors of splicing, can also be under the control of phosphorylation. SF1, a member
of the hnRNP K family, is phosphorylated by PGK-I which inhibits its interactions with
U2AF

65

preventing spliceosome assembly {Wang 1999}. Casein kinase II-type activity is

responsible for hnRNP C phosphorylation, affecting the RNA binding capacity {Fung
1997}. Fas-activated Ser/Thr kinase {FAST} phosphorylates the hnRNP protein TIA-1,
strengthening its interactions in the spliceosome and enhancing its pro-apoptotic effects
{Tian 1995}. Phosphorylation of hnRNP A1 by Mnk1 in a p38 MAP kinase-dependent
manner in response to osmotic stress causes its localization to the cytoplasm {van der
Houven van Oordt 2000}, and induces senescence in normal human fibroblast cells
{Shimada

2009}.

Changes

in

localization

are

also

observed

with

SR

protein

phosphorylation, such as the changes in associations between SRi and importin and
transportin families {Kataoka 1999, Lai 2000, 2001}.
The mechanism by which SPF45 concerts its effects is still under investigation.
Although initially found to be recruited by the polypyrimidine-tract binding protein
(PTB) to the cryptic 3' AG-dinucleotide of the Drosophila Sxl pre-mRNA {Lallena 2002},
SPF45 exerts more complicated interactions in the splicing of Fas exon 6. Since neither
the G-patch nor RRM domains are able to bind a RNA oligonucleotide, SPF45
interactions with the pre-mRNA are expected to occur through binding to other factors
within the spliceosome in a UHM-ULM fashion (UHM: U2AF Homology Motif; ULM:
UHM !:igand Motif) (Corsini 2007). UHM-ULM interactions are not uncommon among
proteins within the spliceosome. Indeed, the SPF45 RRM domain coincidently matches a
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UHM domain and interacts with ULMs of the constitutive splicing factors U2AF

65

,

SFl

and SF3bl55: isolated SPF45 UHM domain co-immunoprecipitates with GST-tagged
isolated ULM domains of the aforementioned factors (Corsini 2007). By the same
authors, they show using ULM-selective SPF4s mutants that these interactions are
necessary for SPF45 splicing activity in HeLa cells, while mutations that do not disrupt
the interaction perform equally to the wild type in splicing. Interestingly, they suggest
that phosphorylation events on SF1 and SF3blss to be important in regulating a
potential sequential mode of binding and interactions.
Our interest in SPF4s stems from its involvement in cancer, and ovarian cancer in
particular, where it was shown to confer a multi-drug resistance phenotype in an
ovarian cancer cell line (Perry 2005). Additionally, it is implicated in DNA repair (Chaouki
2006) and alteration of splicing (Lallena 2002, Corsini 2007), yet very little is known
about the mechanism(s) of its actions. Although some splicing factors, such as NOVA,
work in a tissue specific manner (Buckanovich 1993), the majority of these proteins have
universal tissue-independent functions. The balance of the splicing factors expressed in
cells dictates the general pattern of genetic and, consequently, proteomic events
(Mayeda 1993). Accordingly, identifying the targets of SPF45 in ovarian cancer cells is a
crucial step in unveiling its involvement in the pathobiology of the disease. In this
chapter, we determine the effect of phosphorylation of SPF45 by ERK2 and p38MAP
Kinase on Thr71 and Ser222 on its splicing function using a minigene reporter construct.
We also generate stable SKOV3 cell lines expressing ectopic wild type SPF45 or mutants
(SPF4s

AA

and SPF4s

DD

)

and investigate their drug resistance profile. Using the stable
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cells, we perform a gene and exon-array to identify novel downstream genetic and
splicing targets of SPF45 that are dysregulated by SPF45 expression and assess the
impact of the mutation on Thr71 and Ser222 on these targets. Molecular changes
associated with these genetic changes are investigated as well. Finally, we use the stable
cells to determine the role of the phosphorylation sites in SPF45 binding to constitutive
splicing factors, in an effort to understand the mechanism of regulating the interactions
which are believed to dictate SPF45 outcomes.
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Materials and Methods
Plasmids and minigene system
Genomic DNA was isolated from lOSE cells by phenol/chloroform extraction followed by
ethanol precipitation. Fas genomic DNA spanning exon 5 through 44 base pairs into
exon

7

were

amplified

by

PCR

using

the

following

primers:

FasS_primer

AGATGTGAACATGGAATCATCAAGGA & Fas3_primer TTICCTTTCTGTGCTITCTGCATGTI.
The amplicon was subcloned into Topo 2.1 vector (Invitrogen Carlsbad, CAl and the
following primers: FaslnRe5_primer GTAAGAATGAGGCAAATCTTIGTGA-3' and FaslnRe3_primer s'-CCTICTTATATITCTCTTAGTGTGAAAGTA-3' were used to amplify the whole
plasmid leaving out 1105 bp spanning nucleotides 53 through 1183 from the 5' -end of
intron 6 and the resulting amplicon was incubated with T4 DNA ligase (New England
BioLabs Ipswitch, MA) overnight at 16°C for blunt ligation. Fas DNA was cut using EcoRI
(New England BioLabs Ipswitch, MA) and ligated into the multi-cloning sequence of
pCDNA3 downstream of a CMV promoter to generate the !:lfas minigene.
Generation of SKOV3 stable eel/lines
AA

Retroviral plasmids (pQCXIP) encoding empty vector/SPF45/SPF4s /SPF45

DD

were

transfected into 293T cells along with pAMPHO, VSV-G and Gag/Pol for virus production
and packaging. Cellular media containing the viruses were harvested at 36 and 60 hours
post transfection, filtered with 45

~m

syringe filters (Corning Lowell, MA) and mixed

with polybrene (Sigma St Louis, MO) to a final 2llg/ml concentration before infecting the
SKOV3 target cells. Cellular populations expressing the genes of interest were pooled
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and selected with 1.5 Ilgjml puromycin for 2 weeks. Following the 2 weeks period,
puromycin is added at half strength as a maintenance dose.
SPF45 binding assays

SKOV3-Vecj-SPF45j-SPF45

AA

j-SPF4S

DD

cells were grown to confluence in a 10 cm cell

culture dish (Corning Lowell, MA) at 37°C, 5% C02 and harvested with M2 lysis buffer
(150 mM NaCl, 5 mM KCI, 1 mM CaCI2, 1 mM MgCI2, 50 mM HEPES, pH 7.4) on ice.
Homogenized Iysates were incubated on ice with occasional vortexing followed by
centrifugation for 15 min at 15000 rpm 4°C to separate the debris from the soluble
phase. Standard BCA (Pierce Rockford, IL) assay was used to quantify protein
concentrations. 1000 Ilg of protein Iysates were incubated with protein agarose beads
pre-conjugated to Myc antibody for 24 hours at 4°C. The beads were spun down quickly
and washed three times with gentle vortexing three times using M2 buffer before
adding 1X Laemmli sample buffer and boiling for 3 minutes. The proteins were
separated on a 10% 50S-PAGE gel (Biorad Hercules, CAl and transferred onto
nitrocellulose membrane.
!Jfas alternative splicing assay
A- Transfections
5

2.5x10 Cos-1 cells were plated the night before transfection on 6-well plates (Corning
Lowell, MA) and transfected the following day with 1.2 Ilg total of DNA. Briefly, 1.2 Ilg
total DNA and 4.8 III of Lipofectamine 2000 (Invitrogen Carlsbad, CAl were suspended in
0.25 ml of Optimem (Invitrogen, Carlsbad) each for 5 minutes at RT, then mixed
together for a total of 20 minutes at RT before drop wise addition onto cells. The media
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and transfection mixture were recollected 5-6 hours following transfection, washed
once in PBS and incubated in fresh media supplied with 10% FBS. The cells were
harvested in TRlzol (Invitrogen Carlsbad, CAl 24 hours post-transfection.
8- RNA isolation

RNA was isolated from cells by phase separation using TRlzol (Invitrogen Carlsbad, CAl
followed by chloroform (Sigma St Louis, MO) extraction and isopropanol (Sigma, St
Louis) precipitation. The RNA was washed twice in 75% ethanol and re-suspended in 25

III of DEPC (Fisher Pittsburgh, PAl-treated water. Total RNA purity and concentration
were assessed by UV-spectrophotometry.

C- RT-PCR and gel-electrophoresis
2.0 Ilg of total isolated RNA were reverse-transcribed in a 20.0 111 reaction using the High
Capacity cDNA Reverse Transcription Kit {Applied Biosyst Carlsbad, MA} according to the
manufacturer's protocol. Cycling parameters were the following: 25°C for 10 min, 37°C
for 120 min, 85°C for 5 min then hold at 4°C. Randomly-primed cDNA was used for
subsequent amplification. 1.0 111 cDNA was mixed with 200nM of each of the forward
and reverse primers and 23.5 111 PCR supermix (Invitrogen Carlsbad, CAl. Cycling
parameters were the following: 94°C for 5 min, followed by 22 cycles of 94°C, 58°C and
72°C for 30 sec each, followed by 10 min extension at 72°C then hold at 4°C. PCR
products were separated and quantified on an ethidium bromide-stained 2% agarose
gel.
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Real time qRT-PCR

Total cellular RNA for use in quantitative RT-PCR assay was extracted from confluent
AA

SKOV3 cells stably expressing empty vector/SPF4S/SPF4S /SPF4S

DD

using TRlzol

(Invitrogen Carslbad, CAl lysis followed by chloroform/isopropanol extraction and
precipitation and ethanol washes. RNA samples purity was assessed by an A26o/A28o ratio
between 1.9 and 2.1 and total RNA was quantified by UV-spectrophotometry by
absorbance at 260nm wavelength. Total RNA (2.0 Ilg) was transcribed to randomprimed cDNA using High Capacity cDNA Reverse Transcription Kit (Applied Biosyst
Carlsbad, CAl according to manufacturer's protocol in a 20.0 III reaction. The resulting
2
cDNA was subjected to real-time PCR using RT SYBR Green dye (Qiagen Valencia, CAl
and pre-validated primers for the following genes: erbB2, FN1, TGF-f3 and periostin
(Qiagen Valencia, CAl while 18s rRNA (Qiagen Valencia, CAl was used as an internal
2
control. 1.0 III of the first-strand eDNA product was mixed with 12.5 III of RT SYBR Green
qPCR Master Mix (Qiagen Valencia, CAl, 10.5 III of H20 and 1.0 III of gene-specific 10uM
PCR primer pair stock in a 25.0 III reaction. Each sample was run in duplicate and a total
of 3 independent repeats were performed. Cycling parameters were 50°C for 2 min and
95°C for 10 min followed by 40 cycles of 95°C and 60°C for 15 and 60 seconds,
respectively. A single band for each of the PCR products was observed on an ethidium
bromide-stained 2% agarose gel electrophoresis assessing products integrity. Threshold
cycle (CT ) values were determined for each gene and the corresponding 18srRNA. Fold
change in gene expression was calculated by the l:!l:!C T method.
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Cell proliferation rate

s
SKOV3 stable cell lines (lxl0 ) were plated on 6 well plates on day 1 and counted at 24
hr intervals. Briefly, the cells were gently washed with PBS, trypsinized in 100 Ill, and
collected with 100 III McCoy's supplemented with 50% FBS. Cells were homogenously
suspended and manually counted using a hemocytometer.
Cellular adhesion assay
96-well tissue culture dishes were coated with fibronectin (20 Ilg/ml), laminin-l (10
J,.lg/ml), poly-L-Lysine (10 Ilg/ml) or nothing overnight at 4°C. Plates were washed twice
with washing buffer (0.1% BSA in PBS) and blocked with blocking buffer (0.5% BSA in
PBS) at 37°C for 60 min, followed by washing buffer and chilled on ice. Stable SKOV3

s
cells were suspended at 4x10 celts/ml and 50 III of the suspension were aliquoted into
the wells. Plates were incubated at 37°C, 5% C02 for 30 min, then placed on a plate
shaker at 2000 rpm for 15 sec. Unattached cells were removed by aspiration and the
wells were gently washed with washing buffer, stained with crystal violet (5 mg/I in 2%
ethanol) for 10 min, washed gently three times and dried at room temperature. Crystal
violet stain was solubilized in 2% SDS and plates were read at 550 nm.
MTS cytotoxicity/proliferation assay
SKOV3-pQCSPF45 or control were seeded on 96 well-plates (3.0xl03 celis/1001l1/well)
and treated the following day with increasing concentrations of the following
chemotherapeutic agents: cisplatin, doxorubicin, etoposide, mitoxantrone, paclitaxel
and vincristine (Sigma, St Louis). 72 hours later, cell viability/proliferation was measured
in a colorimetric assay using the tetrazolium salt 3-(4,5-dimethylthiazole-2-yl)-2,5-
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diphenyltetrazolium bromide MTS kit (Promega

Madison, WI) as described by

manufacturer and analyzed on a bioard 96-well plate spectrophotometer. All assays
were performed in triplicate with three independent experiments.

Immunoblotting
Cells were lysed and sonicated in M2 buffer with 0.5% SDS and protease inhibitors mix
(100 11M Na-o-vanadate, 50 mM NaF, 40 mM J3-glycerophosphate, 5 mM Napyrophosphate, Aprotinin and 2 mM PMSF). Lysates were normalized using BCA protein
assay kit (Pierce Rockford, IL). Each sample (100 Ilg) was run on a 10% polyacrylamide
gel (SDS-PAGE) under denaturing conditions and transferred to a Protran nitrocellulose
membrane (Whatman-GE Healthcare, Piscataway, NJ). After blocking with 5% milk for 1
hour at room temperature, the membranes were incubated with relevant primary
antibodies {Myc, erbB2, SFI, SF3b155 and Actin} in PBS with 5% BSA and 0.1% Tween20, 0.1% sodium azide at 4°C overnight. The blots were washed three times in 1X PBS +
0.1% Tween-20 and incubated with the appropriate secondary HRP-conjugated antibody
(Mouse, Rabbit (Biorad Hercules, CA)) in IX PBS-O.I%T with 1% milk for 1 hour at room
temperature. The membranes were then washed 6 times with PBS-O.I%T for a total of 1
hour at room temperature. The membranes were incubated with femto-ECL (Pierce
Rockford, IL) for 2 minutes at room temperature and the bands were exposed on Hyblot
CL films (Denville Scientific South Plainfield, NJ).

Immunofluorescence
4

7.5x10 SKOV-3 stable cells were plated on glass cover slips pre-coated with fibronectin
(10ug/ml) and incubated at 37°C, 5% CO 2 . 24 hours later, the cells were washed 1X with
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PBS and fixed with 4% formaldehyde for 30 min at room temp. The cells were then
permeabilized with ice cold 1% Triton-X on ice for 5 min followed by blocking with 5%
BSA (Fisher Pittsburgh, PAl for 30 min at room temp. The glass cover slips were
incubated with Myc-antibody (1:1000 dilution) for 1 hour at room temperature in the
dark, followed by another hour of incubation with secondary anti-rabbit antibody
conjugated to FITC. The cover slips were washed in lX PBS then ddH 20 and mounted on
microscope glass slides. Nuclei were stained with DAPI. Slides were visualized using epifluorescence on a Nikon microscope.
Gene- and exon-array analysis
Total RNA was amplified using the NuGEN™ Applause™ WT-Amp Plus ST Amplification
System. First-strand synthesis of cDNA was performed using a unique first-strand
DNA/RNA chimeric primer mix, resulting in cDNA/mRNA hybrid molecules. Following
fragmentation of the mRNA component of the cDNA/mRNA molecules, second-strand
synthesis was performed and double-stranded cDNA was formed with a unique
DNA/RNA heteroduplex at one end. In the final amplification step, RNA within the
heteroduplex was degraded using RNaseH, and replication of the resultant singlestranded cDNA was achieved through DNA/RNA chimeric primer binding and DNA
polymerase enzymatic activity.

A modification step targeting the amplified single-

stranded cDNA resulted in the generation of sense-strand cDNA product compatible
with the Affymetrix GeneChip® Exon arrays. The ST-cDNA was purified for accurate
quantitation of the cDNA and to ensure optimal performance during the fragmentation
and labeling process. The ST- cDNA was assessed using spectrophotometric methods in
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combination with the Agilent Bioanalyzer. The appropriate amount of amplified 5TcDNA was fragmented and labeled using the Encore™ cDNA Biotin Module. The
enzymatically and chemically fragmented product (50-100 nt) was labeled via the
attachment of biotinylated nucleotides onto the 3 1-end of the fragmented 5T-cDNA. The
resultant fragmented and labelled 5T-cDNA was added to the hybridization cocktail in
accordance with the NuGEN™ guidelines for hybridization onto Affymetrix GeneChip®
arrays. Following the hybridization for 16-18 hours at 45°C in an Affymetrix GeneChip®
Hybridization Oven 640, the array was washed and stained on the GeneChip® Fluidics
Station 450 using the appropriate fluidics script, before being inserted into the
Affymetrix autoloader carousel and scanned using the GeneChip® Scanner 3000.

Statistical Analysis
Statistical analysis was performed at p< 0.05 level of significance and determined using
one-way ANOVA with Tukey's post-hoc test.
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Results

SPF45 causes increase in ~fas splicing in a dose-dependent manner
Regulation of alternative splicing of Fas cassette exon 6 is influenced by the
increase in SPF45 expression based on a screen of SPF45 splicing targets in HeLa cells
(Corsini 2007). Although the splicing activity has been shown to be confined to its Cterminal RNA recognition motif (RRM) (Corsini 2007), it remains necessary to identify
the factors that influence SPF45-alternative splicing function. The in vivo model of
alternative splicing using a Fas minigene represents an ideal approach to study the
effect of trans factors on regulation of splicing, as it preserves the cellular splicing
machinery in its optimal milieu. Genomic Jas DNA purified from lOSE cells was used to
create a minigene labeled llJas (Fig 3.1 A) (Cascino 1995), spanning exon 5 through 44
base pairs of exon 7 and including introns 5 and 6 with a 1105 bp deletion in intron 6,
previously shown not to hinder the ability of Fas to undergo alternative splicing (Cascino
1997). To determine the appropriate dose of SPF45 to be transfected into the cells along
with llfas, increments of SPF45 DNA were transfected into Cos-1 cells with a fixed ~fas
amount (0.3 (..lg): 0.4, 0.8, 1.2 and 1.6 (..lg of SPF45 DNA were co-transfected with ~fas;
the total DNA mix was kept at a constant amount of 2.0 (..lg by adding the appropriate
amount of empty pCMV3-2c vector (Fig 3.1 a). RT-PCR analysis of the resulting splicing
reaction showed a dose-dependent increase in exon 6 exclusion, reaching around 50%
between 0.4 and 0.8 ~g of transfected SPF45. Accordingly, we considered 0.6 (..lg of
SPF45 as the optimum dose in our splicing model to study the influence of
phosphorylation of SPF45 on its alternative splicing function.
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ERK phosphorylation of SPF45 reduces its alternative splicing activity towards ~fas
Post-translational modifications (PTMs) of proteins play an important role in
determining their functional outcomes and phosphorylation is one of the most studied
and investigated PTMs on proteins, as it mediates the effect of the majority of kinase
signaling cascades. Phosphorylation of spliceosomal proteins and their associated
proteins has been extensively studied and remains mostly carried out by spliceosomal
protein-specific kinases such as SRPKs, ClKs and topoisomerase I. Besides Sam68, no
other splicing factor protein has been identified as a direct target for phosphorylation by
a MAP kinase. As we showed in the previous Aim, SPF45 is a target for phosphorylation
by ERK2/MAP kinase as well as JNK and p38 MAP kinases. We also showed that coexpressing constitutively active MEK1, CA-MEK1-{DD) and ERK2 along with SPF45 caused
phosphorylation of SPF45 on both Thr71 and Ser222 residues. To investigate the role of
ERK2/MAP kinase phosphorylation of SPF45 on its splicing activity, we made use of the

in vivo minigene system described above using the ratio of short/long ~fas isoforms as a
measure of splicing function. CA-MEK1-(DD) and ERK2 were transfected into Cos-1 cells
along with SPF45 and ~fas, and total RNA was isolated 24 hours post-transfection. We
also used the MEK inhibitor U0126 to potentially reverse the role of phosphorylation.
RT-PCR analysis of the spliced ~fas showed an average of 40% decrease in the ratio of
short/long ~fas isoforms in the presence of constitutive ERK2/MAP kinase pathway
activation as compared to vector control (Fig 3.1 C&O). This effect was partially reversed
using U0126 showing only 17% decrease in splicing. Altogether, this experiment
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demonstrated that a continuously n:-aintained phosphorylation of 5PF45 is responsible
for decreasing its alternative splicing activity (Fig 3.1 C&D).
P38MAP Kinase phosphorylation of 5PF45 strongly reduces its alternative splicing
activity towards ~fas
In a similar attempt to determine the impact of p38MAP kinase phosphorylation
on SPF45 splicing function, we transfected Cos-1 with MKK3(E) and p38a MAP kinase
along with 5PF45 and ~fasJ and total RNA was isolated 24 hours post-transfection for
analysis. In this assay, we used the p38MAP kinase inhibitor 5B203580 to determine the
role of p38 inhibition on splicing. RT-PCR analysis of analysis of the spliced ~fas showed
a 65% decrease in the ratio of short/long ~fas isoforms compared to 5PF45 alone.
Inhibition of p38 with 5B203580 completely returned 5PF45 splicing function to basal
level (Fig 3.1 E&F). While p38MAP Kinase phosphorylation caused a more prominent
effect on 5PF45 function, the impact of this finding is still unclear. Experiments
performed in our lab have determined stronger binding to and phosphorylation of
SPF45 by p38 MAP kinase compared to ERK in co-immunoprecipitation and cotransfection assays to assess 5PF45 phosphorylation (data not shown), which can
potentially explain the results of the splicing assay.
While we showed in the previous chapter that JNK1 phosphorylates 5PF45 in
vitro, our efforts to replicate the splicing assay with activated MKK4 and JNK1

expression along with SPF45 and ~fas were unsuccessful. JNK1 and MKK4 displayed
poor expression in Cos-1 cells upon transfection and were not usable to study the effect
of JNK phosphorylation of 5PF45 on its splicing function (data not shown.) We believe
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that MKK4/JNKl transfection in Cos-1 cells induces an apoptotic effect. Further
experiments are required to determine the role of JNK phosphorylation on SPF45
splicing functions.
Mutation of SPF45 phosphorylation enhances its alternative splicing activity and
provides rescue from the decrease induced by MAP Kinase phosphorylation
As continuous phosphorylation of SPF45 caused a decrease in its alternative
splicing activity, we speculated that mutation of both Thr71 and Ser222 into either
alanine

or

aspartate

would

mimic

a

non-phosphorylated

and

a continuously

phosphorylated state, respectively. Vector control, wild-type SPF4S, SPF4S
SPF45

DD

AA

and

were transfected separately into Cos-1 cells along with !lfas; the cells were

harvested 24 hours post-transfection to assess the extent of alternative splicing (Fig 3.1

G&H). Compared to wild-type SPF4S,. SPF4S

AA

showed a 16% increase in the ratio of

short/long !:lIas isoforms (p<O.OS) while SPF4S

DD

showed a significant 37% increase

(p<O.Ol) in its alternative splicing activity. Despite that SPF4S

AA

has a relatively modest

increase in splicing activity,. it is consistent with our previous finding that continuous
phosphorylation of SPF4S causes a decrease in alternative splicing; hence, inhibiting the
phosphorylation by mutation to alanine shows the predicted positive effect on splicing.
We expected SPF4S

DD

-

by virtue of the negative charges on the aspartate residues - to

mimic a continuously phosphorylated state of the protein; surprisingly, it displayed a
more robust increase in alternative splicing. Unlike the native SPF4S protein, which is
subjected to dynamic and continuous upstream phosphorylation by MAP kinases and
downstream de-phosphorylation by cellular phosphatases, SPF4S

DD

is locked in a
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"pseudo-phosphorylated" state. In fact, it has been proposed that a "balanced

JJ

reversible phosphorylation of splicing factors is crucial for their adequate function and is
almost entirely disrupted under "hypo-JJ or "hyper-II phosphorylated states (Cao 1997,
Xiao 1998, Dieker 2008, Chen 2009). Based on these experiments, SPF45

DD

failed to

mimic the dynamic phosphorylation/dephosphorylation cycles required by SPF45 to
carry its functions properly. Therefore, when we compared the splicing activity of wildtype SPF45 to that of SPF45

AA

in the presence of CA-MEK1(DD)/ERK2, SPF45

AA

(Fig 3.1

I&JL it showed a 32% increase in activity compared to wild-type SPF45, which is an

apparent increase due to the attenuating effect of phosphorylation on the native SPF45
but not SPF45

AA

•

SPF45 slows cellular proliferation in a phosphorylation-dependent manner
To further understand the role of SPF45 overexpression in ovarian cancer cells
pathobiology, we generated stable populations of SKOV3 ovarian cancer cells expressing
Myc-SPF45/mutants/empty vector. We used the SKOV3 cell lines for the following two
reasons: i. SPF45 was identified in a screen of ERK2 associated substrates in SKOV3 cells
and ii. SPF45 was expressed at lower endogenous levels in SKOV3 cells compared to the
ovarian cancer cell lines examined. Pooled populations of SKOV3 cells expressing native
SPF45 or mutants were generated by retroviral infection and puromycin selection to
avoid clonal variation. Immunofluorescence microscopy of the different generated
stable cell lines showed populations of cells with a quasi-equal expression levels (Fig 3.2

A). Western blot using Myc antibody showed close expression levels among the
different cell lines (Fig 3.2 B). Comparing the levels of exogenous SPF45 to endogenous
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levels with a western blot using total-SPF4S antibody revealed a 2:1 ratio of exogenous:
endogenous SPF45 (Fig 3.2 C). Cell proliferation rates of the stable cells were
determined by manual count at 24 hours interval, with an initial number of lO,OOO cells
plated per well per cell line. SKOV3-pQCXIP displayed an accelerated proliferation rate
compared to SKOV3-pQCSPF4S which followed an indolent course. Interestingly, we
observed a divergence in the behavior of SPF45 mutants on cellular phenotype in this
assay. SKOV3-pQCSPF4S
pQCSPF4S

DD

AA

proliferation was similar to the control group while SKOV3-

behaved like SKOV3-SPF4S (Fig 3.2 0). Although both SPF4S

AA

and SPF4S

DD

cause an increase in !:lfas splicing, the discordance in their effect on cellular proliferation
suggests that SPF4S

DD

retains a selective phospho-mimetic phenotype depending on the

choice of function involved. We show in a subsequent section of this chapter the
molecular events that regulate SPF4S-mediated cellular proliferation.
SPF4S overexpression in SKOV3 cells does not increase drug resistance
Since SPF4S overexpression in A2780 ovarian cancer cells and HeLa cervical
cancer cells confers a multidrug resistance phenotype, we sought to determine the drug
sensitivity/resistance of SPF45 in SKOV3 cells. SKOV3-pQCSPF45 vs SKOV3-pQCXIP
against cisplatin .. doxorubicin .. etoposide, mitoxantrone, paclitaxel and vincristine .. and
then assess the role of SPF45 phosphorylation in drug resistance, if any. We examined
the drug sensitivity/resistance in an MTS colorimetric assay using cellular proliferation in
a 96 well plate exposed to stepwise lO-fold increasing doses of chemotherapeutic
agents as a measure of survival (Fig 3.3). No difference between SPF45 overexpressing
cells and control cells was observed. While these results were un-expected, it is
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imperative to realize that developing resistance could be cell-type specific based on the
genetic and proteomic makeup. Further experiments investigating the role of SPF45
drug resistance in different cell lines might be required to explain this discrepancy.
Gene- and exon-array analysis
To identify novel SPF45 targets that can explain the implications of this splicing
factor in the pathobiology of ovarian cancer, we performed an exon- and gene-array to
using the stable cell lines generated above. Changes in gene expressions and exon
splicing were compared between SKOV3-pQCXIP and SKOV3-pQCSPF45 on an Affymetrix
Human Exon 1.0 ST gene chip. Differential gene expression analysis revealed thousands
of transcripts to be altered between SKOV3-pQCXIP and SKOV3-pQCSPF45; we divided
the results into two groups based on the stringency (low and high) of the statistical
analysis. We identified 524 transcripts in the low stringency group (136 upregulated,
388 downregulated SPF45 vs. vector) and 158 transcripts in the high stringency group
(39 upregulated, 119 downregulated). We also divided changes in exon expression into
low and high stringency groups based on statistical analysis with 396 potential
alternative splicing events in the low and 138 in high stringency groups.
Based on intensity signals, fold changes and statistical analysis, we concentrated
our efforts in this work on four genes for further validation: ErbB2; FN1; TGF-[3; and
POSTN. We also explored their role in SPF45-mediated cellular phenotypes and their
implication in ovarian cancer. The results are presented in a subsequent section of this
chapter. Below we provide a summary of the top genetic and exonic changes we
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identified in our analysis and then discuss in further detail the roles of the 4 genes
mentioned above.
Clustering of the gene transcripts in the microarray
The low stringency list of differentially-expressed genes provided a richer
content in the amount of transcripts included; therefore we used it to determine the
functional clustering of these genes into specific pathways. Functional analysis was
performed by Almac Diagnostics against a GeneGo annotated Pathway using MetaCore
software system from GeneGo, Inc. The most enriched pathways from the list of
differentially expressed genes are ranked based on the enrichment p-value, which
corresponds to the probability of observing the number of genes in the differentiallyexpressed genes annotated to a particular pathway by randomly picking genes from the
whole array. Furthermore, we divided the list into 2 groups of up- and down-regulated
genes in SKOV3-pQCSPF45 compared to SKOV3-pQCXIP.
Up-regulated gene pathways clusters
Gene pathways with upregulated differentially-expressed genes components
were grouped and ranked based on the multi-testing corrected - using the false
discovery method - enrichment p-value. Twenty two pathways were found to be
significant at an adjusted p<O.OS. Of the 22 pathways, 7 are involved in G-protein
coupled receptor signaling while another 7 are involved in immune response.
Interestingly, SPF45-overexpressing cells upregulated genes in the AP-l transcription
pathway genetic cluster. Since AP-l transcription factor is involved in a diverse group of
functions such as proliferation, differentiation, migration, wound healing, inflammation
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and apoptosis, affecting its regulation could potentially present as a key modulator of
several cellular functions. Cytoskeletal remodeling, neuronal migration and cell cycle
pathways were also upregulated as well as genes of mucin production associated with
cystic fibrosis. Results are summarized in table 3.1.
Down-regulated gene pathways clusters
Similarly, gene pathways with downregulated differentially-expressed gene
components were grouped and ranked based on FDR-adjusted p<0.05 identifying 20
pathways. We determined 6 pathways to be involved in nucleoside metabolism, 3 cell
cycle regulation pathways and 4 pathways of the cystic fibrosis. One apoptosis related
pathway was also among the top 20 downregulated clusters pointing out to the
potential role of SPF45 in decreased cell death. Interestingly, since CFTR-related genetic
pathways appear to be dysregulated both up and down suggests a potentially important
implication for SPF45 in regulating cystic fibrosis; however, investigating this disease is
beyond the purpose of this work. Oxidative phosphorylation, regulation of translation
initiation, alternative complement clusters and antigen presentation by MHC class I
were also downregulated. Results are summarized in table 3.2.
Genetic pathways with altered splicing events
Affymetrix Human Exon 1.0 ST gene chip is designed to handle individual exons
or parts of exons as independent objects, allowing the detection of alternatively spliced
events (inclusion or skipping of exons), and overcoming the limitations of classical
expression arrays which concentrate on transcription events at the 3' end of a gene.
Exon 1.0 ST employs empirical annotations, curated mRNA sequences and ab-initio
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prediction computations of 5.4 million probes annotating 1 million exon clusters for
detection of alternative splicing events at the exon levels. Despite the advanced
technology of the array, it is amenable for a high rate of false positives and the rationale
is summarized in the following points: i. alternative splicing is not an all-or-none
phenomenon; subtle changes carry the potential of significant biological events ii.
alternative splicing is a very common phenomenon, predictably accounting for 90% of
genetic events iii. the exon array does not detect specific transcripts, but rather
assembles several transcripts (defined by Probe Set Regions-PSR) to associated loci
raising the possibility of linking unrelated transcripts and iv. differential gene expression
needs to be accounted for in determining differential alternative splicing events.
Although the rate of false positive might be substantial, the exon array provides a
starting point for the identification of true changes in splicing events; therefore, further
validation by physical and bioinformatics analyses is required. In comparing SKOV3pQCSPF45 to SKOV3-pQCXIP, gene pathways with changes in exon expressions were
clustered and ranked based on adjusted p<0.05. We identified thirty seven (37)
pathways and the top 25 pathways are provided in table 3.3. Of the 25 top pathways, 8
are involved in cell adhesion, 3 in each of cytoskeletal remodeling and immune
response, one pathway is involved in regulation of CFTR activity and one in DNA damage
nucleotide excision repair. These results predict an association between SPF45
overexpression and cellular adhesion (attachment, spreading and migration) as well as
cellular morphology and/or size. The identification of a cluster involving CFTR regulation
was not surprising since CFTR-implicated pathways were shown to be dysregulated up
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or down in the gene-array. As for DNA damage repair, SPF45 is evolutionarily linked
(DRT111: SPF45 homolog in A. thaliana) as well as experimentally to DNA repair
enzymes such as RAD 201 (Chaouki 2006) and RAD 51B (Horikoshi 2010) of the RAD51
family; additionally, mutations in the C-terminus of SPF45 cause a decrease in DNA
repair in drosophila (Chaouki 2006). Hence, it was no surprise to identify DNA repair
pathways affected by SPF45 overexpression. Further investigation of the role of SPF45 in
these pathways, as well as possible interactions, are necessary to determine the impact
of SPF4S in DNA repair, apoptosis and possibly drug resistance.
Validation of target genes expression levels
Based on the results obtained from the gene microarray we performed, we
focused on four different genes: ErbB2, FN1, TGF-J3 and POSTN. The choice of the genes
was based on several factors: i. fold change in the array ii. intensity signal iii. statistical
analysis and iv. relationship to cancer progression and migration. Using pre-validated
2

gene-specific primers and RT SYBR Green chemistry, we determined below the fold
changes of each of the aforementioned genes in wild-type SPF45-overexpressing cells
compared to vector group. Also, we determined the fold changes in SPF4S
SPF4S

DD

AA

and

SKOV-3 stable cells. Total RNA was isolated from each of these cells grown in 6-

well plates to 90% confluence. Gene-changes validation was performed on threeindependent passages for each of the cell lines.
ErbB2

ErbB2 levels were decreased by 69% in SKOV3-pQCSPF45 and by 80% in SKOV3pQCSPF4S

DD

compared to vector control, while it was decreased only by 36% in SKOV3-
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pQCSPF45

AA

•

We further validated ErbB2 expression by western blot (Fig 3.4 A&B).

While ErbB2 protein expression was slighlthy decreased in SKOV3-pQCSPF45AA celis, it
was dramatically decreased in SKOV3-pQCSPF45 and SKOV3-pQCSPF4S

DD

Accordingly,

•

ErbB2 expression represents an example of a SPF45-mediated event that is responsive
to the phosphorylation of Thr71 and Ser222. We further determined that ErbB2
expression in these cells is regulated by Elf3, an Ets-family transcription factor, but not
Elf! or PEA3. Decreased ErbB2 expression correlated with decreased Elf3 expression but
not Elf1 and PEA3 which maintained a relatively constant expression among the
different cell lines (Fig 3.4 C). Interestingly, the decrease in Elf3 expression was
translated by similar effects on ErbB2 expression and cellular proliferation, which
actually paralleled SPF45 expression and phosphorylation pattern. Further experiments
will

be

required to

identify the

link between

MAP

kinase

activation,

SPF45

expression/phosphorylation, and Elf3.
Fibronectin FNl

Fibronectin levels were roughly 5 folds higher in SKOV3-pQCSPF45 compared to
vector control. Unlike with ErbB2 expression, mutation of Thr71 and Ser222 had no
effect on SPF45-induced increase in fibronectin levels, as evidenced by near-equal fold
change in FNl levels in both SKOV3-pQCSPF45

AA

and SKOV3-pQCSPF45

DD

•

We further

validated the qRT-PCR results with a northern blot and a western blot for protein levels
(Fig 3.4 D,E&F). FN expression correlated with SPF45 gene expression and was not
affected by the phosphorylation sites mutations, indicating a non-phosphorylationdependent SPF45 function and adding to the versatility of this protein.
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TGF-8

TGF-J3 levels showed a trend towards decrease in SKOV3-pQCSPF4S compared to
vector control while they were significantly doubled in the SKOV3-pQCSPF4S
SKOV3-pQCSPF4S

DD

AA

and

groups. No further investigation of TGF- J3 was pursued (Fig 3.4 G).

Periostin
Based on the microarray data, we expected periostin - a protein involved in bone
and teeth formation, but also has been shown to be overexpressed in several cancers
and to be linked to migratory effects of some cancer cells (Tischler 2010, Michaylira
2010) -, to have the highest fold increase in wild-type SPF45 group compared to vector
control. Validation by real-time peR failed to show such a difference (Fig 3.4 H);
additionally, we could not obtain consistent fold change levels in the four groups tested
(large standard deviation). This is very likely due to the very low abundance of the
mRNA and the lowest threshold cycle of detection is the 28

th

cycle. Accordingly, slight

changes in the mRNA levels would translate as high fold changes and this is where the
microarray technology fails. Although periostin seemed a luring candidate because of its
predicted fold increase and its function in cancer cells, this case provided a clear
example regarding the limitations of the microarray results and the necessity for further
validation.
Validation of FN-EOA as a splicing target for SPF45
Three regions in the fibronectin mRNA are subject to alternative splicing: extra
domain 3 A (EDIIIA), extra domain 3 B (EOIIIB) and the variable region (V or IIICS) (Fig 3.5

A). EOA and EOB are cassette-exons while the variable region spans two exons over 120
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nucleotides in length. The variable region can generate up to 5 different splice forms
that

are

very

close

in

length

(0

to

120

nucleotides).

The

combination

of

inclusion/exclusion of these different regions potentially generates up to 20 different
isoforms of fibronectin (Schwarzbauer 1983). We showed above, using real-time PCR
and northern blot, that fibronectin levels are increased in SKOV3-pQCSPF45 (and the
mutants cell lines) compared to SKOV3-pQCXIP. Based on the results of the exon array,
we also expected fibronectin to undergo alternative splicing in SKOV3-pQCSPF45. We
employed two approaches to determine changes in EDA and EDB fibronectin splicing
patterns in SKOV3-pQCSPF4S (as well as SPF4S AA and SPF45

DD

mutant cell lines) vs.

SKOV3-pQCXIP: end-point PCR and real-time PCR.

End-point peR fails to validate FN alternative splicing
SKOV3-pQCXIP, SKOV3-pQCSPF4S, SKOV3-pQCSPF4S

AA

and SKOV3-pQCSPF4S

DD

cells were grown to 90% confluence in 6-well plates prior to harvest for RNA extraction
and synthesis of cDNA. Since EDA and EDB are spliced in/out in a cassette-exon splicing
pattern, we used primer sets outside of the corresponding exonic sequences to detect
both the (+) and (-) isoforms of fibronectin. As total fibronectin levels are higher in the
SPF45-overexpressing cells, we used the ratio of EDA (+)jEDA (-) isoforms as well as EDB
(+)/EDB (-), as a measure of change in FN splicing. PCR was first performed with 28
cycles of amplification and the bands were visualized on a 2% agarose gels (Fig 3.5 B

bottom). EDA (+) bands (upper band) were observed in WT-SPF4S, SPF4S AA and SPF4S DD
lanes but not the vector lane, while EDA (-) was present in all lanes; with respect to EDBFN splicing, EDB (-) and (+) isoforms were detected in wild-type SPF4S, SPF4S

AA

and
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SPF45

DD

lanes but not the vector lane. Decreasing the amplification cycle number to 22,

neither EDA (-) nor (+) bands were detected in the vector lane, while both were present
in the wild-type SPF45 lane (Fig 3.5 B middle). Raising the cycle number to 35, both EDA
(-) and (+) isoforms were detected in the vector and the wild-type SPF45 lanes (Fig 3.5 B
top). Since the end-point PCR is not quantitative, no decisions could be made concerning

a change in splicing of either EDA or EDB regions and further experiments were needed.
Real-time peR validates FN alternative splicing
To overcome the hurdles of end-point peR technique in validating a change in
splicing, we employed real-time peR to determine the fold inclusion of EDA(+) and
EDB(+) isoforms (Fig 3.5 C). We isolated total RNA from SKOV3-pQCXIP, SKOV3pQCSPF45, SKOV3-pQCSPF45

AA

and SKOV3-pQCSPF45

DD

cells grown to 90% confluence

in 6-well plates and reverse-transcribed to synthesize cDNA. Three separate passages
2

were harvested and ran on a real-time PCR plate in duplicate. Using RT SYBR Green
chemistry, total fibronectin primer set and exon-specific primers to EDA and EDB
regions were used to determine the fold inclusion of EDA(+) and EDB(+) isoforms. We
used 18sRNA as a housekeeping gene control. The fibronectin primers were designed to
detect a region common to all FN isoforms while EDA and EDB primers were specific to
FN isoforms that contain their corresponding regions. As the fold increase of EDA(+)
mRNA in the Wild-type SPF45 ('" 2.8 folds) group compared to vector exceeds the fold
increase of total FN in wild-type SPF45 compared to vector ('" 2.1 fold), we concluded
that there is an increase in EDA exon inclusion concomitant with an increase in SPF45
expression levels. Fold increase in EDA(+) isoform in SPF45

AA

and SPF45

DD

groups
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compared to vector was similar to that of total fibronectin, indicating that intact Thr71
and Ser222 were necessary for EDA inclusion. Fold increase in EDB exon in wild-type
SPF45, SPF45 AA and SPF45

DD

cell lines compared to vector control were similar to those

of total fibronectin in their corresponding groups. As a result, no change in EDB exon
splicing levels could be deduced. Based on these data, we conclude that fibronectin EDA
exon is subject to alternative splicing regulated by SPF45. Although we showed that
mutation of the MAP kinase target sites reversed the increase in EDA splicing, further
experiments are needed to support the role of phosphorylation on these sites in
controlling EDA splicing. Currently, minigene splicing assays are the standard of choice
to study the effect of trans factors and their modification on splicing; using minigene
plasm ids of fibronectin EDA or EDB along with SPF45 plasmid in Cos-1 cells will likely
support our findings on the effect of SPF45 on fibronectin splicing as well as determine
further impacts of SPF45 phosphorylation.
To determine a potential role for the increase in EDA(+) inclusion in FN1, we
investigated the effect of SPF45 and the phosphorylation mutants on cellular adhesion.
The stable cell lines were plated onto the following matrices for 30 min: tissue culture
plastic, laminin, poly-l-lysine and fibronectin; followed by cell fixation, staining with
crytal violet and measurement at 550 nm. While all cells displayed an equal and nonspecific attachment to plastic, laminin and poly-l-Lysine, there was an overall increase in
attachment to fibronectin. Furthermore, SKOV3-pQCXIP had the highest attachment
with SKOV3-pQCSPF45, -pQCSPF4S

AA

and -pQCSPF45

DD

having 29.6%, 15.8% and 19.5%

decrease compared to SKOV3-pQCXIP, respectively. Of note, the stable cell lines
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adhesion to fibronectin parallels EDA(+) FN expression suggesting a possible implication
for changes in FN isoform and cellular attachment to extracellular matrix.
Mutations on Thr71 and Ser222 does not decrease SPF45 binding to SF1 and SF3b155
In order to understand the role of the phosphorylation sites in the mechanism of
alternative splicing, we investigated the role of the phosphorylation sites and their
mutants on SPF45 binding to two proteins in the spliceosome, SF1 and SF3b155, which
are known SPF45 binding partners (Corsini 2007). Immunoprecipitation of Myc-SPF4S,
Myc-SPF45

AA

or Myc-SPF45

DD

after transient transfection did not show a difference in

binding to SF1 or SF3b155 (Fig 3.6). While we did not observe an effect of the
phosphorylation mutants on interaction with these splicesomal proteins} further
experiments with protein-RNA assays might be warranted to better address this
question.
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Fig 3.2 Generation of SKOV3 stable cells overexpressing SPF45 or mutants A. Immunofluorescent staining
AA
DD
using myc-antibody of SKOV3-pQCXIP, -pQCSPF4S, -pQCSPF4S and -pQCSPF4S . Nuclei were stained
with DAPI. Stable cell lines were generated with retroviral infection and puromycin selection. B. Cell
Iysates of SKOV3 stable cells resolved by 10% 50S-PAGE and immunoblotted with anti-Myc antibody; ~
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SKOV3 stable cells. D. Cell proliferation assay of the four stable cell lines was performed using cell counting
at 24 hours interval; NS, non-significant (n=3, triplicates).
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Gene pathway cluster

1. f3-adrenerglc receptor transactivation of EGFR
2. Angiotensin signaling via Pyk2
3. Cytoskeleton remodeling via Activin A
4. Immune response
s. Gastrin in cell growth and proliferation "
6. EphB receptor in dentritic spine morphogenesis and
syna ptogenesis
7. Mucin expression in cystic fibrosis via IL-G and IL-7
8. Immune response
9. Immune response
10. Olfactory transduction
11. VEGF family signaling
12. ESRl regulation of G1/S transition
13. Regulation of GnRH
14. Gastrin in inflammation - immune response
15. Immune response
16. ligand-dependent activation of ESR1/ AP-1 pathway
17. Transcription role of AP-l in regulation of cell
metabolism
18. Histamine - immune response
19. a2-adrenergic activation of ERK
20. Metabolic pathway
21. Mucin expression in cystic fibrosis via TLRs
22. Muscle contraction-regulation of eNOS activity in
endothelial cells
t

"

Table 3.1 Up-regulated genetic pathways induced by SPF45 overexpression in SKOV3
cells
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Gene pathway cluster
1.
2.
3.
4.
5.
6.
7.
8.

GTP-XTP metabolism
RXR transcription
CTP-UTP metabolism
Chromosome condensation in metaphase

.:"

'J

.

ATP/ITP metabolism
,
Oxidative phosphorylation
Apoptosis and survival - Granzyme A
CFTR translational fidelity
9. APe
10. Spindle and chromosomes assembly
11. ATP metabolism
12. Normal CFTR trafficking
13. 4508 eFTR trafficking
14. Amino acid metabolism
15. Alternative pathway
16. Regulation of translation/initiation
17. Ubiquitin metabolism
18. Antigen presentation by MHC I
19. Regulation of eFTR activity
20. G-protein signaling - RACl in cellular processes
"

~

"

;,

r'

Table 3.2 Down-regulated genetic pathways induced by SPF45 overexpression in
SKOV3 cells
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Gene pathways with altered splicing events

1. Alternative complement pathway

I

:'

,

2. Role of tetraspanins in the integrin-mediated cell adhesion
3. Endothelial cell contact by non-junctional mechanisms
,
4. Nucleotide excision repair
5. Endothelial cell contacts by junctional mechanisms
6. Histamine Hl receptor signaling in the interruption of cell barrier integrity
7. Regulation of CFTR activity (normal and cystic fibrosis)
8. ECM remodeling
9. Role of PKA in cytoskeleton reorganization
.
10. Ligand-dependent transcription of retinoid-target genes
11. Calcium signaling
12. lectin induced complement pathway
13. Integrin-mediated cell adhesion and migration
14. Classical complement pathway
15. Angiotensin signaling via STATs
16. Cadherin-mediated cell adhesion
17. Netrin-l in regulation of axon guidance
18. Cytoskeletion remodeling
19. Dopamine 02 receptor activation of POGFR in CNS
20. Vitamin K metabolism
21. EPO-induced MAPK pathway
"
22. PDGF activation of prostacyclin synthesis
23. Vitamin 86 metabolism
24. Spindle assembly and chromosome metabolism
25. Chemokines and adhesion
I,

,

t

;

"

,1'

Table 3.3 Genetic pathways with identified changes in splicing events accompanying
SPF45 overexpression in SKOV3 cells

~
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Fig 3.3 SPF45 does not confer drug resistance to SKOV3 cells MTS cytotoxicity assay in 96 wells
plates of SKOV3-pQCXIP, -pQCSPF45 using cisplation, doxorubicin, etoposide, mitoxantrone,
paclitaxel and vincristine. 3.0e+3 cells/well were plated onto separate wells and treated the
following day with 10 fold increasing doses from 1.0e-4 JIM to 1.0e+2 JIM. 72 hrs posttreatment, MTS reagent was added and the cells were incubated for 2 hrs at 37°C and analyzed
on a Biorad 96 well plate reader at 492 nm. (n=3, triplicates).
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Fig 3.4 SPF45 induces genetic and transcriptional changes in SKOV3-SPF45 and mutants A. qRTPCR of ErbB2 in in the four stable cell lines. ErbB2 level was set to 1 in SKOV3-pQCXIP and
expressed relative to vector in the rest of the cell lines (p<O.Ol n=3, duplicates) . B. Western blot
of erbB2 in cell Iysates of the corresponding cell lines. C. We?tern blot of Elfl, Elf3 and PEA3
transcription factors in the corresponding cell lines (n=3) . D. qRT-PCR of FNl in the four stable
cell lines. FN 1 level was set to 1 in SKOV3-pQCXIP as in (A) (p<O.Ol n=3, duplicates) . E. Northern
blot of FN 1 using a 32P-labeled single-stranded DNA probe produced by asymmetric PCR to FN
exons 6&7. 28s and 18s rRNA were used as loading control. F. Western blot of FNl in the
corresponding cell lines using total cell Iysates. G&F. qRT-PCR of TGF-~ and Periostin in the
corresponding cell lines treated as in (A) (p<O.Ol n=3, duplicates).
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Discussion
We showed in the previous aim that SPF45 is phosphorylated by MAP kinases on
Thr71 and Ser222, in vitro and in cells. In this chapter, we determined the role of the
phosphorylation on the alternative splicing activity of SPF45 in vivo using a minigene
system of the death receptor Fas, transfected into Cos-1 cells. We first showed that
SPF45 causes a dose-dependent increase in las alternative splicing then used a dose that
generates a 1:1 ratio of the long and short Fas mRNA isoforms in the ensuing
experiments.

Co-expressing

SPF45

and

activated

ERK2/MAP

kinase

(using

constitutionally-active MEK1(DD), we showed a decrease in Fas splicing compared to
SPF45 alone, which was partially reversed when the cells were treated with MEK
inhibitor U0126, reflecting a decrease in SPF4S alternative splicing activity towards Fas
pre-mRNA, upon SPF45 phosphorylation. We also showed a similar and more
pronounced effect of p38 MAP kinase phosphorylation of SPF45 on the alternative
splicing acitivity. To support these findings, we impaired the ability of ERK2 to
phosphorylate

SPF45

using SPF45-alanine-mutant

phosphorylation targeted residues (SPF4S

AA

).

of Thr71

and

Ser222

MAPK-

We also generated a phospho-mimetic

protein as well using SPF4S-aspartate-mutant of the same residues (SPF4S

DD

).

SPF4S

AA

showed a modest increase in SPF45 alternative splicing activity compared to Wild-type
SPF45, while SPF45

DD

remarkably caused a strong increase in SPF45 alternative splicing

activity towards Fas. Comparing wild-type SPF4S and SPF45

AA

in the presence of CA-

MEK1(DD) and ERK2, demonstrated an increase of SPF45-alanine-mutant alternative
splicing activity vs wild-type SPF4S, and we attributed this observation to the
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attenuating effect of the phosphorylation on wild-type SPF4S function, an effect that is
not applicable to SPF4S

AA

•

While SPF4S

DD

was expected to behave similarly to

SPF4SPT71PS222, it may not be necessarily true with respect to splicing. In fact, inducing
phosphorylation of wild-type SPF4S by upstream signal activation is more likely to
represent the true effect of phosphorylation on the protein's alternative splicing
activity, as phosphorylated splicing factors are under a dynamic control of upstream
phosphorylation and downstream de-phosphorylation

(Cao 1997, Xiao

1998). A

plausible explanation is that aspartate mutations of Thr71 and Ser222 influence SPF4S
interaction(s} with other components of the spliceosome (eg SF1, SF3b15S, U2AF) . and
the inability to get dephosphorylated causes the discrepancy observed between SPF4S
and MAPK-phosphorylated SPF4S. Additionally, using SPF4S

AA

DD

to inhibit ERK2-mediated

phosphorylation had the opposite effect of wild-type SPF45, reinforcing the role of
Thr71 and Ser222 in regulating SPF4S function and supporting the observation of
decreased Fas splicing upon SPF4S phosphorylation.
As we are interested in the biological role of SPF45 in ovarian cancer, our aim
was and remains to identify novel targets of genetic and splicing modulation. Of the
large list of potential substrates that were detected by gene and exon array, we focused
on fibronectin and ErbB2 for the purposes of this dissertation. Fibronectin is involved in
a wide

array of cellular functions

including adhesion,

migration,

growth

and

differentiation. In cancer, fibronectin is implicated in cellular mobility, metastasis and
chemoresistance (Kaspar 2006). In development fibronectin occupies a central role, as
FN-/- mice are embryonic lethal (George 1993, Watt 1994). Although complex in
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function, this molecule's amino acid sequence is reduced to three types of repeating
domains (also called FN repeats) totaling 29 to 31: 12 type I, 2 type II and 15-17 type III
(Hynes 1990). Although sequence homology of each of the different repeats does not
exceed 50%, structural homology is conserved. For instance, the different type III
repeats are only 20-40% identical, but they all share similar ~-sandwich structural
topology (Main 1992, Leahy 1992). Two quasi-identical monomers of these different
repeats are linked by disulfide bonds to create a more complex molecule. Fibronectin is
encoded by a single gene but has varied expression and sequence patterns due to
intense regulation by alternative splicing, which is tissue and species-dependent
{Schwarzbauer 1983, Tamkun 1984, Gutman 1987}. In humans, three fibronectin regions
are known to undergo alternative splicing: EDA, EDB and the variable region V. EDA and
EDB are included by the simplest form of splicing - ie exon-cassette inclusion. The
variable region presents a more challenging splicing pattern, as it spans around 120
amino acids that are potentially spliced into 5 different sequences. Accordingly, four
different forms of fibronectin could be formed by the inclusion/exclusion of EDA and
EDB (EDA+/EDB+, EDA+/EDB-, EDA-/EDB+ and EDA-/EDB) and another five could be
formed by the splicing arrangements of the variable region V leading to a total of twenty
different potential isoforms (4xS = 20). Both EDA and EDB are type III repeats known to
influence their surrounding topology unveiling "cryptic" sites in the FN molecule (Muro
1999). The exact roles of these two domains remain elusive: they are both expressed in
several solid cancers such as thyroid, lung, liver and breast (Muro 1999), although the
impact of each domain alone on tumor progression remains unclear. EDB is associated
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with angiogenesis (Khan 2005) and is expressed in the stroma and blood vessels of
tumors. EDA is implicated in rheumatoid arthritis (Shiozawa 2001), tumor spreading
(Manabe 1997) and invasions (Liu 1998) as well as proliferation of the blood vessel
intima (Spargo 1994). While they differ in their spatiotemporal expressions in normal
adult tissues, concomitant EDA and EDB expression is linked to fetal tissues and
neoplastic masses, suggesting an active role of each of these two domains. FN-/- is
embryologically lethal in mice (George 1993), but EDA-/- mice and EDB-/- mice are
viable and fertile (Muro 2003, Fukuda 2002). In recent years, conditional knock-out mice
of both EDA and EDB domains were generated and shown to be embryologically lethal
(Astrof 2007), indicating the necessity of both domains in development. While
fibronectin is known to be overexpressed in ovarian cancers and to be associated with a
poorer prognosis (Ricciardelli 2006), nothing is known about EDA and EDB expression
levels in ovarian cancer. In our experiments, we have observed an increase in
fibronectin expression in SKOV3 cells overexpressing SPF45. Furthermore, we showed
that expression of both the EDA and EDB domains was elevated in the presence of
increased SPF45 expression independent of the mutations of Thr71 and Ser222. Also we
showed that the inclusion of EDA domain in SKOV3-pQCSPF45 cells compared to SKOV3pQCXIP is higher than that of total fibronectin in the same respective cell lines,
suggesting that SPF45 enhances inclusion of EDA domain dependent on intact Thr71 and
Ser222 residues. Additionally, we determined the adhesion profile of the different
stable cells and showed that they adhere to plastic, laminin and poly-L-Iysine nonspecifically after a short 30 min time point. Adhesion to fibronectin was however
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increased around 3 fold compared to the other surface coatings, with SKOV3-pQCSPF45
demonstrating the weakest attachment compared to SKOV3-pQCXIP, -pQCSPF45
pQCSPF4S

DD

,

AA

and -

which can be explained by the increase in EDA-FN expression in SKOV3-

pQCSPF45. The fact that SPF45 increases fibronectin expression and affects EDA splicing
in SKOV3 cells raises several questions: does SPF45 increase fibronectin expression in a
different cell line? What is the role of EDA and EDB inclusions in fibronectin in the
context of ovarian cancer? Does it affect cellular growth, spreading, invasion and/or
chemoresistance? While the answers to these different questions remain unanswered,
it is appropriate to speculate that altered fibronectin levels in cells would be responsible
of adhesive, proliferative and potentially invasive properties.
While FN expression levels were independent of SPF45 phosphorylation status,
we demonstrated a decrease in ErbB2 in SPF4S expressing cells in a phosphorylationdependent manner. A member of the EGFR family and lacking a physiological ligand,
ErbB2 heterodimerizes with other EGFR members (Her1, Her3 and Her4) in order to
activate its protein tyrosine kinase activity (Graus-Porta 1995, 1997; Karunagaran 1996)
leading to activation of several transduction pathways including PI3K/Akt and MAPK
(Campiglio 1999). ErbB2 is overexpressed in several solid cancers including colon
(D'Emilia 1989), primary lung cancer (Shi 1992), breast cancer (Seshadri 1989) and
ovarian cancer (Lichtenstein 1990).

In ovarian cancer, ErbB2 has been found to be

overexpressed up to 50% (Kury 1990). Unfortunately, this elevated expression of ErbB2
in advanced ovarian cancer is associated with a poorer prognosis for survival (Cirisano
1996). Several cellular and physiological disturbances are associated with ErbB2
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overexpression. For instance, it modulates cellular adhesion through interaction with
CD44s, thereby enhancing binding to hyaluronan (Bourguignon 1997). Not limited to the
standard form of CD44, ErbB2 is recruited to another complex containing a variant CD44
(CD44-v3) and Vav2 in response to hyaluronan binding inducing Rac1 and Ras signaling
in SKOV3-ipl ovarian cancer cells inducing cell migration and growth (Bourguignon
2001). In response to heregulin (an EGFR ligand), ErbB2 interacts with PAK1 and actin
stimulating PAK1 activity in a PI3K/ Akt manner, causing cytoskeletal reorganization and
cellular migration of ErbB2-transfected MCF-7 breast cancer cells (Adam 1998).
Heregulin and ErbB2 signaling induce an activating phosphorylation of c-Src in MCF-7
cells influencing their metastasis (Vadlamudi 2003). Also, overexpression of ErbB2 in
another breast cancer cell line MCF-10A enhances cellular proliferation, migration and
invasion (Seton-Rogers 2004). ErbB2 effects on cellular proliferation are not limited to
ovarian and breast cancer cells, as it induces proliferation of head and neck squamous
cell carcinoma in response to LPA (Gschwind 2002) and in prostate cancer cells in
response to CXCL12/CXCR4 chemokine signaling (Chinni 2008). Beyond tumor growth
and cellular migration, ErbB2 has been also been linked to decreased apoptotic
response in MCF-7 cells by upregulating survivin and Bcl-2 through activation of
ERK/MAPK and PI3K/Akt pathways (Siddiqa 2008). In clinical trials of platinum therapy of
ErbB2 positive ovarian cancer cells, it has also been shown to decrease clinical outcome
and enhance tumor resistance (Meden 1998, Verri 2005). Currently, several trials with
ErbB2 monoclonal antibodies are being investigated for adjuvant therapy of advanced
and chemotherapeutic resistant breast cancer (Romond 2005, Siamon 2006) and solid
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tumors (Kaumaya 2009), as targeting ErbB2 harboring cells in athymic nude mice or in
mouse model of tet-controlled ErbB2 cells leads to decreased tumor growth, enhanced
apoptosis and tumor remission (Harwerth 1993, Schiffer 2003). Given the importance of
ErbB2 in mitogenically modifying tumors, it was interesting to see it upregulated in
response to SPF45 overexpression. Our results indicate that elevated SPF45 levels
decreased ErbB2 expression in a phosophorylation-dependent manner: 69% decrease in
SKOV3-pQCSPF45 and 80 % decrease in SKOV3-pQCSPF45

DD

•

As it caused an increase in

cellular proliferation, ErbB2 expression levels parallel the proliferation rates of the
corresponding stable SKOV3 cell lines, suggesting that SPF45 alters SKOV3 proliferation
in an ErbB2-dependent manner. Furthermore, we showed that ErbB2 expression is
regulated by SPF45 possibly in response to Elf3 but not Elf1 or PEA3 Ets transcription
factors. Several questions arise to address the specific role of Erb2 in response to SPF45mediated overexpression such as investigating the adhesive, proliferative and drug
resistance phenotypes of these cells. While SKOV3 cells are ErbB2 positive irrespective
of SPF45 overexpression, the role of added ErbB2 might be elusive. Interestingly,
development of resistance to cisplatin is associated with decreased expression of ErbB2
(Langton-Webster 1994), which can partially explain the mechanism of SPF45-mediated
drug resistance or alternatively, that the decrease in proliferation could result in the
drug resistance.

It will be necessary to determine ErbB2 changes with SPF45

overexpression in different cell lines to test this hypothesis. We are currently generating
stable SPF45-expressing cells in HeLa (human cervical cancer cells) and MCF-7 (human
breast cancer cells) both of which are ErbB2-negative, as well as several ovarian cancer
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cell lines with both ErbB2-negative and -positive genotypes. Generation of these stable
cells in tissues different than ovarian cancer cells will also help establish the role of
SPF45 in cancer biology as well as address the role of ErbB2 in mediating SPF45 effects
on cellular proliferation and drug resistance. If SPF45 does induce genetic changes in
other cell lines similar to the ones observed in SKOV3 cells, it will reinforce our
prediction of the Ifuniversal" role of SPF45; in other words, since splicing factors are not
as ubiquitous as transcription factors, if it happens that they are overexpressed in cells
they will probably induce similar changes. Biological systems tend to be more complex
however, and the "universal" response might not be accurate. It will be interesting
though to determine the percentage of agreement in genetic changes in these different
systems.
Several clones of drug-resistant SKOV3 have been generated with introduction of
increasing doses of chemotherapeutic agents such as cisplatin, taxol, doxorubicin and
etoposide. The different mechanisms of resistance included decreased drug retention
(Mistry 1992), increased BRCA1 and DNA damage repair (Husain 1998), P-glycoprotein
expression (Bradley 1989, Yang 1995), Bcl-xL expression (Liu 1998), MRP-1 (Sharp 1998),
decreased topoisomerase II activity (Kubota 1994), ErbB2 levels (Langton-Webster 1994)
and more recently decreased RICTOR, RAPTOR and mTOR activities (Foster 2010).
Unfortunately, we did not observe any of these changes with the gene array performed.
While one or more of these genetic changes might have evaded detection, we also did
not observe a change in cellular resistance. Generating different cancer cell lines,
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ovarian and non-ovarian, overexpressing SPF45 will be necessary to better address the
role of SPF45 overexpression on drug resistance.
Aside

from

phosphorylation

the

on

its

genetic changes
splicing

activity,

induced
we

by SPF45

sought

to

and the
determine

effect of
how

the

phosphorylation affects SPF45 splicing mechanism. For this end we focused on two
splicing factors, SF1 and SF3b155, which are important for their role in constitutive
splicing of pre-mRNA. SF1 consists of a single polypeptide of 75KDa and is necessary for
the formation of the first ATP-dependent step in spliceosome assembly (Arning 1996).
SF3b155 is a 155 KDa protein that exists in a complex structure of several ~pliceosome
Associated Proteins (SAPs) and therefore is also known as SAP155 (the other proteins
are known as SAP49, SAP130 and SAP145) (Oas 1999). SF1 contains two [KH] RNAbinding domains and binds the adenine branch point; subsequent to ATP-hydrolysis, SF1
is replaced by SF3b155 (Thickman 2006). SF3b155 would then bind the pre-mRNA in the
BPS recruiting U2sNRP forming the A complex (Gozani 1998). Recently, SF3bl55 has
been shown to regulate the selection of the 5' splice site of Bcl-x pre-mRNA inducing
higher expression levels of Bcl-x(s) with its subsequent effect on potentiating the role of
chemotherapeutic agents (Massiello 2006). Besides their role in directing the steps of
splicing,

little

is

known

about

SFl

and

SF3bl55.

Manceau

et al

identified

phosphorylations by KIS on a SPSP motif in SF1 and showed that phosphorylated SF1 has
higher binding to U2AF65 (Manceau 2006). SF3b155 is known to be phosphorylated by
NIPP-1 (nuclear inhibitor of protein phosphatase 1) which recruits PPl to SF3b155 and
subsequently inhibits splicing (Tanuma 2008), although the kinase(s) responsible
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remain(s) elusive. In cancer} SFl deficiency is associated with a decreased incidence of
testicular germ cell tumors in 129-Ter and M19 mice (two strains with high incidence of
spontaneous TGCT): while SF1-/- are embryologically lethal} SFl+/- mice show marked
reduction} indicating a potential role of SF1 in cancer initiation (Zhu 2010). Interestingly}
SF1 levels are inversely correlated with the tumorigenic potential of intestinal epithelial
cells (Shitashige 2007). In our experiments, we investigated the binding of SF1 and
SF3b155 to SPF45 in co-immunopreicipation experiments and the effect of mutating
Thr71 and Ser222 on these interactions. While the SPF45 UHM domain interacts with
ULMs in SFl and SF3b155 (Corsini 2007), we provided the first proof of a total protein
interaction between these proteins. However, we have not observed a change in
binding with SPF4S

AA

or SPF4S

DD

•

While these findings show that SPF45 interaction with

SF1 and SF3b155 is not dependent on intact phosphorylation sites} further experiments
need to be performed to confirm it} such as isothermal calorimetric dissociation and
NMR-based binding assays. The mechanism that explains how phosphorylation of SPF45
alters splicing remains unfortunately elusive. Whether it affects binding SF1 or SF3b155
or maybe RNA sequences remains to be investigated.
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Chapter 4: Summary, limitations, contribution and future directions
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Summary

The purpose of this dissertation is to examine the role of MAP kinase
phosphorylation of SPF45 in modulating its function{s} in ovarian cancer cells. Our
experimental approach is as follows: 1} to show that SPF45 is a substrate of MAP kinase
in vitro and in vivo as well as identifying the targeted residues; 2} to determine the
phosphorylation patterns of SPF45 in ovarian cancer cells in response to exogenous
stimulation of MAP kinase pathways; 3} to determine the effect of the phosphorylation
on regulating SPF45 alternative splicing activity towards ~Fas reporter system; 4) to
identify genetic changes in SKOV3 ovarian cancer cells overexpressing SPF45 and the
effect of phosphosite-mutants on these changes; 5) to identify novel pre-mRNA splicing
targets of SPF45 and 6} to examine the role of SPF45 and the phospho-sites mutants in
multi-drug resistance in ovarian cancer cells.
SPF45 is a novel substrate of ERK/MAP kinase
Previous work performed in our lab showed the generation of a mutant ERK2
kinase capable of identifying specific kinase targets under the desired cellular conditions
{Eblen 2003}. We have also published (Appendix I) a report showing increase in ERK2
phosphorylation in SKOV3 cells upon cellular detachment and anchorage-independent
growth. Using these same conditions, we have identified SPF45 as a potential novel
ERK2 substrate. To demonstrate SPF45 as a genuine MAP kinase substrate, we
expressed and isolated SPF45 from C05-1 cells as well as generated the recombinant
protein and subjected both mammalian and bacterially expressed SPF45 to in vitro
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kinase assays using not only ERK, but also JNK and p38 MAP kinase, as they can possibly
share substrates. We showed SPF45 to be phosphorylated by the three MAP kinase
subfamilies

and

phosphoamino

acid

analysis

detected

serine

and

threonine

phosphorylations. As there are only two residues in SPF45 that satisfy the MAP kinase
targets consensus sequence, namely Thr71 and Ser222, we generated alanine mutants
of these two residues and repeated the kinase assays using active ERK2, which showed
no phosphorylation on SPF4S

AA

,

indicating that Thr71 and Ser222 are the unique MAP

kinase target residues. Although not universally applicable, ERK/MAP kinase binds to its
substrates prior to phosphorylation. We used three approaches to show that ERK2 and
SPF4S exist in a binding complex. First, we identified SPF45 as an ERK2-binding protein
in a co-immunoprecipitation of ERK2 from SKOV3 cells. Second, nuclear extracts from
HeLa cells mixed with His-ERK2 showed SPF45 binding to ERK in a dose-dependent
manner. Finally, using SKOV3 cells stably expressing Myc-SPF45, we showed ERK2 to coimmunoprecipitate with Myc-SPF45, but not empty-vector control. Altogether, we are
confident that SPF45 is a genuine ERK2/MAP kinase substrate and we aimed to
determine its phosphorylation pattern when exogenously expressed in cells, but more
importantly the phosphorylation profile of endogenous SPF4S in ovarian cancer cells.
SPF45 is preferentially phosphorylated in ovarian cancer cells by ERK/MAP kinase and
JNK in response to exogenous stimulation
Identification of the phosphorylation sites in vitro provided an important clue to
generate total SPF45 antibody as well as anti-pThr71-SPF45 and anti-pSer222-SPF45,
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since until the time of writing this dissertation these reagents remain commercially
unavailable. These antibodies were crucial for the subsequent experiments as they
reduced the demand for large amounts of radioactivity to study SPF45 phosphorylation
in response to MAP kinase stimulation, as well as reduced the labor required to reach
the same conclusions (such as using phosphoamino acid analysis and tryptic peptide
mapping). In determining SPF45 phosphorylation in celts, we expressed Myc-SPF45 in
Cos-1 cells along with activated upstream activators of ERK, namely KRas G12V, BRaf
V600E or CA-MEK1(DD) in the presence or absence of exogenous ERK2. Our data
showed phosphorylation of Thr71 and Ser222 under all conditions, however, coexpression of ERK2 increased their phosphorylation, especially Thr71. These results
suggested that SPF45 is phosphorylated in cells similarly to in vitro, and we confirmed
that SPF45 is phosphorylated on both Thr71 and Ser222 when CA-MEK1(DD) and ERK2
are co-expressed in Cos-1 cells, while the phosphorylation of these two residues is lost
when they are replaced by either alanine or aspartate. It is interesting to note that
aspartate mutants displayed an upward mobility shift; phosphorylated wild-type SPF45
equally displayed an upward shift. Prior to examining SPF45 phosphorylation in ovarian
cancer cells, we screened SPF45 expression levels in several ovarian cancer cells and a
benign transformed epithelial ovarian cancer cell line, to determine approrpriate cell
lines for studying SPF45 phosphorylation in response to exogenous stimuli. Compared to
malignant cell lines, lOSE, a benign transformed epithelial ovarian cell line, showed a
low level of SPF45 expression. Of the different ovarian cancer cell line tested, A2780 had
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the highest level; SPF45 expression in ES2 was moderate and SKOV3 had the lowest
expression.

All

three

cell

lines

were

used

to

determine

endogenous

SPF45

phosphorylation patterns in response to stimulation of the MAP kinase pathways using
known activators. Under the conditions of stimuli tested SPF45 was phosphorylated
l

primarily in response to ERK and JNK and weakly to p38 MAP kinase. While it does not
rule out the possible involvement of p38 in regulating SPF45 phosphorylation, these
results suggest that ERK and JNK to be more likely involved in SPF45 regulation. The fact
that SPF45 is phosphorylated by ERK and JNK suggests that SPF45 phosphorylation
occurs in response to both mitogenic and stress stimuli, which translates as a potential
involvement of SPF45 in a wide array of functions. More importantly, it would be
interesting to determine the interplay between different signaling cascades in regulating
SPF45 activity. Additionally, it should not come as a surprise that SPF45 may be
phosphorylated

by other kinases; SPF45 amino acid

sequence predicts several

phosphorylation sites including, but not limited to, Akt and PKA kinases.
MAP kinase phosphorylation of SPF45 decreases its alternative splicing activity towards
~Fas

To examine the implication of SPF45 phosphorylation by ERK/MAP kinase on its
alternative splicing activitYI we utilized a ~Fas minigene reporter system. We optimized
the transfection conditions to obtain, in the presence of SPF45 1 equal splicing of ~Fas
into short and long isoforms; a 1:1 ratio of short:long isoform is used as the basal level
of splicing. We showed that co-transfection of CA-MEK1(DD) and ERK2 with SPF45

156

causes 40% reduction in the ratio of the short/long ~Fas isoforms compared to SPF45
expression alone, and we partially reversed this decrease by using the MEK inhibitor
U0126.

Equally,

we

showed

a similar

effect

by

phosphorylating SPF4S

using

MKK3(E)/p38MAP kinase, while our efforts were unsuccessful in determining the impact
of JNK overexpression on SPF45 alternative splicing function. To further support that
inhibition of phosphorylation would produce the opposite effect, i.e. an increase in
short/long ~Fas isoforms ratio, we compared the splicing activity patterns of wild type
SPF4S, SPF4S

AA

and SPF45

DD

•

While SPF4S

AA

~Fas ratio around 16% on average, SPF4S

induced a modest increase in short/long
DD

unexpectedly displayed the strongest

increase, an average of 37%. Nevertheless, the splicing activities of wild-type SPF4S and
SPF4S

AA

in the presence of CA-MEK1(DD) and ERK2 showed an average of 32% increase

in SPF4S

AA

activity. SPF4S

DD

was generated in the scope of mimicking a continuously

phosphorylated form of SPF4S; however, our experimental data in splicing assays did
not support it and SPF4S

DD

failed to act as a phospho-mimetic of SPF4S toward fas

splicing. A possible hypothesis that could explain this result is the dynamic nature of
splicing

factors

regulation.

Since

alternating

cycles

of

phosphorylation

and

dephosphorylation are thought to direct the function of splicing factors in the regulation
of their activities {Prasad 1999, Shin 2004}, SPF45 mutants cannot participate in these
"regulatory" cycles; wild-type SPF4S on the other hand, is freely available for a
continuous upstream phosphorylation by CA-MEK1{DD}/ERK2 or MKK3{E)/p38MAPK
and downstream dephosphorylation by cellular phosphatases (yet to be determined),
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hence subjected to "phospho-regulation". A potential alternative explanation could lie
in the effect of the phosphorylation and/or the mutations in controlling SPF45
subcellular localization either within the nucleus or through altered nuclear-cytoplasmic
shuttling. Unfortunately, subcellular localization experiments were not successful in our
hands, and they remain potential unanswered questions to be investigated.
SPF45 induces genetic changes in SKOV3 ovarian cancer cells in both phosphorylationdependent and -independent manners
As there are few known targets for alternative splicing by SPF45 and no reports
describing the genetic changes imposed by its overexpression we addressed these
l

questions by performing an exon-array and a gene-array on SKOV3 cells stably
overexpressing exogenous wild-type SPF45; SKOV3-pQCXIP (empty vector control cell
line) was used as a control. We identified 158 potentially altered genes levels (high
stringency criteria) and 139 potential novel splicing targets of SPF45. However, array
data require physical confirmation and we focused on four different genes selected for
their expression level changes in the array and their known involvement in cancer
biology; they are: ErbB2, fibronectin, transforming growth factor-(3 and periostin. We
also investigated their expression levels in SKOV3-SPF4S

AA

and SKOV3-SPF45

DD

to assess

the effect of Thr71 and Ser222 residues/mutations on SPF45 functions. ErbB2 was
roughly 70% decreased in SKOV3-SPF45 compared to vector, while in SKOV3-SPF54
was 36% decreased and SKOV3-SPF45

DD

AA

it

80% decreased. ErbB2 mRNA levels were

equally translated on the protein level in their corresponding cell lines. Fibronectin
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expression was roughly 5 folds increased in wild-type SPF4S, SPF4S

AA

and SPF4S

DD

compared to vector control. Real-time RT-PCR data were supported by northern blot of
fibronectin and the mRNA levels were equally translated on a protein level (data not
shown.) It is interesting to note that Thr71 and Ser222 mutations do not affect
fibronectin levels compared to wild-type SPF4S. Taken together, the role of mutations of
Thr71 and Ser222 on ErbB2 and FN expression suggests the existence of phosphoSPF4S-dependent and -independent effects. Two more genes were tested for their
relative abundance in the generated stable cells: TGF-(3 and perisotin. No statistical
difference was observed in TGF-(3 between SKOV3-pQCXIP and SKOV3-pQCSPF4S while
both SKOV3-pQCSPF4S

AA

and SKOV3-pQCSPF4S

DD

showed 2 fold increase. Finally,

periostin, which - based on the array results - was expected to show the strongest fold
increase with SPF4S overexpression, failed to have any statistical difference among the
four groups tested. Simply, the levels of periostin were so low, that any change in its
concentration from one group to the other would show an lIapparent" difference in the
array analysis that may not necessarily materializes by physical approaches. In fact, the
example of periostin represents one of the crucial reasons to address the results of
gene-arrays cautiously and validate these observations with further experiments.
EDA-Fibronectin but not EDB-Fibronectin is a novel splicing target for SPF4S
In addition to the genetic changes in fibronectin expression, exon-array analysis
predicted several regions within FN to undergo alternative splicing in response to SPF4S
overexpression. A caveat of the exon-array we used is its inability to point out to the

159

specific exons undergoing alternative splicing. Using literature search to check for
reported alternative splicing regions of fibronectin, we identified three FN domains,
extra domain III A (EDA), extra domain III B (EDB) and a variable (V) region that have
been reported to undergo alternative splicing under different disease conditions and in
a tissue specific manner. We directed our attention to EDA and EDB and designed
primers to check for inclusion/exclusion of these regions in SKOV3-pQCXIP, -pQCSPF4S, pQCSPF4S

AA

and -pQCSPF4S

DD

using semi-quantitative reverse-transcriptase PCR. This

method failed to show differences in inclusion/exclusion of these regions as RT-PCR
lacks the ability to calculate with precision the ratios of the different bands when it is
difficult to determine the reactions outcomes in a linear phase. To overcome this
problem, we designed exon-specific primers to EDA and EDB and studied their relative
abundance in the four different groups using real-time quantitative RT-PCR. Similar to
our previous results, fibronectin was equally increased in SPF4S overexpressing cells
(wild type and mutants) and the difference between the three groups was nonsignificant. Also, EDB-FN was equally elevated in the same groups compared to vector
control, and showed a similar fold increase to total fibronectin. However, EDA inclusion
was 37% increased in wild-type SPF4S compared to SPF4S

AA

and SPF4S

DD

as well as total

fibronectin in wild-type SPF45 stable cells. These data showed that SPF4S is implicated
in fibronectin alternative splicing, that mutations of the phosphorylation sites abrogate
its effect on EDA inclusion, and that exon-array data, coupled with biophysical
techniques, bioinformatics and literature search can be used as a tool to identify the
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regulation of alternative splicing of specific genes. Although real-time RT-PCR is not the
standard technique to address alternative splicing, it proved to be a useful approach to
answer this question for the speed of the experiment as well as its high sensitivity and
ability to render a quantifiable measurement. Generation of fibronectin-EDA minigene
and/or a fibronectin-EDA pre-mRNA oligomer could be used to address the alternative
splicing of this region in response to SPF45 overexpression in vivo and in vitro,
respectively. Although these experiments are the gold standard techniques in studying
alternative splicing, they both lack the specificity of studying the splicing in a biological
tissue, as we did in the SKOV3 ovarian cancer cells.
Mutation of Thr71 and Ser222 does not affect SPF45 binding to constitutive splicing
factors
SPF4S-mediated alternative splicing has been explained, in vitro, through
hydrophobic interactions with constitutive splicing factors in the initial steps of the
spliceosome assembly, namely SFl and SF3blS5, via the RNA recognition motif in SPF4S
C-terminus domain. To assess possible interactions of SPF4S with these proteins in vivo,
we performed a co-immunoprecipitation of Myc-tagged SPF45 or mutants using the
stable cell lines generated. Indeed, we show that both SFl and SF3b15S coimmunoprecipitate with Wild-type Myc-SPF45, demonstrating in cells a physical
interaction between SPF45 and constitutive factors of the splicing machinery. While we
expected that SPF4S

AA

and/or SPF4S

DD

to have different binding to SFl and SF3b155, no

difference was observed. Assays that address this process in a dynamic manner, looking
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at spliceosome complex in its development and assembly might provide a better clue
whether the phosphorylation of Thr71 and/or Ser222 is involved in these interactions.
SPF45 overexpression in SKOV3 ovarian cancer cells does not alter their cytotoxic
response to chemotherapy
Although forced SPF45 expression in ovarian and cervical cancer cells is linked to
drug resistance, we did not observe such a phenotype in SKOV3 cells. While it is unlikely
that a single factor, such as the overexpression of a single protein, is responsible for the
multidrug resistance phenotype, SPF45 is a splicing factor that has the potential to
affect a large number of downstream targets, many of which could lead in a combined
effort to the drug resistance phenotype. The only pathway that we identified in the
genetic array to be related to drug resistance in SKOV3 cells involves ErbB2. In fact,
ErbB2 levels were shown to decrease in a cisplatin resistant SKOV3 clone (LangstonWebster 1994). The decrease in ErbB2 level in response to SPF45 overexpression, might
therefore account for the elevated drug resistance profile of SKOV3 cells. While Perry et.
al (Perry 2005) showed that SPF45 induces a drug resistance phenotype in A2780 and
HeLa cells, these studies were performed using few highly-resistant clones selected
among multiple clones generated, not all of which display resistance; the stable cells we
generated represent a heterogeneous population of cells pooled to overexpress SPF45
and hence might not display the similar outcome of individually selected colonies.
Investigating the drug resistance phenotype of SPF45 in multiple cancer cell lines}
ovarian and non-ovarian, is therefore necessary to address this question. Furthermore,
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it would provide a platform to determine the common genetic and splicing events
regulated by SPF45 both in a tissue-specific and -nonspecific manner.

Limitations of the study
This study is based in a large extent on the assumption that MAP Kinases
phosphorylate SPF45 solely on Thr71 and Ser222. While it is typical to identify a priori
phosphorylation sites using in vitro analysis of kinase-subjected proteins, in vivo
determination of phosphorylation remains the gold standard for adequate functional
analysis and for unraveling the impact the phosphorylation imparts on the substrate.
Further experiments using in cells radioactive phosphate labeling of SPF45 for phosphopeptide mapping or alternatively mass spec analysis of SPF45 may possibly reveal
phosphorylation sites not previously suspected or identified. In fact, mass spec analysis
offers

a

powerful

tool

to

determine

multiple

simultaneous

post-translational

modifications on SPF45 and has a strong potential for a wider insight onto
phosphorylated SPF45 regulation. With this technique, the role of other kinases can be
further

investigated

and

SPF45

response

to

kinase

activation

under different

extracellular cues, be assessed. A great advantage of mass spec analysis is its ability to
analyze a large number of treatment in a fast and accurate way, generating a large
amount of information in a timely and effective manner.
From another perspective, while we determined the phosphorylation of SPF45 in
several ovarian cancer cells stimulated with known ERK, JNK and p38 MAPK activators,
SPF45 phosphorylation under physiological and pathophysiological conditions was not
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addressed. Given that the scope from this set of experiments was to show SPF45's
phosphorylation in vivo, the question was answered appropriately. However, the study
fails to investigate the functional significance of SPF45 phosphorylation under these
conditions. It equally fails to address SPF45 phosphorylation under treatment with
chemotherapeutic agents. Although drug resistance experiments are non-contributory
in this

work,

investigating SPF45

response to

anti-neoplastics

adds

additional

information regarding SPF45 phosphorylation status in response to cellular treatment
with chemotherapeutic agents. Unfortunately, the experiments performed in this thesis
are limited to evaluating Thr71 and Ser222 solely and do not anticipate phosphorylation
of SPF45 on different residues in response to activation of MAP kinase enzymes.
Coupling these experiments with mass spec analysis will likely avoid the problem of
unspecific bands due to the reactivity of the phospho-specific antibodies and will
provide a wider view on the different possible post-translational modifications that
occur on SPF45 in response to the different treatments employed.
The data we presented in this thesis showed a role for SPF45 phosphorylation by
MAPKs in altering the splicing pattern of Fas. While we proposed in a previous section
an explanation for the failure of SPF45

DD

to demonstrate a similar response to

phosphorylated SPF45, we cannot exclude the possibility that increased MAPK activity in
the cell can lead to increased Fas alternative splicing in a non-SPF45 mediated
mechanism. Under this scenario, SPF45 overexpression facilitates Fas splicing in
response to a yet-to-be-determined MAPK-dependent mechanism. Additionally, failure
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of SPF4S

DD

mutant to behave similarly to phosphorylated SPF45 raises the suspicion that

SPF4S DD might have a different impact on the cells than SPF4SPT71pS222. Also, since
SPF45

AA

TGF-~}

and SPF4S

DD

display similar response in terms of the genetic changes on FN and

which supports the importance of Thr71 and Ser222 residues in regulating the

functions of SPF4S, it may potentially indicate that SPF4S

DD

is not a true phospho-

mimetic analog of SPF4SPT71PS222 or that it selectively functions as a phosphomimetic. If
this were to be true, caution is required when using SPF4S

DD

as a mimetic for

SP F4SPT71pS222.
In this work, we showed that phosphorylation of SPF4S impacts its alternative
splicing activity towards Fas. Due to the paucity of known pre-mRNA sequences
influenced by SPF45 activity, the study is limited to fas gene spanning exons 5 through 7.
While in vitro alternative splicing has fallen in favor compared to in vivo techniques
using minigene systems and peR approach, partly due to the convenience and simplicity
of the minigene approach} and partly because splicing is studied in its quasi-native
environment} using in vitro techniques offers control over the contents of splicing
complex used, and can potentially substantiate the results of the minigene approach.
Additionally, it can provide further information about the nucleic-proteomic interactions
between SPF45 and the splicing complex, as well as SPF45 interactions with other
splicing factors within the spliceosome. Given the large number of potential splicing
events subjected to SPF45 regulation, as determined by the exon array analysis,
generating minigenes of the predicted sequences will be necessary to further
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understand the relationship between phosphorylation of SPF45 and alternative splicing.
Alternatively, uSing the qRT-PCR approach that we use in this thesis to show the
alternative splicing of the EDA region of FN, can be applied on a larger scale with
specifically designed primers to determine the splicing changes of suspected alternative
splicing events. Unfortunately, the array results do not point directly to the alternatively
spliced sequences, and further bioinformatics analysis coupled with literature search
will be necessary to determine these splicing events.
We have discussed previously the importance of the gene- and exon-array in
determining novel genetic and splicing events regulated by SPF45; we equally discussed
the limitation of this technique in terms of high rate for false positive results as well as
the need for support using biochemical approaches. While we focused our efforts on
four distinct genes from the gene array, the list of targets to be investigated is quite
large and requires substantial dedication to sift through the data and validate the
outcomes. Hence, bioinformatics tools will prove to be essential in speeding up the
process. Functional map analysis is an example of linking different genes in a logical and
biochemically acceptable pattern and has the potential to identify strong candidates for
major molecular changes in the cells. DNA repair, regulation of apoptosis and cellular
adhesion and migration are interesting areas for investigation, specifically in the context
of cancer biology.
One of the major drawbacks of this study is its inability to reproduce the drug
resistance phenotype imparted by SPF45 overexpression in ovarian cancer cells, as

166

published by Perry et al. (Perry 2005) and hence whether phosphorylation of SPF45 by
MAP kinases has any effect on drug resistance. Several caveats can be accounted for to
explain this failure. Our study is based on two publications by the same group, where
the authors claim a link between SPF45 overexpression and multidrug resistance in
A2780 and HeLa cells. Accordingly, the data on which the second aim of our hypothesis
is based are weak, given the paucity of supporting evidence. While the rewards of this
project can be remarkable, the lack of cumulative supporting data places this study in a
high-risk category for failure upon addressing the possible link between phosphorylation
of overexpressed SPF45 and drug resistance. Although we expect SPF45 to induce the
drug resistance phenotype observed by Perry et al. (Perry 2005) in A2780 cells, it is
possible to conclude that the choice of a different cell line, such as SKOV3 cells in this
study, might not exhibit a similar behavior. Unfortunately, multiple efforts to generate
A2780 cells that stably express SPF45 or its mutants were unsuccessful to test this
hypothesis. Additionally, a major difference exists between our approach and that of
the other group. Perry and his colleagues proposed a relationship between SPF45 and
drug resistance based on few A2780 and HeLa clones - selected from a larger number of
SPF45 expressing clones - because of their enhanced drug response profile, while we
based our approach on generating pooled populations of cells stably expressing SPF45.
As such, it may not come as a surprise the failure of our approach. If that turns out to be
the true explanation for this disparity, it would likely be safe to assume that SPF45 does
not have a role in drug resistance. However, until stable populations of cells in A2780

167

and Hela overexpressing SPF45 are generated, this question remains unanswered. Using
a lentiviral system for expression of SPF45 and its phosphorylation-sites mutants and/or
an inducible expression system in the aforementioned cells may overcome the
difficulties of infection using a retroviral plasmid and re-evaluation of drug resistance. If
SPF45 is genuinely responsible for such a phenotype, investigating the mechanism(s) will
be crucial. While glutathionylation, overexpression of MRP, PgP and MDR 1 are possible
mechanisms for drug resistance, the data by Perry et al (Perry 2005) refute their
involvement in SPF45 mechanism of resistance. Enhanced DNA repair and altered
expression of apoptotic genes are common pathways to impart drug resistance to
cisplatin, doxorubicin, etoposide and vincristine. If efforts to express SPF45 in different
cell lines were to be successful and SPF45 does induce a drug resistance phenotype,
investigating genetic changes of DNA repair pathways and altered apoptotic genes,
presents a plausible starting point to understand its mechanism. Using the results of the
gene array in SKOV3 and possibly repeating the gene array analysis among different cell
lines may identify common pathways altered in response to SPF45. An interesting aspect
of these experiments is the richness of information that can be construed regarding
SPF45 roles and functions, regardless of its impact on drug resistance. As mentioned
earlier, DNA repair pathways, altered apoptotic genes, cellular adhesion, spreading and
migration are important venues in cancer biology and drug discovery worth to be
investigated in their own regards.

Contribution and future directions
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The importance of this study was identifying a novel mechanism of regulation of
splicing through the MAP kinase signaling cascade. As mentioned earlier, there are few
accounts of MAP kinase involvement in splicing regulation linking splicing mechanisms
to extracellular cues. This fact can have dramatic results in the context of cancer.
We have determined SPF45 splicing activity towards !lfas upon phosphorylation
by ERK2 and p38 MAP kinase. It would be interesting to identify SPF45's splicing activity
upon phosphorylation by JNK. Similar experiments with activated JNK will unveil the role
of JNK on SPF45. Our findings that genetic changes and splicing events are affected by
mutations of the MAP kinase target sites suggest a potential role of the different MAP
kinase families in controlling SPF45 functions. In fact, such a response is very plausible
especially that MAP kinases are activated in specific response patterns depending on the
external and internal cellular conditions. Obviously, we are still at the beginnings of
identifying the significance of this regulation, especially that SPF45 is overexpressed in,
besides ovarian cancer, a broad range of solid tumors including breast, bladder, colon,
lung and pancreatic cancer all of which display elevated expression and/or activation of
one or more of the different MAP kinase subfamilies as well as several other signaling
cascades secondary to oncogenic activation, environmental conditions of cancerous
behavior or even chemotherapeutic agents. We show a change in the SKOV3-pQCSPF45
attachment to fibronectin coated wells compared to SKOV3-pQCXIP. Cellular adhesion is
a complex process governed by multiple molecules and interactions between the
extracellular matrix and intracellular/transmembrane proteins. Additionally, cellular
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adhesion is of prime importance for cancer cells: migration, invasion and cellular
proliferation are all affected by changes in cellular adhesive properties. Would the
observed decrease in SKOV3-pQCSPF45 attachment within the first hour of seeding have
any significance for cancer progression such as increased migration or invasion, remains
to be determined. Alternatively, the observed increase in TGF{3 together with
fibronectin expression may enhance cellular compactness, increasing multicellular
spheroid formation and invasive phenotypes (Sodek 2009). One approach to identify
possible changes in adhesion is to perform a real-time gene array of adhesion pathways.
In fact, we have recently obtained a pre-validated 96 well array (Qiagen) capable of
detecting changes at the mRNA level of more than 80 different genes involved in cellular
attachment to extracellular matrix; any changes identified will have a great impact in
determining the role of SPF45 on cellular adhesion. Although not a comprehensive
approach, it can provide an important lead into the molecules involved in this
phenotype. Besides, attachment (a measure of bound cells) and spreading (a measure of
the flattening of adherent cells) assays could be performed to better characterize this
phenotype as well as determine the biochemical and structural regulation of the points
of attachments also known as focal adhesions.
In understanding the functions and roles of SPF45, an important question always
arises: are SPF45 effects universal? Would it confer similar genetic changes and
phenotypes in different cell lines? It is actually quite difficult to answer this question.
The fact that splicing factors are not as diverse as transcription factors suggest that they
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tend to rely on the ratios of the different combinations of splicing factors as well as the
strength of interactions with the cis sequences in the introns/exons of the pre-mRNA
(Mayeda 1993, Faustino 2003, Shin 2004). Accordingly, it is almost impossible to predict
the phenotypic outcome because of the heterogeneity of the different cell lines. For
example, SPF45 confers drug resistance in HeLa and A2780 cells (Sampath 2003, Perry
2005); however we do not observe a similar phenotype in SKOV3 cells. If we
simplistically assume that SPF45 induces similar genetic changes in SKOV3 cells that it
induces in HeLa and A2780, then there must be other factors in these cells but not
SKOV3 that causes the drug resistance. To answer this question, it would be imperative
to investigate SPF45 effects when overexpressed in several cell lines.

In fact, we are

currently generating stable cell lines in several ovarian cancer cell lines as well as HeLa
and MCF-7, a breast cancer cell line, of SPF45 and phospho-sites mutants to test this
hypothesis. The importance of our approach is that we generate pooled population of
heterogeneous cells that overexpress SPF45 to circumvent the problem of clonal
variation. As such, if we fail to identify drug resistance changes in these cells, it will
increase our confidence to assume that SPF45-mediated drug resistance is more likely
an isolated event of individually selected clones rather than a true SPF45 effect. If on the
other hand, drug resistance is enhanced in more than one of these cells, identifying the
common genetic/proteomic changes will probably determine the mechanism of this
resistance. Additionally, the cell lines generated in HeLa and MCF-7 will help answer
several other questions; for instance, it will be interesting to compare the common
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genetic changes induced by SPF45 overexpression. It will serve as a direct answer to the
role of splicing factors as universal regulators of genetic outcomes. The higher the
number of common changes observed, the stronger is the support for this hypothesis.
Additionally, common genetic changes determined by gene and exon arrays in different
cell lines are likely to be true events due to their overlap as well as decreased bias; it
would generate higher likelihood of true genetic and splicing changes induced by SPF45.
Testing the adhesive, migratory and invasive properties of the different stable cell lines
would also assess the role of SPF45 in cancer.
As the role of SPF45 in cancer is still to be determined and studied, it would be
necessary to generate knock-out mice of SPF45 to evaluate the role that it plays in
cancer: initiation, progression, maintenance or suppression. Knockout mice of proteins
of interest are an invaluable tool in singling out the properties of a protein. It would
determine the role of SPF45 in development as well as the different phenotypic changes
that could be imparted by lack of its expression. If the deletion turns to be embryonic
lethal, conditional knockouts can be generated to study SPF45 functions in a tissuespecific pattern.
We have already mentioned that SPF45 is expressed in several solid tumors,
which display varying levels of oncogenic signals and activate a multitude of signaling
cascades. The amino acid sequence of SPF45 shows potential phosphorylation sites of
several other kinases, many of which, such as PKC and Akt are of prime importance in
cancer signaling. Determining the potential regulation of SPF45 phosphorylation by
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these different cascades, as well as putative cross-talks with MAP kinase signaling will be
exciting as well as important to better understand the link between signaling cascades
and splicing machinery in regulating cancer cells and in generating efficient therapeutic
interventions.
In conclusion, this dissertation investigated and confirmed the involvement of
MAP kinase signaling in the functions of the splicing factor SPF45, regulating its splicing
activity and potentially modulating its downstream genetic and splicing targets. SPF45 is
but one player among a vast group of cellular factors that widely contribute to the
aberrant nature of cancer cells. As our understanding of the molecular mechanisms that
govern SPF45 interactions, as well as upstream events that modify its activities, we will
get one step closer into developing sound strategies and efficient therapeutic
interventions to overcome drug resistance or even cure cancer.

173

Appendix

ERK ACTIVATION AND NUCLEAR SIGNALING INDUCED BY THE LOSS OF CELL/MATRIX
ADHESION STIMULATES ANCHORAGE-INDEPENDENT GROWTH OF OVARIAN CANCER
CELLS

Adnan AI-Ayoubi\ Adel Tarcsafalvi 3 , Hui Zheng1,Wayne Sakati 1 and Scott T. EblenlJ2J3*,
lDepartment of Cell and Molecular Pharmacology, Medical University of South Carolina,
Charleston, SC
2Hollings Cancer Center, Medical University of South Carolina, Charleston, SC 29425;
3Department of Microbiology, University of Virginia, Charlottesville, VA 22908
Work performed at: Medical University of South Carolina, Charleston, SC and University
of Virginia, Charlottesville, VA 22908
*Corresponding
Pharmacology,

author:

Mailing

address:

Department

of

Cell

and

Molecular

P.o. Box 250505, Medical University of South Carolina, Charleston, SC

29425. Tel: 843-792-1444. Fax: 843-792-9580. email: eblen@musc.edu
Running title: Detachment activates ERK in ovarian cells
Keywords: ERK, ovarian, suspension, detachment, signaling

Figures: 8
Contract grant sponsor: Department of Defense
Contract grant number: W81XWH-04-1-0100

174

ABSTRACT
Ovarian cancer metastasis involves the sloughing of epithelial cells from the
ovary into the peritoneal cavity, where the cells can survive and proliferate in peritoneal
ascites under anchorage-independent conditions. For normal epithelial cells and
fibroblasts, cell adhesion to the extracellular matrix is required to prevent apoptosis and
for proper activation and nuclear signaling of the ERK MAP kinase. The mechanisms of
ERK regulation by adhesion have been determined by our lab and others. In this report,
we elucidate a novel means of ERK regulation by cellular adhesion in ovarian cancer
cells. We demonstrate that ERK and its activator MEK are robustly stimulated after cell
detachment from a substratum in several ovarian cancer cell lines, but not a benign
ovarian cell line, independent of serum and FAK or PAK activity. MEK and ERK activation
was sustained for 48 hr after detachment, while activation by serum or growth factors in
adherent cells was transient. Re-attachment of suspended ovarian cells to fibronectin
restored basal levels of MEK and ERK activation. ERK activation in suspended cells was
dynamically controlled through an autocrine stimulatory pathway and prevalent
phosphatase activity. Suspended cells demonstrated higher levels of ERK nuclear
signaling to Elkl compared to adherent cells. Inhibition of ERK activation with the MEK
inhibitor U0126 had minor effects on adherent cell growth, but greatly decreased soft
agar colony growth. These data demonstrate a unique regulation of ERK by cellular
adhesion and suggest a mechanism by which ERK may regulate anchorage independent
growth of metastatic ovarian cancer cells.
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Extracellular Regulated Kinases (ERKs) are members of the MAP Kinase family of
protein kinases that regulate many aspects of cell biology including, proliferation,
differentiation, migration, survival, and gene expression [Pearson et al.I 2001]. Inactive
ERKs reside in the cytoplasm, but following activation translocate to various cellular
locations including the nucleus [Chen et aL, 1993; Lenormand et aI., 1993] where they
phosphorylate a variety of substrates to affect gene transcription. ERK activation and
nuclear translocation is required for cell proliferation [Brunet et aL, 1999] and cell
adhesion has been reported to be a requirement for ERK nuclear tranlocation and
activation of the Elk1 transcription factor [Aplin et aI., 2002]. Cell adhesion is also
required for ERK activation by mitogens, as cells in suspension fail to activate ERK in
response to growth factors [Lin et aL, 1997; Renshaw et aI., 1997]. Overexpression of an
activated mutant of Focal Adhesion Kinase (FAK) [Renshaw et aI., 1999] or p21 Activated
Kinase (PAK) [Howe and Juliano, 2000] can stimulate anchorage independent activation
of ERK, demonstrating that these proteins act as adhesion-dependent sensors for ERK
activation. FAK is activated in adherent cells through autophosphorylation of Tyr397,
which forms a binding site for Src [Calalb et aI., 1996; Lipfert et aI., 1992]. Activation of
Raf, MEK and ERK and functional coupling between Raf and MEK and MEK and ERK upon
cell attachment to fibronectin is dependent upon activation of PAK [Eblen et aI., 2002;
Edin and Juliano, 2005; Slack-Davis et aI., 2003] through a FAK and Src dependent
pathway [Slack-Davis et al., 2003]. This mechanism occurs in part through PAK

176

phosphorylation of MEK1 on S29B} which is required for MEKl activation and stimulates
MEK1/ERK complex formation in newly-adherent cells [Eblen et al.} 2002; Slack-Davis et
al.} 2003].
Ovarian cancer is the fifth leading cause of cancer deaths in women and the
deadliest form of gynecological cancer. In humans most ovarian cancers originate from
the ovarian surface epithelium (OSE), which is a poorly differentiated mesothelium with
a tenuous attachment to the underlying basement membrane [Dietl and Marzusch,
1993]. Dissemination of ovarian cancer cells to the peritoneal cavity involves the loss of
attachment of the OSE from the underlying basement membrane or their extravasation
from inclusion cysts that form within the ovary [Auersperg et aL, 1998]. Ovarian cancer
patients often develop peritoneal ascites fluid containing metastatic cells growing
individually or as multicellular spheroids, in addition to factors that promote tumor cell
growth [Mills et al., 1990; Westermann et al., 1997; Westermann et al., 1998]. Ascitic
cells survive and proliferate under anchorage-independent conditions until they attach
to the mesothelium of the peritoneal cavity via fibronectin and hyaluronan produced by
peritoneal mesothelial cells [Burleson et aL, 2004; Casey et al., 2001; Lessan et aI.,
1999].
Mouse models have identified ras as a causative agent in the development of
ovarian cancer [Uu et aI., 2004; Orsulic et aL, 2002]. Indeed, in humans two-thirds of
low-grade ovarian tumors have mutations in the k-ras or b-raf oncogenes while 16% of
I

177

high grade tumors carry k-ras mutations [Ho et aI., 2004; Singer et aI., 2003a; Singer et
aI., 2003b]. However, activation ERK is observed in 80% of low grade tumors, 40% of
high grade ovarian tumors [Hsu et aI., 2004], and 91% of pleural and peritoneal
effusions from patients with metastatic disease [Davidson et aI., 2003], suggesting that
other factors

also

contribute to

ERK

activation

in

metastatic ovarian

cancer.

Downregulation of MAP Kinase Phosphatase-1, a negative regulator of ERK, has been
observed in ovarian tumor samples [Denkert et aI., 2002]. Overexpression of growth
factor receptors that stimulate ERK activation, such as ErbB-2 and c-Met, is observed in
ovarian tumors [Berchuck et aI., 1990; Di Renzo et aI., 1994]. In addition, ascites fluid is a
complex milieu rich in mitogens such as lysophosphatidic acid (LPA) and Platelet Derived
Growth Factor (PDGF) [Matei et aI., 2006], among others, but the cellular origins of most
of these factors are unknown.
We examined the regulation of ERK activation by loss of cellular adhesion, an
early step in cancer metastasis, in several ovarian cancer cell lines. We demonstrate a
strong, sustained activation of M EK and ERK in response to loss of cell/matrix adhesion.
Re-attachment of cells restored basal levels of active ERK. Conditioned media from
suspended cells could stimulate ERK activation in serum-starved adherent cells,
suggesting an autocrine mechanism for ERK activation in suspended cells. ERK signaling
to the nucleus was enhanced in suspended cells and inhibition of ERK signaling had
profound effects on soft agar growth. These studies demonstrate a novel means of ERK
regulation by cellular adhesion and suggest that upregulation of ERK activation through
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an autocrine mechanism promotes the ability of ovarian cancer cells to grow anchorageindependent.
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MATERIALS AND METHODS

Cells and Reagents. SKOV-3 cells were purchased from American Type Culture
Collection (Manassas, VA) and grown in McCoy's SA media supplemented with 10 %
fetal calf serum. lOSE cells were a generously provided by Dr. Nellie Auersperg. CAOV3,
ES2, TOV21G, and OV2008 cells were a kind gift from Dr. Runzhao Li. OVCAR3 cells were
a kind gift from Dr. Kristen Atkins. ERK2 antibody was kindly provided by Dr. Michael J.
Weber. Phospho-ERK antibody was purchased from Sigma (St Louis, MO). FAK and
phospho-Y397 FAK antibodies were purchased from Cell Signaling (Danvers, MA).
Phospho-MEK, MEK, phospho-AKT, AKT, tubulin and MKP-l antibodies were purchased
from Invitrogen (Carlsbad, CAl.

Suspension assay. Six-well dishes coated with 1% agarose were prepared by melting 4%
agarose into phosphate buffered saline (PBS). This solution was then mixed with 3 parts
serum-free McCoy's SA media and used to coat 6 well dishes. Adherent cells growing in
media containing 10 % fetal calf serum were washed once with PBS and detached with
trypsin-EDTA. The trypsin was inhibited with 1 mg/ml soybean trypsin inhibitor (Sigma)
in PBS. The cells were collected, counted, pelleted by centrifugation, and resuspended in
serum-free media at a concentration of 1 X10

6

cells / ml for all experiments. Two

milliliters of cells were added to each well. The cells were then incubated for the
indicated time at 37 DC and S % C02 before harvest by gentle pipetting into 15 ml
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conical tubes containing 10 ml of cold PBS on ice. Centrifuged cells were snap frozen and
stored at -70°C until lysis. For replating experiments, fibronectin was coated onto dishes
overnight at 4 °c at a concentration of 10 I11g/ml. Replated cells were put onto these
dishes in the same serum-free media that they were suspended in and incubated at 37
°c and 5 % CO 2 until harvest. Citric saline experiments were performed in a similar
manner, except that cells were washed, incubated with citric saline for 15 min and
collected by gentle pipetting. The cells were centrifuged, washed in PBS, and
resuspended in serum free media.

Western blotting. Cells were lysed in M2 lysis buffer [Eblen et aI., 2001] and protein
concentrations determined using the BeA kit (Pierce, Rockford, IL). Typically, 20 I1lg of
protein was run on an SDS PAGE gel and transferred to nitrocellulose. The membranes
were blocked in 5 % milk and incubated with antibodies from 1 hr to overnight.
Secondary antibodies conjugated to horseradish peroxidase were followed by enhanced
chemiluminescence (Pierce) to visualize proteins.

MTT assay. SKOV-3 or lOSE cells were plated in triplicate into 12 well dishes at a
3

concentration of 1 X 10 cells / well. The following day (day 0) the cells were treated in
duplicate with either 10 111M U0126 or DMSO vehicle control. On each of the next 4
days, triplicate wells of cells were washed and incubated in MTT reagent for 2 hrs before
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harvest in DMSO. MIT activity was measured by reading the absorbance at 570 nm and
reference wavelength of 630 nm. These experiments were performed 3 times.

Luciferase assays. SKOV-3 cells were transfected using UpofectAMINE (Invitrogen) with
1 [1]g of 5X Gal4 Luciferase, 50 ng of Ga14-Elk1 [Roberson et aI., 1995], 100 ng of TK
Renilla luciferase, and either 100 ng of empty vector or 100 ng of mutationally-activated
MEK1 (MEK1 S218/222D) per 6 cm dish. After a 5 hr transfection in serum-free McCoy's
SA medium, the medium was removed, the cells were washed once with PBS and
allowed to recover overnight in 10 % serum containing media. The day after transfection
the cells were washed twice in PBS and either incubated in serum-free media or
trypsinized and suspended in serum-free media, as described above. After 24 hr, both
adherent and suspended cells were harvested, lysed and luciferase activity (Renilla and
firefly) measured. The ratio of firefly:Renilia luciferase was determined for each sample.
Activity in the adherent cells in the absence of activated MEK1 was set to 1 for each
experiment. The results are a combination of 5 separate experiments all performed in
triplicate. Statistical analysis was performed using the Student's t-test and significance
determined as p < 0.05.

3

Soft agar assay. SKOV-3 cells were mixed at a density of 5 X 10 cells / ml in 0.4 % bacto
agar, 10 % serum, and either 10 [liM U0126 or DMSO control. One milliliter of this
mixture was overlayed onto 3S mm dishes containing a 0.6 % agar plug. Assays were
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performed in triplicate. The cells were incubated at 37 DC and 5 % CO 2 for 5 weeks.

U0126 or DMSO was administered to the cells every 3 days by dissolving 11111 DMSO or 1
[1]1 of a 10 mM stock solution of U0126 into 100 ilIl of serum-free media and overlaying it
onto the 1 ml of cells in agar, allowing for drug absorption at a final concentration of 10
[liM. After 5 weeks, four random fields of cells from each plate were photographed
under a 2.SX objective. Distance on the plate was determined using a known standard.
The images were analyzed using Image J software {website: http://rsb.info.nih.gov/ij/} in
order to quantitate colony number and individual colony size. Colonies above 400 111m2
in 4 fields from each triplicate dish were counted. Results from each triplicate were
averaged and the standard deviation determined. A Student's t-test was performed
between DMSO control and U0126 treated dishes and significance determined as p <

0.05. The experiment was performed a total of 3 times with similar results. An identical
experiment performed with lOSE cells did not yield any soft agar colony growth.
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RESULTS

Loss of Cell Anchorage Activates ERK in Ovarian Cancer Cells

Cellular adhesion is required for efficient activation of ERK by mitogens in most
epithelial cells and fibroblasts [Lin et aI., 1997; Meredith et aI., 1996; Renshaw et aI.,
1997]. To determine if serum could stimulate ERK activation in suspended ovarian
cancer cells, adherent SKOV-3 cells were detached with trypsin followed by treatment
with soybean trypsin inhibitor. The cells were then put in suspension culture for 3 hr in
the presence or absence of serum. Cells under these suspended conditions remain
rounded, do not attach to the agarose, and are easily collected by gentle pipetting (data
not shown). Adherent SKOV-3 cells in serum had modest ERK activation, whereas cells
suspended for 3 hr in serum had robust activation of ERK and MEK (Fig. lA). Surprisingly,
suspended cells incubated in serum-free media had a similar level of MEK and ERK
activation as those suspended in serum. Release of cells by both typsin and citric saline
and trypsin resulted in a loss of FAK phosphorylation, but an increase in ERK activation
(Fig. 1B). In addition, we performed a short time course to look at ERK activation
between 0-3 hr after trypsinization or citric sailine treatment. Activation of ERK did not
occur until 1-2 hr after cells were in suspension culture under either condition (Figs. Ie
and 10).
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To determine if activation of ERK also occurred in benign ovarian epithelial cells
in suspension culture, we compared the level of ERK activation in detached SKOV-3 cells
to lOSE cells, a benign cell line derived by SV40 large T antigen immortalization of
normal ovarian surface epithelium [Auersperg et aI., 1994]. After 3 hrs in suspension in
serum free media, the basal level of ERK activation in adherent lOSE cells was lost, while
ERK activation was strongly induced in SKOV-3 cells (Fig. lE). To determine if activation
of ERK upon detachment occurred in other ovarian cancer cell lines, we screened five
other ovarian cancer cell lines for ERK activation in serum free media in response to
cellular detachment. We observed an induction of ERK1 and ERK2 activation at 1 and 3
hr after detachment in four of the six cell lines tested (Figure IF). ERK activation upon
detachment was strongest in SKOV-3 cells, which have wild-type ras and b-raf genes
[Yang et aI., 2003] , but was also observed in OVCAR3, TOV21G, and CAOV3 cells. Like
lOSE cells, ERK activation in adherent OV2008 cells was lost upon cell detachment, as
has been reported in many benign and cancerous cell lines [Eblen et aI., 2002; Fukazawa
et aI., 2002; Honma et aI., 2006; Howe et aI., 2002; Howe and Juliano, 2000; Kraus et aI.,
2002; Lin et aI., 1997; Renshaw et aI., 1997; Slack-Davis et aI., 2003; Zhang et aI., 2006]
while ERK activation in adherent ES2 cells remained unchanged after cell detachment.
Activation of ERK in suspension was also observed in cells incubated for 3 hr in the
presence of 1 % bovine serum albumin, 4 mM EGTA, or a combination of the two,
suggesting that ERK stimulation was not due to cell / cell contact or changes in
osmolarity (Figure IG).
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Prolonged ERK Activation is FAK and PAK Independent
Growth factor stimulation of ERK in adherent cells is transient, often returning to
basal levels within hours of stimulation. SKOV-3 cells are resistant to anoikis and can
survive prolonged times in suspension culture [Frankel et aI., 2001]. To determine the
duration of ERK activation in suspended SKOV-3 cells, we performed a longer time
course to determine the activation of ERK and its activator MEK in cells kept in
suspension for a 2-day period. Activation of both M EK and ERK in suspended cells was
sustained for the entire 48 hr time course (Figure 2A). Microscopic observation (data not
shown) as well as immunoblotting for the phosphorylated, active form of focal adhesion
kinase {FAK} demonstrated that the cells were not attached to the agar (Figure 2A), as
Y397 phosphorylation of FAK only occurs in adherent cells [Calalb et aI., 1996]. We have
previously reported that MEKI and ERK activation by cellular adhesion to the
extracellular matrix requires phosphorylation of MEKI on Ser 298 by PAK [Eblen et aI.,
2002; Slack-Davis et aI., 2003L is negatively regulated by ERK feedback phosphorylation
of MEKI on T292 [Eblen et aI., 2004] and that both were cell adhesion-dependent [Eblen
et aI., 2004; Slack-Davis et aI., 2003]. To investigate whether activation of MEKl and ERK
in suspended ovarian cancer cells was controlled by enhanced phosphorylation of MEKl
S298 in the absence of T292 phosphorylation, we immunoblotted for both of these
phosphorylation sites on endogenous MEKl using phospho-specific antibodies. The
results demonstrate that the prolonged activation of MEK and ERK in suspended SKOV-3
cells was independent of PAK signaling, due to the absence of Ser 298 phosphorylation
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in suspended cells. Interestingly, Thr 292 phosphorylation of MEKl had become
anchorage independent due to the enhanced activation of ERK in suspended cells. These
data demonstrate that MEK and

ERK activation in suspended ovarian cells is

independent of signaling from FAK and PAK and occurs even in the presence of a
negative feedback loop. We next compared the duration of MEK and ERK activation in
suspended cells in the presence or absence of serum. MEK and ERK activation were
equally robust in suspended cells under both conditions at 3, 24, or 48 hr (Figure 2B).
Phosphorylation of AKT, which was present in adherent cells, was not significantly
enhanced upon cell suspension, while FAK activation was greatly reduced.

Acute Mitogen Treatment of Adherent Cells Stimulates Transient ERK Activation
Mitogen stimulation of cells typically results in robust ERK activation within
minutes, returning to basal levels after several hours. To determine if the prolonged
activation of ERK in suspension under serum and serum free conditions also occurred in
adherent cells stimulated with mitogens, we first determined the ability of serum,
epidermal growth factor {EGF}, and hepatocyte growth factor {HGF} to stimulate ERK in
adherent SKOV-3 cells. SKOV-3 cells overexpress both ErbB-2 [Wiechen et aI., 1999] and
c-Met [Corps et al.I 1997], the HGF receptor, and both EGF and HGF have been shown to
be important in ovarian cancer biology [Berchuck et aI., 1990; Huntsman et aI., 1999;
Meden et aI., 1998]. Cells were serum-starved overnight and then stimulated with
increasing amounts of each mitogen for 10 min. (Figure 3A).

Serum was a poor
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stimulator of ERK activity at this time point, while EGF induced robust ERK activation at
all concentrations. HGF was a moderate activator of ERK at the highest concentration
tested. To determine the duration of ERK activation by each mitogen, a time course was
performed after stimulation with 1 ng/ml EGF, 10 ng/ml HGF (Figure 38) or 10% serum
(Figure 3C). ERK activation with each mitogen was transient, returning to basal levels
within several hours. These data demonstrate a fundamental difference in the duration
of ERK activation stimulated by growth factor addition in adherent cells versus
activation due to loss of cell attachment.

Cell / Matrix Re-attachment Restores Basal MEK and ERK Activation
To directly test the effects of extracellular matrix attachment on ERK activation,
SKOV-3 cells were detached and put into suspension for 3 hr. The cells were then either
left in suspension for additional time or allowed to re-attach to fibronectin-coated
dishes (Fig. 4A). Fibronectin is one of the main extracellular matrix proteins that is
produced by mesothelial cells of the peritoneal cavity and is important for attachment
and migration of ovarian cancer cells to the mesothelium [Casey et aI., 2001; Lessan et
aI., 1999]. Replating suspended SKOV-3 cells onto fibronectin resulted in a restoration of
basal MEK and ERK activity within 2 hr, while both proteins remained active in parallel
cultures of cells that were kept in suspension. Phosphorylation of MEK1 on Ser298 and
FAK on Tyr397 were both restored upon cell adhesion. To compare the response of
benign versus malignant ovarian cancer cells in this assay, lOSE and SKOV-3 cultures
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were detached and suspended in parallel. The cells were then either kept in suspension
or replated onto fibronectin-coated dishes, as in Figure 4A. MEK and ERK activation was
enhanced in detached SKOV-3 cells (Fig. 48), as above. Upon reattachment of the cells
to fibronectin coated dishes, basal levels of MEK and ERK activation were restored
within hours. Conversely, the level of activation of ERK and MEK in adherent lOSE cells
was lost in detached cells, but restored upon adhesion of the cells to fibronectin.
Phosphorylation of FAK and 5298 of MEKl were adhesion dependent in both cell lines.
Protein levels of MKP-l, a nuclear MAP Kinase phosphatase, are down-regulated in
ovarian cancer [Denkert et aI., 2002], were much lower in 5KOV-3 cells compared to
rOSE cells, but did not significantly vary with the attachment state of the cells.
Collectively, these data directly demonstrate that cellular adhesion to extracellular
matrix and/or cell spreading acts to down-regulate ERK in malignant, but not benign,
ovarian cells.

Dynamic Regulation of ERK Activation by an Autocrine Mechanism
We reasoned that if the activation of MAP Kinase in suspended ovarian cancer
cells is due to low expression/ activity of ERK-specific phosphatases, such as MKP-l,
suspended cells should have low MEK activity and there should be a slow turnover of
ERK phosphorylation. Therefore, inhibition of upstream signaling with the MEK inhibitor
U0126 should only decrease MAP Kinase phosphorylation after a prolonged treatment.
We put 5KOV-3 cells in suspension for 3 hr and treated them with U0126 for the last 2
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min, S min, 10 min, 15 min, 30 min or the entire 3 hr before harvest (Fig. SA).
Interestingly, inhibition of MEK activity with U0126 for as little as 2 minutes before
harvest caused the complete dephosphorylation of active ERK within the cell. Similar
results were seen with 2 minutes of U0126 addition over a 48 hr time course in
suspension (Fig. 5B). Therefore, even in the presence of reduced MKP-1 expression, the
enhanced activation of ERK in suspended cells is not due to loss of phosphatase activity
towards ERK, but is instead a very dynamic process involving activation by MEK followed
by a rapid inactivation of ERK by phosphatases.
Since activation and inactivation of ERK in suspended cells was dynamic, we
sought to determine if this activation was due to an autocrine stimulatory pathway. We
collected conditioned media from serum starved cells suspended for either 3 hr or 24 hr
(Fig. 6A). Activation of MAP Kinase in SKOV-3 cells was evident at both 3 and 24 hr in
suspension, with greater activation at 24 hr. Either fresh serum-free media or the
conditioned media from the suspended cells was then added to adherent, serumstarved SKOV-3 cells. Addition of conditioned media from suspended cells, but not fresh
serum-free media, to adherent SKOV-3 cells resulted in a rapid activation of MEK and
ERK in the adherent cells. A strong activation, equal to the level in suspended cells, was
observed at S min after addition. Activation was reduced at 15 and 60 min after addition
but was much higher than basal levels. Performing a longer time course of ERK
activation using conditioned media from 24 hr suspended cells demonstrated that basal
levels of ERK activation were restored between 3 and 6 hr after addition (Fig. 68). These
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data demonstrate that suspended cells produce a soluble factor that acts in an
autocrine fashion to stimulate intracellular signaling to MEK and ERK.

Enhanced ERK Nuclear Signaling in Suspended Cells
Upon activation of adherent cells with a mitogen, ERK translocates to the
nucleus [Chen et aI., 1993; Lenormand et aI., 1993], which is required for cellular
proliferation [Brunet et aI., 1999]. It has been reported that ERK cannot signal to its
nuclear substrate Elk1 in the absence of cellular adhesion [Aplin et aI., 2001). We used
an Elk1-responsive luciferase reporter system [Roberson et aI., 1995] to test for the
ability of ERKs to signal to the nucleus in suspended SKOV-3 cells. Cells were transfected
with plasmids encoding a GAL4-Elk1 fusion protein, 5X GAL4 luciferase [Roberson et aI.,
1995], and TK Renilla luciferase. The following day the cells were either serum starved
or put in suspension in serum free media. Adherent and suspended cells were harvested
24 hr later and luciferase activity determined (Figure 7). The TK Renilla reporter
demonstrated an overall reduction in transcription in suspended cells (data not shown).
Normalizing to Renilla luciferase, ERK-responsive firefly luciferase activity was 2.5 fold
higher in suspended SKOV-3 cells compared to adherent cells (Fig. 7). Co-transfection of
a mutationally activated MEKl enhanced ERK nuclear signaling in both adherent and
suspended cells, demonstrating that enhanced ERK activation in adherent cell lines
could stimulate luciferase production and that the difference in endogenous signaling
was due to the enhanced ERK activation in suspended cells. These results demonstrate
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that cellular detachment in SKOV-3 cells enhances MAP Kinase signaling to the nucleus
and regulation of gene transcription.

Enhanced Role of ERK in Suspended Cells
ERK activation has a known role in cell proliferation. To determine the effect of
ERK activation on anchorage dependent versus anchorage independent cell growth, we
first performed cell proliferation assays on adherent SKOV-3 and lOSE cells. Cells were
plated and treated the following day with either 10 [z]M U0126 or DMSO control. Cells
were treated with MTT reagent 2 hr before harvest over the next 4 days (Fig. BA). After
4 days of treatment, cell proliferation in U0126 treated cells was decreased 22 % in lOSE
cells and only 12% in SKOV-3 cells, both of which, while small differences, were
statistically significant. These results suggest that SKOV-3 cells have a reduced
requirement for ERK activity in regards to adherent proliferation compared to lOSE cells.
Since we have observed an enhanced activation of ERK in detached SKOV-3 cells, we
hypothesized that ERK inhibition may have a greater effect on anchorage independent
growth. Therefore, we determined the ability of lOSE and SKOV-3 cells to grow in soft
agar in the presence of DMSO or the MEK inhibitor U0126. Cells were treated with
DMSO or U0126 at the time of plating and every 3 days afterwards. lOSE cells
demonstrated no growth in soft agar (data not shown), as expected. Conversely, SKOV-3
cells produced colonies in soft agar, as reported [Pegues et aI., 1999; Popadiuk et aI.,
2006]. We observed an overall reduction in colony number and size in the presence of
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U0126 (Figs. 88 and 8e). U0126 treatment decreased colony growth by 69% compared
to DMSO treated cells, demonstrating that inhibition of ERK activation has profound
affects on anchorage independent growth of ovarian cancer cells.
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DISCUSSION

We present the novel finding of strong and sustained activation of MEK and ERK
in ovarian cancer cell lines in response to loss of cell adhesion. To our knowledge, this is
the first report of loss of cell adhesion stimulating an induction of ERK activity. ERK
activation in suspension was dynamically regulated by autocrine activation and robust
phosphatase activity. Re-attachment of suspended cells restored basal ERK activity. ERK
signaling to the Elk1 transcription factor was enhanced in suspended cells and MEK
activity was required for soft agar growth. These results demonstrate a unique mode of
ERK regulation by cell attachment and demonstrate a novel mechanism of ERK
activation that occurs specifically during loss of cell adhesion, which has implications for
anchorage independent growth of ovarian cancer cells.

In benign epithelial cells and fibroblasts, ERK activation by growth factors
requires cell adhesion to the extracellular matrix [Lin et aL, 1997; Renshaw et aL, 1997]
Loss of cell attachment inactivates the ERK pathway due to inhibition of PAK by PKA
[Howe and Juliano, 2000] and uncoupling of MEK and ERK [Eblen et aI., 2002]. ERK
inactivation in suspended cells has also been noted in several cancer cell lines, including
breast cancer [Fukazawa et al., 2002], small cell lung cancer [Kraus et aL, 2002], and in
highly metastatic melanoma [Zhang et al., 2006] and hepatocellular carcinoma [Honma
et aI., 2006] cell lines. This suggests that loss of ERK activation in suspension does not
just occur in benign cells, but also in cancer cells as well.
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ERK activation in newly-adhering cells requires activation of the Rac / PAK
pathway, which

acts to enhance activation of the ERK pathway through

PAK

phosphorylation of Raf on Ser338, leading to Raf activation [Edin and Juliano, 2005]. We
have shown that PAK phosphorylation of MEKl on Ser 298 is required for MEK1
activation upon cell adhesion [Slack-Davis et aI., 2003] and functional coupling between
MEKl and ERK, which are dissociated in suspended cells [Eblen et al., 2002]. Expression
of mutationally-activated FAK [Renshaw et aI., 1999] or PAK [Howe and Juliano, 2000] in
suspended cells has been shown to result in ERK activation. However, we demonstrate
that MEK and ERK activation in suspended ovarian cancer cells does not occur through a
mechanism

involving

aberrant

PAK

activity

leading

to

anchorage-independent

phosphorylation of MEKl on Ser298. These results suggest that signaling to MEK and
ERK in suspended SKOV-3 cells is through a mechanism that does not require pathways
that crosstalk for ERK activation in adherent cells. Indeed, inactivation of FAK was
observed in suspended SKOV-3 cells and we have previously shown that PAK activation
in newly-adherent cells requires FAK activity [Slack-Davis et aI., 2003]. Interestingly, we
observe that feedback phosphorylation of MEK1 on Ser292 [Mansour et aI., 1994],
which is normally adhesion dependent and acts as a negative regulatory mechanism for
MEK1 activation during cell adhesion [Eblen et aI., 2004], is not diminished in suspended
SKOV-3 cells due to sustained activation of ERK. We currently show that it does not play
an inhibitory feedback role in the context of loss of cell adhesion.
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ERK activation in response to EGF stimulation in adherent SKOV-3 cells was
robust and returned to basal levels within hours, as has been reported extensively in the
literature for other cell types. However, ERK activation in newly-detached cells in the
absence of any external mitogen stimulation occurred with slow kinetics accompanied
by sustained activity. One possibility for this slow but sustained activation of ERK is the
loss of ERK-directed phosphatase activity, through a mechanism in which basal
activation of MEK slowly phosphorylates ERK and there is insufficient phosphatase
activity to restore basal levels of ERK activity. Indeed, reduced expression of MKP-l
occurs in ovarian tumor specimens compared to normal ovarian tissue [Denkert et al.,
2002] and we observed lower levels of MKP-l in SKOV-3 cells compared to benign lOSE
cells. Steinmetz [Steinmetz et aI., 2004] demonstrated that forced overexpression of
MKPl in malignant granulosa cells, which normally express low levels of MKPl and have
elevated levels of active ERK, lowers basal levels of ERK phosphorylation to that seen in
benign ovarian cells. They concluded that low levels of MKP-l result in enhanced ERK
activity in these cells, which was supported by undetectable levels of active MEK
[Steinmetz et al., 2004]. However, we observed normal kinetics of growth factor
stimulation of ERK in adherent SKOV-3 cells by EGF, HGF, and serum and no difference
in MKP-l protein levels in suspended versus adherent SKOV-3 cells. Moreover, we
demonstrate a robust and sustained activation of MEK in suspended SKOV-3 cells and
demonstrate that blocking upstream signaling from MEK to ERK by the addition of
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U0126 for as little as 2 minutes resulted in a complete dephosphorylation of ERK. Thus,
while MKP-l levels are lower in SKOV-3 cells compared to benign lOSE cells, there is
sufficient phosphatase activity present from either M KPl or other ERK phosphatases
[Camps et aI., 2000] to stimulate rapid turnover of ERK phosphorylation. Our results
demonstrate that ERK activation in detached SKOV-3 cells is dynamically regulated by a
skewed balance between robust upstream activation by MEK through an autocrine
mechanism, which is favored over and counteracted by prevalent phosphatase activity.
This balance is shifted towards MEK and ERK inactivation in adherent cells to allow for
inactivation of MEK and ERK after cell stimulation. The signaling pathways that restore
this balance upon cell adhesion will be an interesting area to investigate, as they
regulate production of the autocrine factor or the way that the celt responds to the
factor.

Aplin et at. [Aplin et aI., 2001] demonstrated a requirement for cellular adhesion
in order for ERK to signal to the nucleus in NIH3T3 cells, correlating with an inhibition of
ERK activity in suspended cells. While co-transfection of a mutationally-activated form
of Raf or MEK could stimulate ERK activity in suspended NIH3T3 cells, signaling to Elk! in
the nucleus required cell attachment [Aplin et aI., 2001]. We demonstrate that the
enhanced activation of MEK and ERK in suspended SKOV-3 cells allows for enhanced
nuclear

signaling to transcription

factors

compared

to

adherent

cells.

Overall

transcription was greatly reduced in suspended cells, but ERK signaling to Elk! was 2.5
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fold higher than in adherent cells. When endogenous ERK was artificially activated by
co-transfection of a constitutively activated MEK, ERK nuclear signaling was not
statistically significant between adherent and suspended cells. This suggests that some
ovarian cancer cells have developed mechanisms to support nuclear translocation of
activated ERK under conditions of anchorage independence. The enhanced gene
transcription may then contribute to anchorage independent growth. The mechanism of
ERK nuclear translocation under anchorage independent conditions has not been
elucidated, but may provide novel targets for therapeutic intervention.

The effects of ERK signaling in suspended cells may not only be transcriptional,
but non-genomic as well. In MCF7 cells, arrest of cells at Gl/S results in transient
activation of ERK in suspended cells, preventing apoptosis through suppression of BimEL, which is pro-apoptotic [Collins et aI., 2005]. ERK phosphorylation of Bim-EL
stimulates its degradation, promoting cell survival [Ley et aI., 2004; Luciano et aI., 2003;
Marani et al., 2004]. However, the mechanism for anchorage-independent activation of
ERK in ovarian cancer cells is apparently not due to Gl growth arrest, as MEK was
inactive in the suspended MCF7 cells and activation of ERK was thought to occur
through loss of phosphatase activity [Collins et aI., 2005].

We have shown that conditioned media from serum-starved suspended cells was
able to stimulate ERK activation in serum-starved adherent cells, demonstrating the
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presence of an autocrine pathway activated in detached cells. At present, the identity of
the autocrine signal is unknown. Several mitogens, such as lysophosphatidic acid (LPA),
platelet derived growth factor (PDGF) [Matei et aI., 2006] and others have been
identified in ovarian ascites fluid. LPA was shown to be secreted by peritoneal
mesothelial cells, stimulating the migration of ovarian cancer cells [Ren et aI., 2006]. It is
doubtful that LPA is responsible for the autocrine signal, as LPA is the main mitogen in
serum and serum was a weak stimulator of ERK activation in adherent SKOV-3 cells;
however, we have not ruled out this possibility, as high levels of LPA may be produced
from suspended cells. Signaling through the EGF receptor by either direct or indirect
means could also be a possibility, as SKOV-3 cells overexpress EGF receptor family
members and EGF stimulates robust ERK activation in these cells. EGFR and ErbB-2 are
both overexpressed in a significant percentage of ovarian tumors and correlate with
poor prognosis [Berchuck et aI., 1990]. The identification of the autocrine signal is
currently under investigation in our laboratory, as it could serve as a marker for
metastatic ovarian cancer. In addition, we are currently discerning the upstream
intracellular signaling proteins that are utilized by the autocrine signal to enhance ERK
activation, as these may give insight into signaling pathways induced by anchorage
independent conditions of ovarian cancer cell growth in pleural and peritoneal ascites.
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FIGURE LEGENDS

Figure 1. Activation of ERK in suspended ovarian carcinoma cells. A: Adherent (Adh)
SKOV-3 cells were detached with trypsin and treated with soybean trypsin inhibitor. The
cells were centrifuged, resuspended in either serum free medium (SF) or media
containing 10 % FBS, and put in suspension culture for 3 hr before harvest. Cell Iysates
were immunoblotted for ERK2, MEK, FAK, and the activated forms of these proteins. B:
Adherent SKOV-3 cells were detached with either trypsin or citric saline and put in
suspension culture for 3 hr in serum-free media. C and 0: Adherent SKOV-3 cells were
detached with trypsin (C) or citric saline (D) and put in suspension culture in serum free
media for the indicated time. E: Adherent (A) lOSE and SKOV-3 cells were detached with
trypsin and put in suspension (S) for 3 hr in serum free media. Lysates were
immunoblotted for ERK2 and active ERK. F: Six adherent (A) ovarian cancer cell lines
were detached with trypsin and placed in suspension in serum-free media for 1 or 3 hr.
G: Adherent (Adh) SKOV-3 cells detached with trypsin and put in suspension for 3 hr in
either serum-free media (-), or serum-free media containing 0.5% bovine serum albumin
(BSA), 4 mM EGTA, or BSA and EGTAo

Figure 2. Sustained activation of MEK and ERK in suspended cells. A: Adherent (Adh)
SKOV-3 cells were trypsinized and suspended in serum-free media for the indicated
time. Ceillysates were immunoblotted as indicated. The p-218 MEK antibody recognizes
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the active form of the kinase, while the p-298 and p-292 antibodies recognize the PAK
and ERK phosphorylation sites on MEK1, respectively. B: Adherent (Adh) SKOV-3 cells
were put in suspension for 3, 24, or 48 hr in 10 % serum or serum-free media. Lysates
were immunoblotted as indicated.

Figure 3. A: Adherent SKOV-3 cells were serum-starved for 12 hr and then treated with
either fresh serum free media {SF} or increasing concentrations of serum, EGF, or HGF
for 10 min. Cell Iysates were immunoblotted for total and active ERK and MEK. B:
Adherent (A) SKOV-3 cells were washed twice and incubated in serum-free (SF) media
overnight. The cells were then stimulated for the indicated time with either 1 ng/ml EGF
(top) or 5 ng/ml HGF (bottom). Ceillysates were immunoblotted for phosphorylated ERK
and ERK2. C: Adherent cells were serum-starved overnight (SF) and then stimulated with
10

%

serum

for

the

indicated

times.

Cell

Iysates

were

immunoblotted

for

phosphorylated ERK and ERK2.

Figure 4. Re-attachment of SKOV-3 cells to an extracellular matrix restores downregulation of ERK activity. A: Adherent (A) SKOV3 cells were detached with trypsin and
suspended in serum-free media for 90 min or 3 hr. After 3 hr the cells were either left in
suspension for the additional time indicated or replated onto fibronectin-coated dishes
for the same amount of time. Cell Iysates were prepared and immunoblotted for total
and the activated forms of ERK, MEK, and FAK. B: Adherent (A) lOSE and SKOV-3 cells
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were detached with trypsin and put in suspension for 3 hr. The cells were either kept in
suspension for the number of hours indicated or replated onto fibronectin-coated
dishes for the number of hours indicated. Ceillysates were immunoblotted for total and
the activated forms of ERK, MEK, and FAK as well as MKP-l and tubulin.

Figure 5. Sustained activation of ERK in suspended cells is not due to loss of
phosphatase activity. A: Adherent (Adh) SKOV3 cells were trypsinized and put in
suspension in serum-free media for 3 hr. The MEK inhibitor U0126 was added to the
media at a final concentration of 10 111M for the indicated number of minutes prior to
harvest of the suspended cells. Ceillysates were immunoblotted for phosphorylated ERK
and ERK2. B: Adherent (Adh) SKOV-3 cells were put in suspension culture for 3 hr, 24 hr,
or 48 hr. Two minutes before harvest the cells were treated with either DMSO or 10 111M
U0126. Ceillysates were immunoblotted for phosphorylated ERK and ERK2.

Figure 6. Activation of ERK is suspended ovarian cells occurs through an autocrine
mechanism. A: Adherent SKOV-3 cells (Adh) were put in suspension (Sus.) for 3 or 24 hr.
The cells were harvested and conditioned media from these cells was collected. Either
fresh serum-free media (SF) or conditioned media from the suspended cells was then
added to serum-starved adherent SKOV-3 cells for 5, 15, or 60 minutes. Cells Iysates for
the suspended and adherent cells were prepared and immunoblotted for ERK, MEK, and
the activated forms of these proteins. B: Adherent {Adh} cells were put in suspension for

211

24 hr (Sus.). Conditioned media from the suspended cells was collected and added to
serum-starved adherent SKOV-3 cells from 10 min. to 6 hr. Cell Iysates were
immunoblotted with antibodies to ERK2 and phospho-ERK.

Figure 7. ERK nuclear signaling is enhanced in suspended ovarian cancer cells. SKOV-3
cells were co-transfected with GAL4-Elk1, SX GAL4 luciferase, TK Renilla luciferase, and
either empty vector or mutationally-activated MEK1. After a 5 hr transfection in serumfree media, the cells were incubated in 10% serum overnight. The following day, the
cells were washed twice with PBS and either incubated in serum free media or
trypsinized and incubated in serum-free media in suspension. After 24 hr all cells were
harvested and both Renilla and firefly luciferase determined using a dual luciferase
assay kit (Promega). Firefly luciferase activity was normalized to Renilla. Solid bars
represent adherent cells and checked bars represent suspended cells. The results from
the adherent cells transfected with the reporter construct, GaI4-Elk1, TK Renilla and
empty vector (first column) was set at 100%. The results are an average of 5
experiments performed in duplicate. There was a significant difference (*, p<O.OS)
between normalized firefly luciferase activity between adherent and suspended cells
(left columns). There was not a significant difference in normalized firefly luciferase
activity between the adherent and suspended cells that were transfected with
mutationally activated MEKI.
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Figure 8. Inhibition of ERK activation impairs anchorage independent growth. A: SKOV4

3 and lOSE cells were plated in triplicate at a density of 1 X 10 cells per well in 12 well
dishes in 10% serum-containing media. The following day the cells were treated with
either 10 111M U0126 or DMSO control. MIT reagent was added for 2 hrs before cell
harvest for the next 4 days. MTT activity was measured after harvest. The data shown is
a representative experiment that was performed 3 times. (*, p< 0.05). B: Adherent
SKOV-3 cells were trypsinized and placed in 1ml of soft agar containing 10% serum at a
density of 5000 cells per ml. The assay was performed 3 times in triplicate. Cells were
treated every 3 days with either 10 IlIM U0126 or DMSO control. Four random fields
were photographed using a 2.5 objective. A representative field from each treatment is
shown. C. Colony count (>400 [1]m

2

)

and size was determined using Image J software.

Quantitation of the total colony count from 4 photographed fields per dish were
averaged and then compared within each group. There was a statistical significant
difference (*, p< 0.05) between U0126 and the DMSO control.
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